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GENERAL INTRODUCTION
Worldwide cancer currently is one of the leading causes of morbidity and mortality. 
Its’ global burden is expected to increase even more, with a predicted 24 million new 
cancer cases in 2035, compared to the 18 million in 2018 and 14 million in 2012.1–3
With the rising life expectancy, the prevalence of cancer – being a disease mainly 
of the aging – will increase. Also, prevalence will increase due to more accurate 
detection and the expansion of treatment possibilities leading to an often more 
favourable prognosis. Cancer will influence more lives for a longer time and 
therefore will increasingly be a global health challenge.
In 2018 breast, lung, colorectal, prostate, and stomach cancer represented 55% of 
the global cancer incidence and about 25% of the cancer related deaths was caused 
by lung or stomach cancer.3 In the Netherlands, in 2017, also around 25% of all 
cancer related deaths were caused by lung or stomach cancer.4
Multidisciplinary cancer care
In most solid cancers, surgery has an important role in curative treatment. There is a 
growing evidence for the added value of (neo)adjuvant therapy with chemotherapy, 
radiotherapy, hormone therapy, targeted therapy or combinations of these 
therapies. In some cases surgery is even replaced as the main curative treatment.5,6
Gastric cancer and non-small cell lung cancer (NSCLC) are two types of cancer 
eminently treated with combined (multimodal) therapy. In gastric cancer 
perioperative chemotherapy is recommended for all patients with non-metastasised 
resectable gastric cancer (excluding stage I) provided that the patient is in good 
condition.7,8 In lung cancer there is a range of treatment options depending on 
tumour stage. Stage I NSCLC is preferably treated surgically, though in patients 
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unfit for surgery stereotactic radiotherapy is considered as a good alternative.9,10 
Surgically treated patients with NSCLC stage II-IIIA benefit from adjuvant 
chemotherapy.9 For patients with locally advanced (stage III) NSCLC the optimal 
treatment consists of combined chemoradiotherapy. Selected patients may benefit 
from chemoradiotherapy followed by surgery, so called trimodality therapy.
With the growing possibilities and rising complexity in oncologic care, 
multidisciplinary teams (MDTs) are widely incorporated in the standard of oncologic 
care. MDTs are considered to improve communication, patient coordination, clinical 
decision-making, practice of evidence-based medicine and thereby overall quality 
of care.11
Quality evaluation and variation in cancer care
An increase in possibilities also arises the chances on variation. Considerable 
variation in the treatment and outcomes of various types of cancer in the 
Netherlands was demonstrated for the first time on a national level in the “quality 
of cancer care” report by the Dutch Cancer Society.12 However, from the available 
data, reasons for these differences could hardly be defined.
In order to gain insight in the observed variation and to provide medical teams 
with performance information, nationwide clinical audits were introduced. Clinical 
auditing is defined as the systematic analysis of processes and outcomes with the 
ultimate aim of improvement and typically follows the plan-do-check-act (PDCA) 
cycle.13 Within this cycle, data are compared with pre-defined quality indicators and 
continuously fed back to participating centres.
Against this background, the objective of this thesis was to provide insight in 
the development and implementation of clinical audits for the evaluation of 
multidisciplinary care and to investigate treatment variation of two eminently 
multimodal treated cancer types; lung cancer and gastric cancer.
Introduction and  outline
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OUTLINE OF THESIS
Part I. Quality assurance in multidisciplinary cancer care
In 2010, the “quality of cancer care” report by a signalling committee of the Dutch 
Cancer Society concluded that the overall quality of care for patients with cancer was 
high, though could be further improved by the reduction of regional and between-
hospital variation. One of the pillars to improve quality and equality of oncologic 
care was the development of quality standards. Since the report was published, 
professional societies like the Association of Surgeons in the Netherlands have 
started to define quality standards for the surgical treatment of various tumours. 
Subsequently, the Dutch federation of oncological societies (SONCOS) started to 
develop multidisciplinary general oncologic and tumour specific standardisation 
reports with requirements to assure high quality multidisciplinary cancer care in 
every hospital in our country.14
The second pillar to improve quality of care is the participation in a national clinical 
audit.
The fundamental thoughts for auditing in medical practices already exist longer 
with ideas described by doctor Thomas Percival (1803), nurse Florence Nightingale 
(1820) and doctor Ernest Codman (1869). The latter stated that “every hospital 
should follow every patient it treats, long enough to determine whether or not 
the treatment has been successful, and then to inquire ‘if not, why not’ with a view 
to preventing similar failures in the future”. This so-called ‘end-result theory’ is 
considered as the foundation for modern clinical audits.
One of the leading organisations providing clinical auditing in the Netherlands is 
the Dutch Institute of Clinical Auditing (DICA, founded in 2011). Chapter II provides 
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insight into how Codman’s clinical auditing concept has been implemented on a 
nationwide scale in the Dutch healthcare system. It describes the development of 
DICA and demonstrates its effects on care processes and outcomes for patients. 
Initially, DICA audits were mono-disciplinary and treatment-specific, mainly 
focusing on the surgical treatment of cancer. Following the increasing importance 
of multidisciplinary care, audits expand to include non-surgical treatments 
such as radiotherapy and medical oncology. The ultimate intend is to integrally 
evaluate the entire multidisciplinary care pathway. One of the first national audits 
to multidisciplinary evaluate cancer care is the Dutch Lung Cancer Audit. Its core 
principles, initiation and development, first results and what lessons can be learned 
from its development are described in Chapter III.
Quality information is of primary importance to clinicians and medical teams. 
However, amongst other stakeholders in healthcare there is a rising interest in 
hospital-specific performance information. The demand to use so called ‘quality 
indicators’ as public information for policy makers, insurers and patients is growing. 
To accommodate to this more wide use of data, its presentation must meet a 
number of conditions, such as relevance, usability, reliability and validity.15
When using outcome indicators to benchmark hospitals, differences might not 
only reflect the differences in quality, but also differences in patient population 
per hospital. This so-called ‘casemix’ is a combination of patient- and disease 
characteristics. In Chapter IV we examined the need for casemix adjustment 
evaluating hospital outcomes specifically for lung cancer surgery and a casemix 
adjustment model useful in practice is proposed.
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Part II. Variation in multidisciplinary cancer treatment
In all DICA audits variation on structural, procedural and outcome indicators is 
monitored. Between-hospital variation on indicator scores is typically displayed 
with funnel-plots as graphical aids. In these figures all hospitals are represented by 
a dot. The benchmark to which the hospitals can be compared can be set at the 
national average or any defined norm. The confidence intervals around this norm 
demonstrate to which extent hospitals deviate from the set value. Hospitals outside 
the confidence intervals could be identified as outliers and can subjected to in-depth 
investigations. When relevant, casemix adjustment is applied.
Variations in outcome measures such as mortality, fortunately, seem low. However, 
the potential of using variation for outcome improvement is influenced by the 
number of events and the patient volume per hospital. For diseases or outcomes 
with a low incidence it is more challenging to identify improvement potential based 
on variation. Several studies focused on this issue by investigating alternative 
statistical approaches or composite measures.16–18
At the start of most DICA audits there was a considerable between-hospital variation, 
mainly in process indicators (e.g. discussion in MDTs, pre-operatively recorded TNM 
stage and completeness of pathology records). After providing caregivers with this 
information, variation notably declined and improvement on the national mean was 
observed. Providing caregivers with feedback information on procedural measures, 
such as the use of certain diagnostic tools, therapies or for instance risk-increasing 
modalities like neoadjuvant treatment can also influence final outcomes.19,20
In lung cancer surgery, such a high-risk procedure is pneumonectomy, the removal 
of an entire lung. The postoperative mortality of this procedure is about 3 times 
higher compared to less extensive resections.21 The proportion of pneumonectomies 
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was therefore suggested as a quality indicator by Jakobsen et al.22 To apply such a 
quality indicator, between-hospital variation and possibilities for proper casemix 
adjustment first need to be studied. Chapter V focuses on this subject.
Variation between hospitals or regions is assessed to identify either opportunities for 
quality improvement, e.g. by learning from best practices, or potential controversies 
guiding new research or guideline improvement. While current guidelines in 
curatively treated gastric cancer recommend perioperative chemotherapy to 
improve survival, recent studies using audit data show substantial variation in its 
use.23,24 In Chapter VI underlying (organisational and process) factors associated 
with the use of perioperative therapy were identified. The multidisciplinary aspect 
of care was a subject of interest in particular. For this in-depth investigation a 
composite database was developed, using pre-existing data from the Dutch Upper 
GI Cancer Audit (DUCA) combined with data derived from in-hospital medical 
records.
In addition to this, a qualitative approach with semi-structured interviews among 
surgical and medical oncologists was used in Chapter VII to evaluate ‘physician 
supply-side factors’ such as clinicians’ preferences as a potential underlying factor 
for between-hospital variation. All variation studies aim to provide leads to minimise 
unwanted variation in the operative en perioperative treatment of cancer.
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PART I
ASSURING QUALITY IN
MULTIDISCIPLINARY
CANCER CARE

CHAPTER 2
The Dutch Institute for Clinical Auditing: 
achieving Codman’s dream on a nationwide basis
N. Beck, A.C. van Bommel, E.H. Eddes, N.J. van Leersum, R.A.E.M. Tollenaar, 
M.W.J.M. Wouters. On behalf of the Dutch Clinical Auditing Group*
* Can be found under the heading ‘Collaborators’
Ann Surg. 2020 Apr;271(4):627-631
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BACKGROUND
For the medical community, information on care processes and outcomes of their 
daily clinical practice is often lacking. An important tool in gaining insight and 
improving healthcare quality is clinical auditing, defined as the systematic analysis 
of processes and outcomes of medical care with the ultimate aim of improvement. 
The concept was introduced over a century ago by Dr. Ernest Amory Codman.1 His 
‘end-result theory’ states: “that every hospital should follow every patient it treats, 
long enough to determine whether or not the treatment has been successful, (…) 
with a view to preventing similar failures in the future”. 
In the Netherlands, one of the leading organisations that facilitates clinical auditing 
is the Dutch Institute for Clinical Auditing (DICA). DICA was founded in 2010, at a 
time when the demand for transparent, hospital-specific performance information 
was growing. Simultaneously, professional organisations wanted to redirect the 
performance discussion from merely procedural volume to a broader outcome-
based evaluation.2 The main goal of DICA is to gain better outcomes for patients by 
measuring quality of care, giving benchmarked feedback to clinicians, stimulating 
short-cycled improvement initiatives, enabling external transparency and reducing 
healthcare costs.
This article provides insight into how Codman’s clinical auditing concept has been 
implemented on a nationwide scale in the Dutch healthcare system.
26
DEVELOPMENT
Origins and organisation
In the Netherlands, the Dutch Colo-Rectal Audit (DCRA) was the first nationwide 
professional-driven initiative to provide medical teams with benchmarked, 
hospital-specific performance information, offering new opportunities to improve 
their care.3 It was launched in 2009 as an initiative of the Association of Surgeons of 
the Netherlands. The DCRA served as a blueprint for subsequent DICA audits.
Figure 1 visualises DICA’s governance structure. A key feature is the leading role of 
those “personally engaged in the activity concerned”: the clinicians. The Scientific 
Committee (SC) determines audit objectives and dataset content, takes the lead 
in interpreting data and functions as a link with other clinicians in the professional 
associations. DICA’s scientific bureau provides methodological and operational 
support and is backed by a methodological advisory committee and a privacy 
committee. 
DICA is a non-profit organisation. Since 2016, audits are structurally financed by an 
umbrella organisation of healthcare insurance companies (ZN). They consider DICA 
audits as an important source of reliable, independent hospital specific information. 
Although ZN participates in the establishment of the transparent indicator sets, it 
does not influence or have access to audit content or data analyses.
Dataset development and quality measurement 
The SC composes the dataset using (inter)national evidence-based guidelines, taking 
into account what is meaningful and actionable information for clinicians. Quality 
indicators meet the requirements of relevance, validity, reliability and feasibility. In 
accordance with the Donabedian model, indicator sets consist of structure, process 
and outcome indicators.4 Indicators are primarily of use in quality assurance and 
improvement initiatives by participating hospitals (local quality cycle), though data 
The D
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are also used to evaluate performance at national level (national quality cycle). To 
ensure their continuing value, the audits’ focuses and quality indicators are critically 
evaluated on a yearly basis.
Data entry, storage and quality assurance
Depending on the indicators defined, datasets contain information on hospital 
structure variables, care processes and patient outcomes. Baseline patient 
characteristics are included to enable risk adjustment. 
For data collection, encryption, storage and processing there is close cooperation 
with a certified data processor: Medical Research Data Management (MRDM). 
Participating hospitals retain ownership of their data. All data is subjected to 
several validation processes: in the web-based registration system, by means of 
an electronic error report and by in-hospital verification of registered data by an 
independent third party.
Figure 1. Organisational structure of the Dutch Institute for Clinical Auditing (DICA). 
^ Medical Research Data Management.
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Internal feedback and external transparency
Through a weekly updated, secure, online environment called ‘MyDICA’ 
participating physicians are provided with hospital-specific feedback, including 
information on patient, disease and treatment characteristics. Quality-indicator 
results are presented in funnel-plots with 95% confidence intervals around the 
national average or a defined norm, anonymous with regard to other hospitals. 
If indicators are found relevant and valid, indicator scores can be used as public 
information, casemix adjusted when applicable. Hospital-specific information 
becomes externally available in a stepwise process agreed on by all stakeholders 
– patients, professionals, payers and government organisations, collaborating in a 
biannual meeting to define transparent indicator sets.
Hospitals authorise the sharing of their indicator scores through a DICA-facilitated 
web-portal, being unable to change these scores.
Quality improvement at national level
The SC plays a major role in evaluating and interpreting audit data. Between-
hospital variation is assessed to identify opportunities for quality improvement, e.g. 
by learning from best practices, or potential controversies guiding new research 
or guideline improvement. The medical community is informed through an annual 
report, conferences and scientific articles. Professional organisations use audit 
results in their integrated quality policy, e.g. to verify adherence to guidelines and 
quality standards, and to catalyse quality improvement at national level.
Outcomes research
Detailed population-based audit data become available for research provided 
they are complete and verified. Research applications are assessed for relevance, 
methodology and availability of data. Types of research questions that have 
arisen thus far include: evaluation of clinical practice patterns for diagnostics and 
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treatments, reports on the introduction of new techniques, mechanisms behind 
hospital variation, identification of best practices and methodological research 
developing new (composite) measures or risk stratification models.
The next section highlights the most important accomplishments. All publications 
using DICA-data up to 2018 are included in Supplemental Table 1.
ACCOMPLISHMENTS
Expansion of the audits
DICA was founded in 2011. Up to December 2017, 21 nationwide audits have been 
initiated, resulting in the registration of over 700,000 patients (Figure 2). Initially, 
audits were mono-disciplinary and treatment-specific, mainly focusing on cancer 
surgery. Over time, this has expanded to include non-malignant diseases, non-
surgical treatments and evaluation of the entire multidisciplinary care pathway. 
Audits with additional functionalities include the Dutch Melanoma Treatment 
Registry, used to study cost-effectiveness and real-world performance of newly 
developed treatments (immune and targeted therapies) at population level, and 
the Dutch Head and Neck Cancer Audit additionally evaluating paramedical care, 
like swallowing and speech therapy. 
The number of medical associations involved increased from five (2011) to seventeen 
(2017). In parallel, the number of clinicians actively involved in the SCs and CABs 
rose from 32 to 243.
The number of transparent indicators calculated from DICA audits rose from six 
(2012) to 161 (2017). National improvements were observed together with a decline 
in between-hospital variance. 
DICA data provided a reliable source to ascertain compliance with the volume 
standards and to study the volume-outcome relationship in several diseases.5,6
30
Developments in quality evaluation
Since single-measurement indicators can be less suitable for hospital comparison, 
new composite measures were developed, such as ‘failure to rescue’ and ‘textbook 
outcome’ for colorectal cancer, oesophagogastric cancer and elective aneurysm 
Figure 2. The evolution of DICA-facilitated audits: type of audits, number of registered 
patients and publications per year. 
^ An overview of all publications can be seen in Supplemental Table 1, an abbreviation list of 
all DICA audits can be seen in Supplemental Table 2.
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surgery.7 Risk adjustment models were developed to enable valid hospital 
comparisons.
Insights into national clinical practice
Variation observed between caregivers, hospitals or internationally is an important 
stimulus for in-depth investigation of underlying causes and improvement. For 
example, the relatively high use of neoadjuvant radiotherapy for rectal cancer in 
the Netherlands compared to other countries in 2011, led to guideline adjustment 
in 2014. Rapid implementation was observed, with a decrease in radiotherapy use 
from 84.2% to 64.4% in two years, without compromising oncologic outcomes.8 
Other findings include the increased use of minimally invasive surgery at national 
level.9 Although learning curves were observed, minimally invasive procedures 
proved to be safely introduced and were considered to be important drivers for 
postoperative outcome improvement.9
Nationwide quality improvements
Figure 3 shows two examples of process indicator improvements for lung cancer 
and breast cancer, with an increased national average and a decreased between-
hospital variation. For example, the national percentage of patients undergoing lung 
cancer surgery with a preoperatively recorded clinical TNM stage increased from 
75.4% to 98.3% (2012-2016) (Figure 3a-b). Subsequently, variation decreased from 
0-100% to 82-100%. Several process indicators regarding time to treatment also 
improved at national level with a decline in between-hospital variation. The number 
of patients treated within a certain time limit increased for the surgical treatment 
of carotid stenosis (63% to 79%) and lung cancer (41% to 71%), the radiotherapeutic 
treatment of lung cancer (60% to 71%) and any treatment of ovarian cancer (77% to 
86%), rectal cancer (49% to 56%) and oesophageal cancer (31% to 47%).
32
Improvements on the outcome indicator ‘postoperative 30-day or in-hospital 
mortality’ were seen in various DICA audits. For example, between 2012 and 2015, 
postoperative mortality decreased from 4.2% to 2.5% after resection for colon 
cancer and from 2.5% to 1.7% for rectal cancer, resulting in a reduction of more than 
200 care-related deaths per year in the Netherlands.10 In surgical colorectal cancer 
treatment improvements were also seen in severe complication rates, ‘failure to 
rescue’ (the proportion of patients that die following severe complications) and 
oncologic resection quality. For carotid artery interventions, there was a decrease 
in ‘complicated course’ from 4.3% to 2.7% (2013-2016). A decrease in hospitalisation 
days was observed after resection for gastric cancer: from a median of ten days in 
2012 to eight days in 2016.
Figure 3. Decrease in variation in process indicators for lung cancer (a,b) and 
breast cancer (c,d).
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In colorectal cancer surgery, improvements in mortality and complication rates 
reduced the mean cost per patient from €14,237 to €13,145 (-7.7%).11 Extrapolating 
to national level, the potential additional savings could be over 20 million Euros per 
three years if all hospitals perform as best practices.
The observed improvements are likely to be multifactorial – with simultaneous 
centralisation, specialisation and introduction of new techniques – and not 
solely attributable to the audits. Nevertheless, the audits provided insights into 
performance of the national healthcare system and individual providers that were 
previously not available. Reliable, actionable data from the audits form the basis for 
improvement.
PERSPECTIVES
Worldwide many initiatives have been developed to monitor and improve healthcare 
quality by using data. What distinguishes DICA-facilitated audits is the central role 
of clinicians and their professional societies, close collaboration with other parties 
involved in healthcare provision, short-cycled benchmarked feedback, national 
coverage and data verification processes to secure data quality. The leading role 
of clinicians and cooperation with other parties is essential to produce meaningful 
quality information. DICA data is simultaneously used to provide internal feedback 
to medical teams at hospital level and to calculate externally transparent indicators. 
Instead of a merely volume-based discussion, DICA’s hospital specific outcome 
information has led to a more solid quality of care discussion. Integrating audits 
into quality assurance policies, e.g. via mandatory ‘participation indicators’ and 
stepwise external transparency has stimulated nationwide participation, allowing 
better hospital comparisons and the provision of unbiased information, in contrast 
to registries of more voluntary nature.
34
Today, there are some limitations to the current audits, whether or not to be 
resolved by DICA. One limitation is the administrative burden associated with data 
collection. A solution already being worked on is partly automated data collection 
from Electronic Patient Records. To achieve this, in-hospital workflow redesign will 
be necessary and close cooperation between doctors and hospital IT providers is 
indispensable. Increasingly stringent privacy legislation could be a barrier in linking 
various data sources for audit purposes. Second, finding a balance with demands 
on transparency is challenging. In DICA’s view, caregivers should retain the option 
of evaluating data internally, allowing medical teams to act on their results in a 
safe environment. Third, a current barrier to achieving maximum benefit from 
clinical auditing is the fixed format in which feedback information is offered. More 
dynamic, interactive systems could optimise information provision for clinicians and 
stimulate data use for quality improvement cycles and data-driven discussions by 
medical teams. For that reason DICA introduced exploratory ‘Codman dashboards’ 
in 2019, in which clinicians can select certain patient groups and compare their 
results in these groups with a national benchmark.
Generally, a potential flaw of transparent indicators is their potential influence on 
clinical decisions and risk-averse behaviour. There are no indications in the current 
audits for the latter.12 A more ‘disease-focused’ rather than treatment-specific 
quality evaluation could contribute to insights into risk-averse behaviour. Future 
perspectives therefore focus on quality evaluation of the entire care spectrum per 
condition. 
Recapitulating, the digital era has brought opportunities to realise Codman’s dream, 
by implementing his clinical auditing model on a nationwide basis. This brings the 
insights and improvements in healthcare quality he intended one hundred years 
ago. Although there are challenges to be overcome, the DICA example shows 
important principles for a successful introduction of these audits: clinicians in 
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the lead, close collaboration with various stakeholders in healthcare, use of audit 
outcomes in improvement initiatives of professional associations and real-world 
data with timely actionable feedback information for clinicians. Clinical audits can 
catalyse internal quality improvement, ultimately leading to equal distribution of 
healthcare quality and accountability to all stakeholders.
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 re
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 c
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 m
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r c
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 c
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r p
at
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at
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 re
se
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 m
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 p
at
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r r
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r r
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l c
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 c
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op
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at
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 c
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 b
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at
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l c
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 m
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 c
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 re
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 d
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 c
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 o
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t c
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r c
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l c
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 c
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se
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 d
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 c
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 d
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 c
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 m
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, m
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os
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l s
ta
y,
 e
ve
n 
af
te
r p
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 c
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 m
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os
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at
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 p
at
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l c
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f p
os
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 re
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f c
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 c
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at
io
ns
 a
nd
 m
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l c
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 c
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ns
 c
an
 b
e 
pr
ev
en
te
d,
 re
du
ci
ng
 c
om
pl
ic
at
io
ns
 w
ill
 re
su
lt 
in
 
co
ns
id
er
ab
le
 c
os
t s
av
in
gs
.
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 c
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s
O
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or
ec
ta
l c
an
ce
r s
ur
ge
ry
 is
 a
ss
oc
ia
te
d 
w
it
h 
a 
si
gn
ifi
ca
nt
 in
cr
ea
se
 in
 h
os
pi
ta
l c
os
ts
, 
co
m
pa
re
d 
to
 n
or
m
al
-w
ei
gh
t p
at
ie
nt
s.
 T
hi
s 
m
ay
 b
e 
ex
pl
ai
ne
d 
by
 th
e 
si
gn
ifi
ca
nt
ly
 h
ig
he
r s
ev
er
e 
co
m
pl
ic
at
io
n 
ra
te
 in
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be
se
 p
at
ie
nt
s.
20
16
G
ov
ae
rt
 e
t a
l.5
0
H
ea
lth
 c
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e 
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r s
im
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ta
ne
ou
s 
qu
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ity
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pr
ov
em
en
t a
nd
 c
os
t r
ed
uc
tio
n 
in
 c
ol
or
ec
ta
l c
an
ce
r 
su
rg
er
y.
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pr
ov
in
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ill
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ot
en
tia
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 c
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al
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e 
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 c
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iv
e 
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n 
ca
nc
er
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ur
ge
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, l
ap
ar
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pi
c 
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se
ct
io
n 
w
as
 s
ig
ni
fic
an
tl
y 
le
ss
 e
xp
en
si
ve
 th
an
 o
pe
n 
re
se
ct
io
n.
 T
he
 la
rg
es
t c
os
t r
ed
uc
ti
on
 w
as
 s
ee
n 
in
 p
at
ie
nt
s 
ag
ed
 ≥
 7
5 
ye
ar
s 
w
it
h 
A
SA
 I-
II.
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le
ct
iv
e 
re
ct
al
 
ca
nc
er
 s
ur
ge
ry
 w
as
 s
ig
ni
fic
an
tl
y 
m
or
e 
ex
pe
ns
iv
e 
w
he
n 
pe
rf
or
m
ed
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pa
ro
sc
op
ic
al
ly
.
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pl
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en
ta
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n
N
at
io
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id
e 
im
pl
em
en
ta
tio
n 
of
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n 
au
di
t o
f t
he
 s
ur
gi
ca
l t
re
at
m
en
t o
f u
pp
er
 G
I c
an
ce
r i
n 
th
e 
N
et
he
rla
nd
s 
ha
s 
be
en
 s
uc
ce
ss
fu
l, 
sh
ow
in
g 
im
pr
ov
em
en
ts
 o
n 
va
rio
us
 p
ro
ce
ss
 a
nd
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ut
co
m
e 
in
di
ca
to
rs
.
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pp
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en
ta
l T
ab
le
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. (
co
nt
in
ue
d)
.
D
is
ea
se
S
ub
je
ct
Fi
nd
in
g
Ye
ar
R
ef
er
en
ce
N
at
io
na
l c
lin
ic
al
 
pr
ac
tic
e
In
 e
so
ph
ag
ea
l c
an
ce
r s
ur
ge
ry
, t
he
 n
um
be
r o
f l
ym
ph
 n
od
es
 (L
N
s)
 re
tr
ie
ve
d 
in
cr
ea
se
d 
be
tw
ee
n 
20
11
 
an
d 
20
16
. R
et
ri
ev
al
 o
f ≥
15
 L
N
s 
w
as
 n
ot
 a
ss
oc
ia
te
d 
w
it
h 
in
cr
ea
se
d 
po
st
op
er
at
iv
e 
m
or
bi
di
ty
/m
or
ta
lit
y.
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 d
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ua
lit
y 
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di
ca
to
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A
 c
om
po
si
te
 m
ea
su
re
 d
efi
ne
d 
as
 ‘t
ex
tb
oo
k 
ou
tc
om
e’
 (T
O
),
 to
 a
ss
es
s 
qu
al
it
y 
of
 c
ar
e 
w
as
 d
efi
ne
d.
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e 
va
ria
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ls
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ng
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e.
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tr
ic
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an
ce
r a
re
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or
e 
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el
y 
to
 d
ie
 if
 a
 (m
aj
or
) p
os
to
pe
ra
tiv
e 
co
m
pl
ic
at
io
n 
oc
cu
rs
 
(f
ai
lu
re
 to
 re
sc
ue
 –
 F
TR
). 
N
ex
t t
o 
m
or
bi
di
ty
 a
nd
 m
or
ta
lit
y,
 F
TR
 s
ho
ul
d 
be
 c
on
si
de
re
d 
as
 a
n 
im
po
rt
an
t 
ou
tc
om
e 
m
ea
su
re
 a
ft
er
 e
so
ph
ag
og
as
tr
ic
 c
an
ce
r r
es
ec
tio
ns
.
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 p
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ct
io
n
In
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as
tr
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to
m
y 
fo
r g
as
tr
ic
 c
an
ce
r, 
A
SA
 g
ra
de
, n
eo
ad
ju
va
nt
 c
he
m
ot
he
ra
py
 a
nd
 ty
pe
 o
f r
es
ec
tio
n 
ar
e 
in
de
pe
nd
en
t p
re
di
ct
or
s 
of
 m
or
bi
di
ty
 a
nd
 d
ea
th
, i
rr
es
pe
ct
iv
e 
of
 a
ge
.
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ua
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es
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tr
ic
 c
an
ce
r s
ur
ge
ry
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av
e 
be
en
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af
el
y 
in
tr
od
uc
ed
 in
 th
e 
N
et
he
rla
nd
s 
w
ith
 o
ve
ra
ll 
m
or
bi
di
ty
 a
nd
 m
or
ta
lit
y 
co
m
pa
ra
bl
e 
to
 o
pe
n 
su
rg
er
y 
an
d 
w
ith
 s
ho
rt
er
 h
os
pi
ta
liz
at
io
n.
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ev
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ua
tio
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e 
N
et
he
rla
nd
s,
 th
er
e 
is
 a
n 
in
cr
ea
si
ng
 tr
en
d 
to
w
ar
ds
 m
in
im
al
ly
 in
va
si
ve
 e
so
ph
ag
ec
to
m
y 
(M
IE
) 
co
m
pa
re
d 
to
 o
pe
n 
es
op
ha
ge
ct
om
y 
(O
E)
 fo
r c
an
ce
r. 
Th
er
e 
ar
e 
no
 re
le
va
nt
 d
iff
er
en
ce
s 
in
 m
or
ta
lit
y 
an
d 
pu
lm
on
ar
y 
co
m
pl
ic
at
io
ns
 b
et
w
ee
n 
O
E 
an
d 
M
IE
. A
na
st
om
ot
ic
 le
ak
s 
an
d 
re
-i
nt
er
ve
nt
io
ns
 w
er
e 
m
or
e 
fr
eq
ue
nt
ly
 o
bs
er
ve
d 
in
 p
at
ie
nt
s 
af
te
r M
IE
. M
IE
 w
as
 a
ss
oc
ia
te
d 
w
ith
 a
 s
ho
rt
er
 h
os
pi
ta
l s
ta
y.
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ev
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ua
tio
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 w
ee
ks
 b
et
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ee
n 
en
d 
of
 n
eo
ad
ju
va
nt
 c
he
m
or
ad
io
th
er
ap
y 
an
d 
es
op
ha
ge
ct
om
y 
fo
r 
ca
nc
er
 is
 a
ss
oc
ia
te
d 
w
it
h 
hi
gh
er
 p
at
ho
lo
gi
c 
co
m
pl
et
e 
re
sp
on
se
 (p
C
R
),
 b
ut
 n
ot
 w
it
h 
in
cr
ea
se
d 
in
tr
a-
 o
r 
po
st
-o
pe
ra
ti
ve
 c
om
pl
ic
at
io
ns
. 
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r c
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ce
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at
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ci
c 
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to
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 (c
om
pa
re
d 
to
 c
er
vi
ca
l) 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
lo
w
er
 a
na
st
om
ot
ic
 le
ak
 ra
te
, l
ow
er
 ra
te
 o
f r
ec
ur
re
nt
 n
er
ve
 p
ar
es
is
 a
nd
 a
 s
ho
rt
er
 h
os
pi
ta
l s
ta
y.
 R
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k 
fa
ct
or
s 
fo
r a
na
st
om
ot
ic
 le
ak
 w
er
e 
co
-m
or
bi
di
ti
es
 a
nd
 p
ro
xi
m
al
 tu
m
ou
rs
.
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os
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os
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tio
n 
in
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ei
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ng
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dj
uv
an
t c
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ra
di
o)
th
er
ap
y 
af
te
r 
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st
ric
 c
an
ce
r r
es
ec
tio
n 
w
as
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er
ve
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om
is
si
on
 w
as
 s
tr
on
gl
y 
as
so
ci
at
ed
 w
ith
 p
os
to
pe
ra
tiv
e 
co
m
pl
ic
at
io
ns
, u
nd
er
lin
in
g 
th
e 
ne
ed
 to
 fu
rt
he
r r
ed
uc
e 
pe
rio
pe
ra
tiv
e 
m
or
bi
di
ty
.
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ta
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va
ria
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Th
er
e 
is
 c
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si
de
ra
bl
e 
ho
sp
ita
l v
ar
ia
tio
n 
in
 th
e 
us
e 
of
 p
er
io
pe
ra
tiv
e 
th
er
ap
y 
in
 p
at
ie
nt
s 
w
ith
 g
as
tr
ic
 
ca
nc
er
. B
es
id
es
 k
no
w
n 
ca
se
m
ix
 fa
ct
or
s,
 u
se
 o
f p
er
io
pe
ra
tiv
e 
th
er
ap
y 
w
as
 a
ss
oc
ia
te
d 
w
ith
 th
e 
le
ve
l o
f 
in
vo
lv
em
en
t o
f m
ul
tid
is
ci
pl
in
ar
y 
ca
re
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 c
ar
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s
Co
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pl
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at
io
ns
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ft
er
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ph
ag
ec
to
m
y 
fo
r c
an
ce
r a
re
 a
ss
oc
ia
te
d 
w
ith
 a
 s
ub
st
an
tia
l i
nc
re
as
e 
in
 h
os
pi
ta
l 
co
st
s.
 A
na
st
om
ot
ic
 a
nd
 c
hy
le
 le
ak
ag
e 
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su
lte
d 
in
 th
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la
rg
es
t a
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iti
on
al
 c
os
ts
.
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rs
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ft
er
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st
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hm
en
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D
ut
ch
 P
an
cr
ea
ti
c 
C
an
ce
r A
ud
it
 w
as
 im
pl
em
en
te
d 
at
 
na
ti
on
al
 le
ve
l, 
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s 
hi
gh
-q
ua
lit
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ta
 a
nd
 re
po
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od
 o
ut
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es
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f p
an
cr
ea
ti
c 
su
rg
er
y 
at
 n
at
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na
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V
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 p
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 b
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it
al
 v
ar
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ti
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in
 m
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ta
lit
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w
er
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ex
pl
ai
ne
d 
m
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nl
y 
by
 
di
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er
en
ce
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in
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ilu
re
 to
 re
sc
ue
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an
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of
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 c
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pl
ic
at
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l c
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ry
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 c
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 c
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l f
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 b
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et
he
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at
io
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of
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ra
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os
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 p
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te
 b
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t c
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l c
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 p
at
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ce
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e 
us
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of
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eo
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ju
va
nt
 c
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ot
he
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py
 (N
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 w
as
 7
9%
. 
C
on
si
de
ra
bl
e 
be
tw
ee
n-
ho
sp
it
al
 v
ar
ia
ti
on
 in
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se
 o
f N
A
C
 w
as
 o
bs
er
ve
d,
 e
ve
n 
af
te
r a
dj
us
tm
en
t f
or
 
pa
tie
nt
, t
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cl
in
ic
al
 m
an
ag
em
en
t a
nd
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pi
ta
l f
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to
rs
.
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pr
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em
en
t
N
at
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nw
id
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im
pl
em
en
ta
tio
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of
 a
n 
au
di
t o
f b
re
as
t c
an
ce
r t
re
at
m
en
t i
n 
th
e 
N
et
he
rla
nd
s 
ha
s 
be
en
 
su
cc
es
sf
ul
. D
at
a 
sh
ow
 th
at
 o
ve
ra
ll 
qu
al
ity
 o
f b
re
as
t c
an
ce
r c
ar
e 
in
 a
ll 
ho
sp
ita
ls
 is
 h
ig
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 Im
pr
ov
em
en
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lit
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to
rs
 h
as
 b
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se
en
 o
ve
r t
im
e.
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 re
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r c
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ot
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l o
r n
at
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m
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 re
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pl
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 c
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r c
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pl
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en
te
d 
na
tio
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at
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 p
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r p
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t c
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 b
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 d
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m
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et
en
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m
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 p
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l C
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 p
at
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f s
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 c
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 c
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Supplemental Table 2. Abbreviation list of DICA audits.
DACI Dutch Audit for Carotid Interventions
DAPA Dutch Audit for Peripheral Artery Disease
DASA Dutch Acute Stroke Audit
DATO Dutch Audit for Treatment of Obesity
DBIR Dutch Breast Implant Registry
DCRA Dutch ColoRectal Audit
DGEA Dutch Gastroinestinal Endoscopy Audit
DGOA Dutch Gynaecological Oncology Audit
DHBA Dutch Hepato Biliary Audit
DHFA Dutch Hip Fracture Audit
DHNA Dutch Head and Neck Audit
DLCA Dutch Lung Cancer Audit
DMTR Dutch Melanoma Treatment Registry
DPCA Dutch Pancreatic Cancer Audit
DPIA Dutch Parkinson’s Insight Audit
DRCE Dutch Registration of Complications in Endoscopy
DSAA Dutch Surgical Aneurysm Audit
DSSR Dutch Spine Surgery Registry
DUCA Dutch Upper GI Cancer Audit
EPSA European Pediatric Surgery Audit
NBCA Nabon Breast Cancer Audit
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ABSTRACT
Background | quality registries play an important role in the professional quality 
system for cancer treatment in the Netherlands. This article provides insight into 
the Dutch Lung Cancer Audit (DLCA); its core principles, initiation and development, 
first results and what lessons can be learned from the Dutch experience.
Methods | cornerstones of the DLCA are discussed in detail, including: audit aims; 
the leading role for clinicians; web-based registration and feedback; data handling; 
multidisciplinary evaluation of quality indicators; close collaborations with all 
stakeholders in healthcare and transparency of results.
Results | in 2012 the first Dutch lung cancer specific sub-registry, focusing on surgical 
treatment was started. Since 2016 all major treating specialisms (lung oncologists, 
radiation-oncologists, general- and cardiothoracic surgeons – represented in the 
DLCA-L, -R and -S sub-registries respectively) have joined. Over time, the number 
of participating hospitals and included patients has increased. In 2016, the numbers 
of included patients with a NSCLC were 3502 (DLCA-L), 2427 (DLCA-R) and 1979 
(DLCA-S). Between sub-registries mean age varied from 66 to 70, occurrence of 
ECOG performance score 2+ varied from 3.3% to 20.8% and occurrence of clinical 
stage I-II from 27.6% to 81.3%. Of all patients receiving chemoradiotherapy 64.2% 
was delivered concurrently. Of the surgical procedures 71.2% was started with a 
minimal invasive technique, with a conversion rate of 18.7%. In 2016 there were 17 
publicly available quality indicators – consisting of structure, process and outcome 
indicators- calculated from the DLCA.
Conclusions | the DLCA is a unique registry to evaluate the quality of multidisciplinary 
lung cancer care. It is accepted and implemented on a nationwide level, enabling 
participating healthcare providers to get insight in their performance, and providing 
other stakeholders with a transparent evaluation of this performance, all aiming for 
continuous healthcare improvement.
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BACKGROUND
As in the rest of the world, in the Netherlands lung cancer is the leading cause of 
cancer related mortality.1,2 On a population of almost 17 million inhabitants, in 2016 
over 12,000 persons were diagnosed with primary lung cancer.2,3 Of these, the vast 
majority is Non-Small Cell Lung Cancer (NSCLC).
In the Netherlands, there is a national multidisciplinary evidence-based guideline 
on the diagnoses and treatment of NSCLC, which is revised about every 5 years. 
Despite this, in 2010, a study using population-based data from the Dutch Cancer 
Registry showed significant regional differences and between-hospital variation in 
treatment patterns and outcomes for patients with NSCLC and other malignancies, 
though reasons for these differences could hardly be identified.4 In order to improve 
the quality and equality of cancer care in the Netherlands, multidisciplinary quality 
standards were developed, by The Dutch Federation of Oncologic Societies.5 In 
these standards general and cancer specific requirements for optimal cancer care 
are described, including organisation of care, the presence of certain facilities and 
minimum volume standards.
At the same time, nationwide clinical audits – facilitated by the Dutch Institute for 
Clinical Auditing (DICA) – were introduced in the Netherlands. Clinical auditing is 
a process of systematic analysis of quality of healthcare, with the aim to improve 
patient outcomes. With a clinical audit system, guideline adherence, patient 
outcomes and other quality indicator results can be accurately studied and 
compared.
The first Dutch lung cancer-specific audit started in 2012 and was focussed on 
surgical treatment. Since then more specialties involved in lung cancer care have 
joined and nowadays quality of lung cancer care is evaluated multidisciplinary in the 
nation-wide Dutch Lung Cancer Audit (DLCA).
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This article provides insight into the DLCA; its core principles, initiation and 
development, first results and what lessons can be learned from the successful 
Dutch experience.
 
METHODS
Aim
The care for patients with lung cancer ideally takes place in a multidisciplinary 
setting, for both the diagnostic and treatment process. The DLCA therefore is a 
collaboration of multiple disciplines involved in the treatment of lung cancer. The 
aim of the DLCA is to evaluate the multidisciplinary care for lung cancer patients, 
with the potential to improve care processes and outcomes on a national level. 
Development 
The development of the DLCA was facilitated by DICA and design was in accordance 
with the DICA blueprint.6 In 2012 the first national quality registry on lung cancer 
was initiated, focussing on surgical treatment: the Dutch Lung Surgery Audit. 
In the Netherlands, lung surgery is performed by cardiothoracic surgeons and by 
general surgeons with a specialisation in lung surgery. Initially, mainly the hospitals 
with general surgeons participated in the audit, but from 2015 on all cardiothoracic 
centres joined as well. In 2014 a quality registry was launched focussing on the 
radiotherapeutic treatment of lung cancer: the Dutch Lung Radiotherapy Audit. 
As of 2016, in addition to these two registries, pulmonologists joined the audit. 
Therefore, from 2016 on the audit was renamed as the DLCA, with sub-registries for 
lung oncologists (DLCA-L), surgeons (DLCA-S) and radiation-oncologists (DLCA-R), 
together encompassing the whole care path of lung cancer patients in Dutch 
hospitals. 
The DLCA was developed in close collaboration with all relevant professional 
associations (the Dutch Society of Physicians for Lung Diseases and Tuberculosis 
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- NVALT, the Netherlands Association for Cardio-Thoracic Surgery - NvT, the Dutch 
Society for Lung Surgery - NVvL-NVvH and the Dutch Society for Radiotherapy and 
Oncology - NVRO).
Organisation
The organisational structure of the DLCA is visualised in Figure 1. Clinicians 
mandated by their professional association and a patient representative form a 
joint clinical audit board (CAB). The CAB is responsible for the development and 
progress of the complete audit. Overarching quality issues, interdisciplinary quality 
Figure 1. Organisational structure of DLCA. 
* L = lung-oncologists, R = radiotherapeutic-oncologists, S = surgical-oncologists. 
^ Medical Research Data Management.
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indicators and joined meetings are the responsibility of the board. In addition, 
the three sub-registries have their own scientific committee (SC), responsible for 
the content of the audit and participation of their colleagues in the institutions 
providing lung cancer care. In the CAB each SC is represented by its chairman. 
The audit is supported by the DICA scientific bureau, which in turn is backed by 
a methodological council and a privacy committee. The SC’s have approximately 
three separate meetings a year in which the datasets, results and future goals are 
discussed. The joint results and objectives are discussed in the CAB approximately 
twice a year.
Funding
The development and implementation of all DLCA sub-registries were project based. 
These projects were funded and executed via quality improvement grants from the 
federation of medical specialists (FMS – SKMS). Since 2017, the DLCA is completely 
financed by an umbrella organisation of ten healthcare insurance companies in the 
Netherlands (ZN). Apart from funding, these companies do not influence the DLCA 
organisation. Costs of data registration for participating hospitals are not centrally 
compensated.
Inclusion
The DLCA includes all patients with primary lung cancer of any stage. In addition, 
in the DLCA-S there are audit possibilities for patients undergoing surgery for other 
mediastinal diseases, lung metastasis or benign lung diseases. In the DLCA-L, 
besides primary lung cancer, there is also a minimal registration of patients with 
malignant mesothelioma and thymomas or thymic carcinoma. In the DLCA-R only 
patients with stage I-III disease, treated with curative intent, are included. In the 
DLCA-L and -S this selection does not apply.
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Dataset
The collected data is primarily based on established or future quality indicators – 
reflecting quality of care on a hospital level – and potential casemix factors one 
should account for in between-hospital comparisons. The International Consortium 
of Health Outcome Measurement (ICHOM) standard dataset was adopted as much 
as possible.7
Registered information for casemix adjustment includes baseline patient (e.g. age, 
gender, performance score) and tumour characteristics (e.g. disease stage and 
histology). The development of a suitable casemix model is subject of a separate 
methodology that is described elsewhere.8 Furthermore the registry includes items 
regarding processes of care (e.g. modalities used in the diagnostic process, time to 
treatment and evaluation of the patient in a Multi Disciplinary Team (MDT) meeting) 
and outcomes (e.g. short-term mortality, complications or toxicity, reinterventions 
and length-of-hospital-stay).
The content of the dataset is evaluated by the SC and can be adjusted on a yearly 
base.
Data collection and security
Data collection is preferably prospective and takes place through a secured web-
based survey system or via batches of data uploaded by the hospital. Data can 
be supplemented or modified online when needed, for instance when follow-
up information is available. An example of the web-interface of the DLCA-S 
data collection and feedback report is shown in Figure 2. Hospitals can decide 
themselves which method they prefer and who carries out data collection (for 
example: clinicians themselves or trained data-managers). For every hospital, the 
final responsibility for the completeness and correctness of collected data rests with 
a clinician. The ownership of the own data remains with the hospital. Current data 
dictionaries are freely available online.9
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Figure 2. Illustration: ‘What does the doctor see? 
Example of the web interface of the DLCA data collection (1), feedback reports (2) 
and authorisation portal for external transparency (3).
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There is a close cooperation with a data processor: Medical Research Data 
Management (MRDM) for data-collection, -encryption and safe storage. MRDM 
has a user agreement with all participating hospitals. A servicedesk is available by 
telephone or e-mail during working hours for all questions.
Data quality
Assurance of data quality takes place in multiple ways. One of these is the on-site 
verification of registered data in the (electronic) patient records of the hospital, by an 
independent third party. During the data verification, the completeness of patient 
inclusion by hospitals is checked, as well as the accuracy of the most important data 
on patient level. Verification takes place for the first time approximately 3 years 
after the start of the registry. Thus, a registry has to be more ‘mature’ for this data 
validity check. The data verification process and results of the DLCA-S verification 
in 2016, as well as other methods to assure data quality are described as a separate 
topic by Hoeijmakers et al.10
Auditing process
Feedback information is provided through weekly updated online reports, of 
which an example of the DLCA-S is shown in Figure 2. Participating hospitals can 
use these reports to continuously monitor their results compared to a national 
benchmark. DICA provides two types of online reports: ‘the basic report’ and ‘the 
indicator report’. The more unprocessed information on the treated population is 
displayed in the basic report and divided into different sections. The indicator scores 
are displayed in the indicator report, typically in funnel plots with 95% confidence 
intervals around the national average or a defined norm and adjusted for casemix 
factors when relevant.
Quality indicators and transparency
To reflect quality of care on a hospital level, quality indicators were developed. 
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Quality indicators primarily serve as information for healthcare providers (internal 
use). Clinicians thus play a leading role in the development and determination of the 
DLCA indicator sets.
Since quality information is also of interest for other parties in the Dutch healthcare 
system (e.g. insurance companies, patient federations, government), a part of the 
set is agreed to be of use as transparent information (external use or ‘transparency’). 
Indicators are tested on relevance, validity, reliability and feasibility.11 The decision 
whether an indicator is suitable for external use is made tripartite with mandated 
representatives from the SC and the external parties in Figure 1. In accordance with 
the Donabedian concept, indicator sets consist of structure, process and outcome 
indicators.12 Twice a year the content of indicator sets for public transparency is 
discussed between all relevant parties in a meeting facilitated by DICA’s scientific 
bureau.
Public transparency of hospital specific indicator scores follows a stepwise model: 
participation and structure indicators are released in the first year of the audit, 
process indicators in the second and outcome indicators in the third. External 
indicator scores are calculated after a ‘database-lock’ three months after expiry of 
the registration year. Hospitals are obliged to provide external parties with their 
external indicator scores. Hospital boards are facilitated to share this information 
with different stakeholders after the annual database lock through a web based 
authorisation portal facilitated by DICA, shown in Figure 2.
Statistical analysis
Information of all patients registered in the DLCA for primary lung cancer between 
1 January 2012 and 31 December 2016 (DLCA-R: 2014-2016, DLCA-L: 2016) was 
used for analysis. A minimum number of items per patient was required in order 
to consider a patient eligible for analysis. Descriptive statistics were used to assess 
patient, tumour and treatment characteristics for all analysable patients with a 
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NSCLC registered in the DLCA-L, -R or -S in 2016.
Statistical analyses were performed using SPSS (IBM SPSS Statistics for Macintosh, 
Version 23.0).
RESULTS
Growing participation in the DLCA
Figure 3 displays the development of the DLCA from 2012 on. The number of 
participating hospitals and included patients with a NSCLC increased over time. The 
participation of all cardiothoracic centres in the DLCA-S from 2015 on is also clearly 
visible in this figure.
Figure 3. Evolution of the DLCA. 
Number of participating hospitals and number of registered patients with NSCLC per sub-registry. 
* L = lung-oncologists, R = radiotherapeutic-oncologists, S = surgical-oncologists.
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With the more multidisciplinary character of the audit, the number of cooperating 
specialists in the DLCA CAB and SCs rose to 55 (representing five medical 
professional associations) and one patient representative.
Patient characteristics
In 2016, the total numbers of registered patients in DLCA-L, -R and -S were 
respectively 4544, 2883 and 2391. For the DLCA-L 4192 patients (92.3%) were 
considered eligible for analysis. For the DLCA-R and -S the number of analysable 
patients were 2767 (96.0%) and 2349 (98.2%) respectively.
Of these analysable patients, in DLCA-L 3502 (83.5%) were diagnosed with NSCLC. 
In the DLCA-R 2427 (87.7%) and in the DLCA-S 1979 (84.2%) NSCLC patients were 
included.
Patient and tumour characteristics of all patients with a NSCLC included in the 
DLCA in 2016 are shown in Table 1.1, stratified per DLCA sub-registry. As expected, 
there are differences in these characteristics between the sub-registries, with the 
surgically treated patients being younger, with better performance score and more 
frequently having a clinically stage I-II NSCLC.
Diagnostic characteristics
Of all analysable patients with NSCLC registered in the DLCA-L in 2016 (n = 3502), 
2867 (81.9%) had pathologically proven disease. Of these the majority was proven 
histologically (1566, 54.6%) (Table 1.2). Of all analysable patients with a NSCLC 
registered in the DLCA-R (n = 2427), 1230 (50.7%) had pathologically proven disease, 
703 (29.0%) did not and in 494 (20.4%) it was not recorded in the database (data not 
shown).
The most used invasive diagnostic, according to the DLCA-L, was endoscopic 
ultrasound, with 985 of 3502 (28.1%) undergoing an EUS and/or EBUS in the 
diagnostic work-up of a NSCLC (Table 1.2).
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Table 1.1. Patient and tumour characteristics of patients with a NSCLC in the DLCA -L, -R 
and -S in 2016.
[L]
(Total N = 3502)
[R]
(Total N = 2427)
[S]
(Total N = 1979)
N % N % N %
Age in years,
mean (± SD) [median]
68.9 (10.1) [70] 70.0 (9.5) [70] 66.4 (8.8) [67]
Age (years)
<60 604 17.2% 355 14.6% 436 22.0%
60-74 1819 51.9% 1240 51.1% 1177 59.5%
75+ 1079 30.8% 832 34.3% 366 18.5%
Gender       
Male 1998 57.1% 1392 57.4% 1079 54.5%
Female 1504 42.9% 1035 42.6% 900 45.5%
Performance score a       
ECOG 0-1 2378 67.9% 1494 61.6% 1604 81.1%
ECOG 2+ 729 20.8% 423 17.4% 66 3.3%
Unknown 395 11.3% 510 21.0% 309 15.6%
ASA b       
I-II  NA   NA  1187 60.0%
III+  NA   NA  603 30.5%
Unknown  NA   NA  189 9.6%
Lung function       
FEV1 c and DLCO d ≥80%* 454 13.0% 228 9.4% 550 27.8%
FEV1 c or DLCO d <80% 1659 47.4% 1184 48.8% 1223 61.8%
FEV1 c and DLCO d unknown 1389 39.7% 1015 41.8% 206 10.4%
Clinical stage e       
Stage I 689 19.7% 1265 52.1% 1050 53.1%
Stage II 278 7.9% 223 9.2% 558 28.2%
Stage III 588 16.8% 701 28.9% 263 13.3%
Stage IV 1239 35.4% NA 20 1.0%
Unknown 708 20.2% 238 9.8% 88 4.4%
a Performance score according to WHO or ECOG 
b American Society of Anaesthesiologists score 
c Forced Expiratory Volume in 1 second, percentage of expected 
d Diffuse Lung Capacity for Oxygen, percentage of expected 
e TNM7 staging 
* FEV1 and DLCO ≥80% or one of the values missing
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Table 1.2. Diagnostic and treatment characteristics of patients with a NSCLC in the DLCA-L 
in 2016 (N = 3502).
 N %
Diagnostic
Pathologic proven disease   
No 573 16.4%
Unknown 62 1.8%
Yes, with: 2867 81.9%
Histology 1566 54.6%
Cytology 899 31.4%
Unknown 402 14.0%
Invasive diagnostics^
Transthoracic punction^ 948 27.1%
EUS and/or EBUS^ 985 28.1%
Mediastinoscopy^ 228 6.5%
Molecular diagnostics
No / unknown 2129 60.8%
Yes 1373 39.2%
Which successful 1310 95.4%
Treatment
Treatment goal
Curative 1449 41.4%
Palliative with active anti-tumour treatment 901 25.7%
Palliative without active anti-tumour treatment 886 25.3%
Unknown 266 7.6%
Initial treatment plan (n = 2350)
Surgery (combined with other therapy) 615 26.2%
Radiotherapy (combined with other non-surgical therapy) 933 39.7%
Systematic treatment* only 618 26.3%
Different 145 6.2%
Unknown 39 1.7%
^ In case of the invasive diagnostic techniques, only the ‘yes’ option is shown, therefore the total does not 
add up to 100%. EUS: endoesophageal ultrasound, EBUS: endobronchial ultrasound. 
* Includes: chemotherapy, immunotherapy, targeted therapy.
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Treatment plan (DLCA-L)
Of all analysable patients with NSCLC registered in the DLCA-L in 2016 (n = 3502), 
the primary treatment goal was curative in 1449 patients (41.4%) and palliative in 
1787 patients (51.0%). In 266 patients (7.6%) information on the treatment plan is 
missing.
An active anti-tumour treatment (n = 2350) comprised of combinations of surgery, 
radiotherapy, chemotherapy, immunotherapy and targeted therapy. Surgery, 
whether or not combined with another treatment, was planned for 615 patients 
(26.2%). Radiotherapy, whether or not combined with another non-surgical 
treatment, was applied in 933 patients (39.7%). And another 618 patients (26.3%) 
were planned for systemic therapy only (Table 1.2).
Radiotherapy (DLCA-R)
Of all analysable patients with a (stage I-III) NSCLC undergoing radiotherapeutic 
treatment and registered in the DLCA-R (n = 2427), most were treated with 
Stereotactic Body Radiation Therapy (SBRT, n = 1294, 53.3%). Other patients were 
treated with conventional radiotherapy (296, 12.2%) or chemoradiotherapy (837, 
34.5%), of which 64.2% was delivered concurrently (Table 1.3).
Surgery (DLCA-S)
Of all analysable patients with NSCLC undergoing surgery and registered in the 
DLCA-S (n = 1979), 166 (8.4%) underwent a pneumonectomy, 1618 (81.8%) a (bi)
lobectomy, 55 (2.8%) an anatomic segment resection, 127 (6.4%) a subparenchymal 
resection and 13 (0.7%) did not undergo a resection. Most operations were started 
with a minimal invasive technique, video or robotic assisted resection (VATS or 
RATS): 1409 (71.2%), with a conversion rate of 18.7% (n = 263) (Table 1.4).
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Quality indicators
In Table 2 all quality indicators that are part of the externally transparent indicator 
sets in 2016, 2017 and 2018 are demonstrated. Also shown in Table 2 are the results 
of national quality indicators of 2016, with for all indicators the number of patients 
included in the indicator calculation (‘denominator’) and the percentage meeting 
the indicator definition (numerator divided by denominator). For the two volume 
indicators only the numerators are displayed.
Table 1.3. Treatment characteristics of patients with a NSCLC in the DLCA-R in 2016 
(N = 2427).
 N %
Type of radiotherapy   
Conventional 296 12.2%
SBRT* 1294 53.3%
Chemoradiotherapy 837 34.5%
Of which concurrent 537 64.2%
* SBRT = Stereotactic Body Radio Therapy
Table 1.4. Treatment characteristics of patients with a NSCLC in the DLCA-S in 2016 
(N = 1979).
 N %
Surgical approach   
VATS / RATS* 1409 71.2%
Converted to open 263 18.7%
Primary thoracotomy 479 24.2%
Different / unknown 91 4.6%
Resection type
Pneumonectomy 166 8.4%
(Bi)lobectomy 1618 81.8%
Anatomic segment resection 55 2.8%
Wedge / different 127 6.4%
No resection (open-close) 13 0.7%
* VATS: Video Assisted Thoracoscopic Surgery, RATS: Robot Assisted Thoracoscopic Surgery
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The structure indicator “completeness of data entry…” is scored ‘yes’ on patient 
level when all items required for calculating external indicators are registered and 
thereby gives an indication on the validity of other indicator results. In 2016, the 
average data completeness on patient level was 90.7% in the DLCA-S and 84.0% in 
the DLCA-R.
The percentage of patients with NSCLC discussed in a meeting prior to 
radiotherapeutic treatment was 95.1%. Of the surgically treated patients with a 
NSCLC, 97.1% was discussed in a postoperative MDT meeting, an increase of 15% 
compared to the 82.2% in 2012. 
Outcome indicator results are calculated over a period of two consecutive years. 
The national average 30-day/in-hospital mortality of patients after a resection for 
primary lung cancer was 2.3% in 2015-2016. The national average 90-day mortality 
of all patients treated with combined chemoradiotherapy for a primary NSCLC was 
6.4% in 2015-2016.
DISCUSSION
In the Netherlands, clinical audits are integrated as a part of the professional quality 
system. This report provides insight in the Dutch Lung Cancer Audit (DLCA), one of 
the first nationwide-implemented quality registries to evaluate the multidisciplinary 
care for patients with lung cancer worldwide. The DLCA was developed according 
to the blueprint of the Dutch Institute for Clinical Auditing, one of the leading 
organisations facilitating clinical auditing in the Netherlands. Although the audit 
in its current format is still ‘immature’ (with 2016 as the first registration year for 
lung oncologists), the core principles are clear. In this paper the first results were 
presented.
Several initiatives to monitor quality of (surgical) lung cancer care have been 
developed worldwide.13–18 The design and intents of these initiatives differ in various 
ways. 
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The DLCA distinguishes itself from other initiatives through; the central role 
of clinicians, weekly updated feedback information with national benchmark 
information, participation of all major treating specialisms, a centrally financed 
system and close collaboration with other parties in healthcare with tripartite 
agreements on data transparency. Furthermore, participation in the DLCA has been 
incorporated in the professional quality system, thereby stimulating nationwide 
implementation and unbiased information, in contrast with registries with a 
more voluntary nature. Implementation of evidence-based guidelines and quality 
standards is evaluated with the audit, on a local as well as a national level.
Design and implementation of the DLCA sub-registries has been a phased process. 
After independent data-verification of the surgical part of the audit, the data of 
the DLCA-S are considered mature and the data of the DLCA-R will follow soon. 
The pulmonologists joined the DLCA-L only recently and the number of analysable 
patients with NSCLC included in this sub-registry in 2016 is limited to 35-40 percent 
of the national incidence.2 It is expected that case ascertainment will rapidly increase 
over time, especially from the moment hospitals are provided with benchmarked 
feedback.6,19–21 The great incentive for clinicians to participate in the audit is the 
information they receive on the quality of their performance in clinical practice 
with indicator results benchmarked to the national average (intrinsic motivation). 
In addition, the Netherlands Healthcare Inspectorate demands participation in the 
audit, insurance companies use the audit information for reimbursement and the 
National Healthcare Institute demands indicator scores from the audit for public 
transparency, which makes participation more or less mandatory for hospitals 
(external stimulus).
In this first year of multidisciplinary collaboration in the DLCA, one of the biggest 
advantages experienced by all specialism was the opportunity to address overlapping 
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issues in the combined CAB and SC meetings and the quick implementation of new 
knowledge into national clinical practice. This has contributed to the implementation 
of TNM8 in the DLCA in 2017, only a few months after publication,22 leading to a 
nationwide in-hospital adoption of TNM8.
Sub-registries in themselves also provided important information already. DLCA-S 
data showed that national use of minimally invasive techniques (VATS/RATS) is 
high, around 70%. Internationally this percentage varies between 22-63%.23,24 
Postoperative mortality after primary lung cancer resection in the Netherlands 
has been as low as between 2.0 and 2.5% from the start of the DLCA-S. This is 
comparable to international data.23–26
An important issue that arose from the DLCA-S is the unfavourable quality of 
staging compared to for example Denmark.27,28 In the DLCA-S staging accuracy 
was assessed comparing clinical with pathological TNM stage, regardless of 
whether discrepancies influenced treatment strategy. This definition differs from 
Danish studies, which reported inaccuracy only if this had clinical consequences. 
Nevertheless, the DLCA studies demonstrated there is room for improvement in 
preoperative staging in the Netherlands. In the diagnostic path – leading to a clinical 
stage – pulmonologists play a major role. Hence, to improve pre-treatment staging, 
a multidisciplinary approach is essential.
The primary aim of clinical auditing is to improve outcomes for patients by providing 
meaningful, actable, benchmarked, short-cycled feedback information on daily 
clinical practice to the multidisciplinary teams in hospitals. Thereby stimulating 
improvement initiatives on both local and national level. Ultimately, quality 
assurance for the whole clinical care path of every lung cancer patient is intended. 
Therefore, the DLCA evolves from a procedure based mono-disciplinary audit to 
a condition based multidisciplinary audit, tracking patients from diagnosis until 
death.
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Simultaneously, a shift of focus on structural and process indicators towards 
outcome indicators, clinical as well as patient reported, is intended. The standard set 
for lung cancer of the International Consortium of Health Outcome Measurement 
(ICHOM) was adopted, to be able to participate in international comparisons in the 
near future. On the other hand, the DLCA is also a platform for clinicians themselves 
to develop new meaningful quality indicators. DICA’s well-respected agreement 
with external stakeholders on ‘stepwise’ transparency is imperative in this context, 
because it gives clinicians the opportunity to evaluate the validity of an indicator 
and its results, before hospital specific information is made public.
Initially, the idea was to set up the DLCA as a multidisciplinary audit in which 
multiple disciplines distributed over various hospitals could contribute to 
registration of one patient. Unfortunately, the construction of such a ‘chain registry’ 
has not been achieved yet. Largely, this is due to privacy legislation, causing 
difficulties in sharing patient data across different hospitals.29 Additionally, such 
a ‘chain registry’ needs clear agreements on who registers what and how, since 
part of the feedback information (including externally transparent indicators) will 
be based on information provided by a clinician one might not know. Taking into 
account the aforementioned issue of low case ascertainment in the novice DLCA-L, 
completeness of data – that should be relied on – is not guaranteed. Therefore the 
current design was chosen: 3 DLCA sub-registries (DLCA -L, -R and -S). This has the 
disadvantage that some information is repeatedly registered unnecessarily.
In extension to this, a general limitation of quality registries is the administrative 
burden associated with data collection, which frequently rests on the shoulders 
of clinicians themselves. Still, to evaluate the quality of all essential points in the 
patients’ care path a substantial amount of data is needed. In addition, proper 
casemix adjustments are imperative in between-hospital comparisons, for which 
a set of patient and disease characteristics has to be registered for each case. A 
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meaningful registration may be an administrative burden, though on the other 
hand reduces the obligations to provide less-meaningful – but externally imposed – 
indicators to other partners in healthcare (e.g. insurance companies).
One of the solutions to reduce administrative burden is (partly) automated data 
extraction from existing data sources (e.g. Electronic Patient Records (EPDs), 
structured reports of diagnostics, treatment or pathology). Being part of a larger 
platform, like DICA, can be an advantage in this, when close cooperation is sought 
between the registry platform, the data processor and hospital-IT-providers.
The main challenge of the DLCA in the (near) future is the integration of three 
separate sub-registries, the DLCA-L, -R and -S into one ‘chain registry’ system 
as described above. This integrated system facilitates registration of data by 
different disciplines and institutions in one patient record, thereby maximizing 
multidisciplinary quality evaluation possibilities and minimizing administrative 
burden of the registration.
In addition, there should be more focus on outcome indicators in the audit. Next 
to clinical outcomes, functional outcomes and quality of life are of great value for 
patients. Measuring such patient reported outcomes (PROMs) or patient reported 
experiences (PREMs) in daily practice can be challenging, especially low response 
rates can hamper valid comparisons between hospitals. Though, linkage of patient 
reported data to clinical data could provide clinicians with ‘new’ valuable information 
and can facilitate (shared) personalised treatment decisions.
In conclusion, with the start of the DLCA in 2016, there is a unique nationwide audit 
system to evaluate the quality of multidisciplinary lung cancer care. The DLCA is 
accepted and implemented on a nationwide level, enabling healthcare providers 
insight in their performance together with a national benchmark, and providing 
other stakeholders with a transparent evaluation of this performance. When 
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challenges of shared data input and access – mostly concerning privacy legalisation 
– are solved, the accomplishment of a completely integrated audit remains a main 
aspiration. The possibilities of multidisciplinary quality evaluation will be maximised 
further, with the highest aim of continuous healthcare improvement.
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ABSTRACT
Background | When comparing hospitals on outcome indicators, proper adjustment 
for casemix (a combination of patient and disease characteristics) is indispensable. 
This study examines the need for casemix adjustment in evaluating hospital 
outcomes for non-small cell lung cancer surgery.
Methods | Data from the Dutch Lung Cancer Audit for Surgery were used to validate 
factors associated with postoperative 30-day mortality and complicated course with 
multivariable logistic regression models. Between-hospital variation in casemix was 
studied by calculating medians and interquartile ranges for separate factors on the 
hospital level and the ‘expected’ outcomes per hospital as a composite measure.
Results | A total of 8040 patients, distributed over 51 Dutch hospitals, were included 
for analysis. Mean observed postoperative mortality and complicated course 
were 2.2% and 13.6%, respectively. Age, American Society of Anesthesiologists 
classification, Eastern Cooperative Oncology Group performance score, lung 
function, extent of resection, tumour stage, and postoperative histopathologic 
findings were individual significant predictors for both outcomes of postoperative 
mortality and complicated course. A considerable variation of these casemix 
factors among hospital populations was observed, with the expected mortality 
and complicated course per hospital ranging from 1.4% to 3.2% and from 11.5% to 
17.1%, respectively.
Conclusions | The between-hospital variation in casemix of patients undergoing 
surgical treatment for non-small cell lung cancer emphasizes the importance of 
proper adjustment when comparing hospitals on outcome indicators.
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INTRODUCTION
Lung cancer is the most common cause of cancer-related death in Europe and the 
United States.1 Upfront surgery is the cornerstone of curative treatment in patients 
with non-small cell lung cancer (NSCLC) stage I to II, which accounts for about 
one third of the clinical stages.2,3 Additionally, about 15% of patients with stage III 
disease are treated surgically, with or without (neo)adjuvant therapy.4
In 2012 the Dutch Lung Cancer Audit for Surgery (DLCA-S) was started.5,6 This 
nationwide, mandatory clinical registry includes all patients undergoing surgical 
treatment for lung cancer. The main purpose is to provide caregivers with feedback 
on quality of care and thus enable a national benchmark.
Interest in using outcome measures, such as mortality, as public information is 
increasing. To facilitate meaningful between-hospital comparisons, it is important 
to take the ‘casemix’ (a combination of patient and disease characteristics that 
displays disease burden) into account. A casemix factor can affect outcomes but is 
not part of the decision made for the specific intervention.
Previous studies investigated the effect of patient, disease, and treatment 
characteristics on outcomes in lung surgery, but they did not provide insight into 
whether hospitals differ in casemix and how this could influence outcomes of these 
hospitals.7–9
This study, in patients undergoing surgical treatment for NSCLC, aimed to:
1. Validate risk factors for ‘postoperative mortality’ and ‘complicated course’.
2. Examine differences in casemix between hospitals.
3. Develop a casemix adjustment model useful in practice for both outcome 
indicators.
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PATIENTS AND METHODS
Data source and study population
Data were derived from the DLCA-S.5 The database includes information on patient 
and tumour characteristics, diagnostic workup, surgical procedure, postoperative 
outcomes, and pathologic features. Data are collected through a secured Web-based 
system. Participating hospitals receive weekly updated feedback, benchmarked to 
the national average. In-hospital data verification by an independent third party 
is part of the evaluation cycle. The last verification, completed in July 2016, shows 
sufficient data quality, with 99.4% complete patient inclusion and 0.0% under-
registration of ‘postoperative mortality’ and ‘complicated course’.10
Patients undergoing NSCLC surgery between January 2012 and December 2016 
were included. Minimum data registry criteria –to be eligible for analysis – included 
information on age, sex, operation date, type of surgical procedure, and vital status 
30 days postoperatively or at the time of discharge.
Main outcomes
The outcomes assessed were postoperative mortality and complicated course. 
Postoperative mortality was defined as mortality within 30 days after surgical 
treatment or during the primary hospital admission. The composite measure 
postoperative complicated course was defined as a complication leading to a 
prolonged hospital stay (≥14 days),11 unplanned reintervention, or death, and it was 
used to reflect only severe complications.
Casemix factors
Selected casemix factors were determined on the basis of literature and expert 
opinion (DLCA-S Scientific Committee) and included the following: age; sex; 
comorbidities; previous thoracic surgical procedure; Eastern Cooperative Oncology 
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Group Performance Score (ECOG PS); American Society of Anesthesiologists (ASA) 
classification; lung function (forced expiratory volume in 1 second percentage 
of normal [FEV1%]; diffusing lung capacity for oxygen percentage of normal 
[DLCO%]); tumour, node, metastasis (TNM) stage (TNM7);2 primary or recurrent 
disease; induction therapy; extent of resection; and histopathologic findings.
Statistical analysis
The association of selected casemix factors on postoperative mortality and 
complicated course was investigated by two separate multivariable adjustment 
models. For this multivariable model, factors from univariable logistic regression 
(P<0.10) were selected after controlling for collinearity. Model discrimination was 
assessed by the C-statistic.
The effect of age was calculated as an increase per decade. Lung function was 
analysed as a composite measure of FEV1% and DLCO%, divided in three categories: 
(1) FEV1 and DLCO ≥80% or one of the values missing, (2) FEV1 or DLCO <80%, 
and (3) both FEV1 and DLCO values missing. These cut-off values are in accordance 
with the evidence-based Dutch guideline.3,12 Using a composite measure reduced 
the missing data on lung function from 20.2% (1628 of 8040) to 6.5% (521 of 
8040). Missing items were analysed as a separate group if they exceeded 5%, and 
subgroups of missing items ≤5% were excluded from logistic regression analyses.13
To study between-hospital variations in patient population, medians, interquartile 
ranges, and minimum and maximum values for selected patient and tumour 
characteristics were calculated on a hospital level.
Using coefficients from the multivariable model, ‘expected’ mortality was calculated 
per patient. On the basis of all patients in one hospital, the expected and observed 
mortality rate was calculated per hospital. The adjusted mortality per hospital 
was calculated as follows: (observed/expected)*mean. The same was done for 
postoperative complicated course.
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Because of statistical restriction of multivariable regression models, the number 
of events limits the number of casemix factors one can adjust for.14 When needed, 
models were restricted by selecting factors on the basis of expert opinion.
To minimize statistical artifacts resulting from small sample size, only hospitals that 
performed ≥20 parenchymal resections per year (the minimum volume standard 
according to the Association of Surgeons in The Netherlands)15 were included in the 
calculations for between-hospital variation.
Statistical significance was set at a threshold of 0.05, with p values calculated 
by two-sided tests. Statistical analyses were performed using SPSS (IBM SPSS 
Statistics for Macintosh, Version 23.0, IBM Corp, Armonk, New York).
RESULTS
Population characteristics
A total of 8040 patients, distributed over 51 hospitals, who underwent NSCLC 
surgical procedures were eligible for analyses. Baseline characteristics are 
displayed in Table 1. Median age was 67 years, and 56.1% (n = 4508) of patients 
were male. More than one half of all patients had clinical stage I (n = 4379; 54.5%). 
Lobectomy was the most commonly performed resection type (n = 6203; 77.2%). 
Most operations (5366; 66.8%) started using a minimally invasive technique, and 
787 (14.7%) were converted to thoracotomy.
The average postoperative mortality was 2.2% (n = 176). The average postoperative 
complicated course was 13.6% (n = 1094). The overall complication rate, regardless 
of complication severity, was 34.4% (n = 2763).
Predictors of postoperative mortality and complicated course
In 358 patients information on ASA classification (n = 285; 3.5%) or pathologic 
T-stage (n = 79; 1.0%) was missing. After excluding these patients, 7682 patients 
were included for univariable and multivariable logistic regression analyses.
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Table 1. Population characteristics. Hospitals: N = 51, patients: n = 8040
 N %
Age, y, median[IQR] 67[60 - 73]
Gender   
Male 4508 56.1 
ASA-classification   
I-II 5634 70.1 
III+ 2121 26.4 
Unknown 285 3.5 
ECOG PS   
0-I 6117 76.1 
II+ 314 3.9 
Unknown 1609 20.0 
Charlson comorbidity index   
0 2546 31.7 
1 2270 28.2 
2+ 3224 40.1 
Cardiac comorbidity a   
Yes 2135 26.6 
Lung function   
FEV1 and DLCO ≥80% b 2474 30.8 
FEV1 or DLCO <80% 5045 62.7 
FEV1 and DLCO unknown 521 6.5 
Primary tumour/ recurrence   
Primary c 7905 98.3
Recurrence 135 1.7
Induction   
No/unknown 7502 93.5 
Chemoradiotherapy 298 3.7 
Different d 228 2.8 
Urgency   
Elective 7726 96.1 
Urgent/acute e 197 2.4 
Unknown 117 1.5 
Approach
Minimally-invasive 5366 66.8
Primary thoracotomy 2640 32.8
Different/unknown 34 0.4
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Table 1. (continued)
 N %
Side   
Left 3475 43.2 
Right 4565 56.8 
Extent of surgery   
Pneumonectomy 641 8.0 
Bilobectomy 450 5.6 
Lobectomy 6203 77.1 
Segmentresection 151 1.9 
Wedge resection 495 6.2 
No resection 100 1.2 
Pathological stage f   
Stage I/occult 4258 53.0 
Stage II 2112 26.3 
Stage IIIa+ 1283 15.9 
Unknown 387 4.8 
Pathological T-stage f   
pT1a-b(/T0/Tis) 3215 40.0 
pT2a-b 3167 39.4 
pT3 1271 15.8 
pT4 308 3.8 
Unknown/Tx 79 1.0 
Pathological N-stage f   
N0 5816 72.3 
N1 1325 16.5 
N2 717 8.9 
N3 13 0.2 
Unknown 169 2.1 
Postoperative histopathology   
Adenocarcinoma 4762 59.2 
Squamous cell 2742 34.1 
Adenosquamous 105 1.3 
Different g 431 5.4 
a Missing was considered as ‘no’ 
b FEV1 and DLCO ≥80% or one of the values missing 
c Including second primary tumours 
d Chemotherapy/radiotherapy alone 
e Surgery performed <12 (urgent) <6 (acute) hours after indication 
f TNM7 
g Large-cell carcinoma and neuro-endocrine tumour
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Age, ASA classification, ECOG PS, lung function, extent of resection, pathologic 
T-stage, and histopathologic findings were individual significant predictors of 
postoperative mortality (Table 2). The C-statistic (95% confidence interval [CI]) of 
the model was 0.81 (0.77 to 0.84).
For postoperative complicated course, individual significant predictors were age, 
sex, ASA classification, ECOG PS, lung function, induction therapy, extent of 
resection, pathologic T-stage, and histopathologic findings (Table 2). The C-statistic 
(95% CI) of the model was 0.66 (0.64 to 0.68).
Between-hospital variation
After excluding hospitals performing <20 parenchymal resections per year, 6600 
patients across 37 hospitals were selected to analyse between-hospital variation in 
casemix characteristics. Of the 14 excluded hospitals, 11 stopped performing lung 
cancer surgery, and three hospitals were excluded on the basis of annual volume (on 
average seven, nine, and 19).
Considerable between-hospital variation in casemix was observed (Figure 1, 
Supplemental Table 1). For example, the proportion of patients with pathologic 
T-stage 3 to 4 was 10.3% in one hospital and 31.8% in another. Significant 
between-hospital variations were also seen in age 80+ years (0.5% to 16.7%), ASA 
classification III+ (6.5% to 65.2%), induction chemoradiotherapy (0% to 24.8%), and 
pneumonectomy (3.0% to 21.6%). Expected mortality and complicated course per 
hospital ranged from 1.4% to 3.2% and from 11.5% to 17.1%, respectively (Figure 
2a-b).
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Casemix adjustment in practice
With an event rate of postoperative mortality of 70 per 2 years, the casemix 
adjustment model – to be useful for audit purposes – had to be restricted to 
age, ECOG PS, ASA classification, extent of resection, pathologic T-stage, and 
histopathologic findings. Because of a higher event rate of complicated course (±435 
per 2 years), further restriction of the casemix adjustment model was not necessary.
In the DLCA-S, postoperative mortality and complicated course are evaluated over 
a 2-year period and are presented using funnel plots with 95% CIs. Depending on the 
expected outcome (representing the complexity of patient population per hospital) 
the adjusted percentage can be higher or lower than or equal to the observed 
percentage. This is demonstrated for complicated course in Figure 3.
Figure 1. Boxplot illustrating between-hospital variation of specific casemix characteristics of 
patients undergoing surgical treatment for NSCLC. Hospitals: N = 37, patients: n = 6600. 
 Hospital outside 95% C.I. 
 Hospital outside 99% C.I. 
|––| Hospitals within the 95% C.I. 
* CRTx = chemoradiotherapy
Age 80+ 
ASA III+ 
ECOG 2+
pT 3 - 4
Lung function < 80%
Induction with CRTx * 
Pneumonectomy
Squamous cell 
carcinoma
0% 20% 40% 60% 80%
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Figure 2. Scatterplots of the percentage of (a) expected mortality and (b) complicated course 
per hospital. Hospitals: N = 37, patients: n = 6600.
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COMMENT
Using a nationwide mandatory registry, this study emphasized the importance 
of casemix adjustment when benchmarking hospitals on outcome measures 
in NSCLC surgery. Age, ECOG PS, ASA classification, lung function, extent of 
resection, pathologic tumour stage, and histopathologic findings were confirmed as 
individual significant predictors for both postoperative mortality and complicated 
course. Postoperative complicated course was also influenced by sex and induction 
chemoradiotherapy. Considerable variation of casemix among hospital populations 
Figure 3. Illustration of a funnelplot with casemix adjustment in practice. 
X-axis: number of patients undergoing surgery per hospital (2015-2016). 
Y-axis: percentage complicated course per hospital (expected , observed , adjusted ). 
 = Based on: age, gender, ECOG PS, ASA-classification, lung function, induction therapy, 
extent of resection, pathological tumour stage and postoperative pathology. 
 = Calculated by: (observed/expected)*mean. 
A, B and C are examples of hospitals. The expected percentage of patients with a 
‘complicated course’ in hospital A is lower than the mean. Based on the selected casemix 
factors, this hospital has a less complex patient population. In the ‘adjusted’ calculation the 
denominator is smaller and the ‘adjusted’ becomes higher than the ‘observed’. The opposite 
applies to hospital C. The ‘expected’ in hospital B is similar to the national average so the 
‘observed’ and ‘adjusted’ values are equal. (CI = confidence interval.)
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was observed, with expected outcomes for mortality and complicated course 
varying, respectively, between 1.4% to 3.2% and 11.5% to 17.1%. Given the low 
event rate of mortality, for the casemix adjustment model to be usable for audit 
purposes it was restricted to age, ECOG PS, ASA classification, extent of resection, 
pathologic tumour stage, and histopathologic findings.
Risk stratification in lung (cancer) surgery is a popular topic that may have been 
studied in cohorts larger than the current study.7–9 However, the basis of the 
current study is a registry with mandatory participation for all Dutch hospitals, with 
resulting national complete coverage.5 Participation in other databases is usually on 
a voluntary basis and thus is prone to selection bias.
Previous studies focused on prediction for individual patients, but they did not 
study between-hospital differences in casemix, relevant for outcome adjustment. 
The current study adds this information, combined with practical implications of 
casemix adjustment in national audit data and benchmarking.
The observed unequal distribution of patients over Dutch hospitals in this study is 
not entirely unexpected, given the structure of oncologic care in The Netherlands 
and in line with similar studies on colorectal carcinoma.3,16 Factors associated 
with the postoperative outcomes in this study are comparable to those used in 
previous studies.7–9 In other studies, associated factors also included body mass 
index, dyspnoea grade, and steroid use. A one-on-one adoption of previous models 
on DLCA-S data was not possible because registered data items differ among 
databases.
In addition, casemix adjustment models intended for between-hospital quality 
of care comparison should include as few factors in the decisional pathway or 
attributable to hospital characteristics (e.g., case volume) as possible. If these factors 
are included in the adjustment model, the effect of what one wants to measure 
(quality of care delivered by the hospital) can be distorted or even nullified.17
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Extent of resection is shown to influence postoperative outcomes. The extent of 
resection partly depends on preoperative decisions of surgical teams or occasionally 
on preoperative events and hence is not purely a casemix characteristic. However, 
extent of resection was chosen as proxy measure because the used data set lacks 
information on central tumour location or extension into an adjacent lobe.
Similarly, one could state that ‘surgical approach’ (minimally invasive or open) is a 
proxy for complexity. However, whether a procedure is started and is successfully 
performed minimally invasively depends on correct patient selection by the (surgical) 
team and ultimately the team’s technical skills. Therefore, surgical approach was 
not included in the model.
From 2017 on, data on tumour location are registered. When this or other new 
information contributes to the casemix adjustment models, models will be taken 
into reconsideration.
Postoperative mortality is the most unfavourable event. Providing caregivers 
with insight into this outcome is of great importance. However, an event rate of 
2% means that in the largest-volume hospitals, with 160 resections per 2 years, 
about 3 patients die within 30 days or during primary admission. One can discuss 
whether this information lacks discriminative power for hospital comparison. In 
low-volume hospitals, outliers can be determined by chance and not by excellent 
or substandard performance. For this reason benchmark information is always 
provided with a 95% CI.
Because an inverse relationship between postoperative mortality and hospital 
volume was shown,18 it is also questionable whether a volume standard of 20 
resections is sufficient. However, the cut-off value for high-volume is unclear. 
Currently, the Association of Surgeons in The Netherlands visits hospitals 
structurally not complying with standards, as well as structurally underperforming 
hospitals. Additionally, the Dutch Health Care Inspectorate and the National Health 
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Care Institute monitor volume and quality standards. On indication, assistance for 
improvements is provided.
Composite measures, such as complicated course, typically have a higher event 
rate and can be more distinctive in hospital comparisons. Event rate can also be 
increased by extending the follow-up (e.g., 1-year mortality). However, this is less 
usable for audit purposes focused on enabling rapid insight and improvement 
of outcomes. Long-term follow-up is also more likely to be affected by other 
(nonsurgical) treatments. Other potential outcomes for quality of (surgical-
oncologic) care evaluation are resection completeness, disease recurrence, and 
patient-reported outcome measures. In this study, the outcomes postoperative 
mortality and complicated course were chosen to mainly reflect the quality of the 
(peri)surgical process.
Although casemix does influence postoperative outcomes and should be taken into 
consideration in quality of care comparisons among hospitals, it remains essential 
to provide caregivers with their own unadjusted data. Every adverse outcome, 
regardless of patients’ characteristics, should trigger opportunities to improve care 
processes.
A strength of this study is the large, national cohort that was investigated. 
National audit data enable analysis of information without patient selection such 
as in randomized studies with strict inclusion protocols and are therefore highly 
representative of current national practice.
On the downside, there may be less insight in patients who are falsely not registered 
or incorrectly registered. Therefore, in-hospital data verification by an independent 
third party is incorporated into the DLCA-S.10
Another limitation, related to (large) data sets in general, is missing data. Overall, 
the percentage of exclusion for the multivariable logistic regression resulting 
from missing data was considered acceptable (358 of 8040; 4.5%). Imputation to 
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handle missing data seemed less desirable because the study focused on practical 
implications of casemix adjustment in a national quality registration with weekly 
updated feedback and benchmark information. Techniques to handle missing 
data in this study were categorization of missing data in a separate subgroup and 
exclusion.13 Participating hospitals should be stimulated to register data that are as 
complete as possible.
Future research should focus on developing informative outcome indicators that 
provide caregivers with information to implement changes and simultaneously 
have sufficient discriminative power for hospital comparisons. Minimization of 
registration burden with maximized reliability and data quality should be another 
focus. Finally, if comparisons on an international level are made, consensus should 
be reached on what casemix adjustment model can be used best.
In conclusion, the large between-hospital variation in population demographics and 
disease burden of patients undergoing surgical treatment for NSCLC emphasizes 
the importance of proper casemix adjustment when comparing hospitals on 
outcome indicators.
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APPENDICES
Supplemental Table 1. Variation between hospital populations in casemix. Hospitals: N = 37, 
patients: n = 6600.
Between hospital comparison
Median IQR h Min - Max
Age 66 66 - 67 63 - 70
Age categories       
<60 21.8% 18.7% - 23.9% 14.0% - 34.2%
60-69 38.4% 35.3% - 40.7% 24.4% - 48.5%
70-79 34.5% 29.8% - 38.2% 24.5% - 46.0%
80+ 5.7% 4.5% - 6.9% 0.5% - 16.7%
Gender
 Male 56.2% 53.4% - 59.9% 40.5% - 65.9%
ASA a score
I-II 71.7% 65.4% - 77.1% 14.1% - 93.1%
III+ 27.2% 19.3%  34.1% 6.5% - 65.2%
ECOG score
0-I 88.2% 56.2% - 93.4% 2.8% - 100.0%
II+ 2.6% 1.8% - 6.2% 0.0% - 20.8%
Unknown 6.3% 1.5% - 41.9% 0.0% - 97.2%
Lung function       
FEV1 b and DLCO c ≥80% d 29.5% 27.2% - 35.1% 19.6% - 50.0%
FEV1 b or DLCO c <80% 64.6% 58.0% - 69.4% 40.9% - 77.5%
FEV1 b and DLCO c unknown 4.1% 2.4% - 6.0% 0.0% - 35.6%
Induction therapy       
No 95.4% 91.4% - 96.6% 68.8% - 100.0%
Chemoradiotherapy 2.5% 0.9% - 5.3% 0.0% - 24.8%
Different e 2.0% 1.1% - 3.4% 0.0% - 10.1%
Size of resection
Pneumonectomy 7.7% 6.5% - 9.5% 3.0% - 21.6%
Bilobectomy 5.1% 3.8% - 6.9% 2.0% - 10.6%
Lobectomy 77.1% 74.8% - 81.5% 62.2% - 87.2%
Segmentresection 1.1% 0.0% - 2.5% 0.0% - 10.5%
Wedge resection 4.8% 2.7% - 7.8% 0.0% - 20.4%
No resection 0.9% 0.0% - 1.6% 0.0% - 5.0%
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Supplemental Table 1. (continued)
Between hospital comparison
Median IQR h Min - Max
Pathologic T-stage f       
≤pT2 80.4% 77.5% - 83.1% 65.7% - 89.7%
pT3-pT4 19.6% 15.6% - 22.3% 10.3% - 31.8%
 Postoperative histology       
Adenocarcinoma 58.7% 55.2% - 63.6% 43.9% - 71.0%
Squamous cell 33.5% 30.5% - 38.0% 20.0% - 51.5%
Different g 6.4% 4.3% - 8.0% 1.4% - 11.7%
a American Society of Anaesthesiologists score 
b Forced Expiratory Volume in 1 second, percentage of expected 
c Diffuse Lung Capacity for Oxygen, percentage of expected 
d FEV1 and DLCO ≥80% or one of the values missing 
e Chemotherapy or radiotherapy alone 
f TNM7 staging 
g Adenosquamous or large-cell carcinoma 
h Interquartile range
Supplemental Table 2. Abbreviations and acronyms.
ASA = American Society of Anaesthesiologists
CI = Confidence Interval
DICA = Dutch Institute for Clinical Auditing
DLCA-S = Dutch Lung Cancer Audit for Surgery
DLCO% = Diffusing Lung Capacity for Oxygen percentage of normal
ECOG PS = Eastern Cooperative Oncology Group Performance Score
FEV1% = Forced Expiratory Volume in 1 second percentage of normal
IQR = Inter Quartile Range
NSCLC = Non-Small Cell Lung Cancer
OR = Odds Ratio
PART II
VARIATION IN
MULTIDISCIPLINARY
CANCER TREATMENT

CHAPTER 5
Pneumonectomy for lung cancer treatment 
in the Netherlands: between-hospital variation 
and outcomes
N. Beck, T.J. van Brakel, H.J.M. Smit, D. van Klaveren, M.W.J.M. Wouters,
W.H. Schreurs
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ABSTRACT
Background | Pneumonectomy in lung cancer treatment is associated with 
considerable morbidity and mortality. Its use is reserved only for patients in whom 
a complete oncological resection by (sleeve) lobectomy is not possible. It is unclear 
whether a patients’ risk of receiving a pneumonectomy is equally distributed. This 
study examined between-hospital variation of pneumonectomy use for primary 
lung cancer in the Netherlands.
Methods | Data from the Dutch Lung Cancer Audit for Surgery from 2012-2016 was 
used to study the use of pneumonectomy for primary lung cancer in the Netherlands. 
Using multivariable logistic regression, factors associated with pneumonectomy 
use were identified and the expected number of pneumonectomies per hospital was 
determined. Subsequently the observed/expected-ratio (O/E-ratio) per hospital was 
calculated to study between-hospital differences.
Results | Of the 8,446 included patients, 659 (7.8%) underwent a pneumonectomy 
with a mean postoperative mortality of 7.1% (n = 47). Factors associated 
with receiving a pneumonectomy were age, gender, cardiac and pulmonary 
comorbidities, tumour side, size and histopathology. The pneumonectomy use 
in the Netherlands varied considerably between hospitals (IQR 5.5-10.1%). Three 
hospitals out of 51 performed significantly less pneumonectomies than expected 
(O/E-ratio<0.5) and three significantly more (O/E-ratio>1.7). In the latter group 
severe complications were more frequent, taking other influencing factors into 
account (OR 1.51, 95%-CI 1.05-2.19).
Conclusions | There is a considerable between-hospital variation in pneumonectomy 
use in lung cancer treatment. To further optimise surgical lung cancer care we 
suggest centre specific feedback on pneumonectomy use and the development of a 
risk-adjusted pneumonectomy indicator.
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INTRODUCTION
Anatomical parenchymal resection is the cornerstone in curative treatment for 
primary lung cancer. In certain cases a complete oncologic resection cannot be 
obtained by a (sleeve) lobectomy and a pneumonectomy is considered the resection 
of choice. However, pneumonectomy is associated with considerable postoperative 
morbidity and mortality compared to less extensive resections and is an individual 
predictor of these negative outcomes.1–5 Reduction in adverse outcomes of lung 
surgery may therefore be achieved by decreasing the number of pneumonectomies.
Several nationwide registries reported on the national pneumonectomy use.6–12 
Although the optimal target proportion of pneumonectomies is unclear and partly 
depends on casemix, differences in the threshold at which a pneumonectomy is 
performed may identify improvement potential. As suggested by Jakobsen et al. 
the proportion of pneumonectomies could eventually function as a quality indicator 
in surgical lung cancer care.6
To apply such a quality indicator, between-hospital variation in pneumonectomy use 
and possibilities for proper casemix adjustment first need to be studied. Therefore, 
the aim of this study was to investigate between-hospital variation in the use and 
outcomes of pneumonectomies for primary lung cancer in the Netherlands and to 
identify factors associated with pneumonectomy use
METHODS
Data source and study population
Data was derived from the Dutch Lung Cancer Audit for Surgery (DLCA-S).13 The 
DLCA-S is a nationwide mandatory registry including all patients undergoing 
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surgery for lung cancer and is part of the multidisciplinary Dutch Lung Cancer Audit 
(DLCA), in which all major treatment disciplines evaluate care.13
In the DLCA-S, data are collected on hospital level. Distinction on individual 
surgeon level is not possible. In cases of a surgeon operating in different hospitals, 
the procedure is attributed to the hospital where it was performed. Collected data 
includes information on patient- and tumour characteristics, diagnostic work-up 
(e.g. discussion in a multidisciplinary meeting), surgical procedure, postoperative 
outcomes and pathology.14 Independent on-site data verification processes are 
used to ensure data quality.15 From 2015 on there is a 100% coverage of NSCLC 
resection registration.14
For this study, no ethical approval or informed consent was required under Dutch 
law.
Patients with a primary lung cancer resection between January 2012 and December 
2016 were included. Minimum data registry criteria to be eligible for analyses 
included: age, gender, operation-date, type of surgery, tumour side, postoperative 
histology and vital status 30 days after surgery and/or at time of discharge.
Wedge excisions were excluded for the analysis of anatomical resections, since 
these are considered oncologically insufficient. Primary lung cancer comprised a 
postoperative histology of: adenocarcinoma, squamous cell carcinoma, carcinoid, 
large cell carcinoma, small cell carcinoma and non-small cell carcinoma not 
otherwise specified.
Population characteristics and main outcomes
Analysed patient characteristics were: age at time of surgery, gender, lung function, 
ECOG performance status and ASA-classification. Preoperative lung function was 
analysed as a composite measure of FEV1% (forced expiratory volume in 1 second 
percentage of normal) and DLCO% (diffusing lung capacity for oxygen percentage 
of normal), in three categories: FEV1% and DLCO% ≥ 80% or one of the values 
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not-registered (1), FEV1% or DLCO% < 80% (2) and both FEV1% and DLCO% not-
registered (3). These cut-off values are in accordance with the evidence-based 
Dutch guideline.16,17
Disease characteristics and pre-surgical treatment characteristics were: tumour 
side, induction therapy (none/unknown, chemotherapy, radiotherapy and 
chemoradiotherapy), tumour stage (according to the 7th edition of the TNM staging 
system) and postoperative histology.
The outcomes assessed were postoperative mortality and postoperative 
complicated course. Postoperative mortality was defined as mortality within 30 days 
after surgery or during the primary hospital admission. Postoperative complicated 
course was defined as any complication leading to prolonged hospital stay (≥14 
days), unplanned re-intervention or mortality, and was used to reflect only severe 
complications.
Between-hospital variation in applying pneumonectomy
Between-hospital variation in applying pneumonectomy was studied by comparing 
the observed with the expected number of pneumonectomies per hospital. With 
a multivariable logistic regression model, after controlling for collinearity, patient 
and tumour characteristics associated with the risk of undergoing pneumonectomy 
were identified. Discriminative ability of the model was assessed by area under the 
ROC-curve (AUC).
Subsequently, by using the coefficients of this multivariable model the expected 
‘pneumonectomy risk’ per patient was calculated, which in turn was used to 
calculate the expected number of pneumonectomies on hospital level. Then, by 
dividing the number of observed by the number of expected pneumonectomies 
per hospital, the observed/expected-ratio (O/E-ratio) was calculated per hospital. 
An O/E-ratio >1 indicates that the hospital performed more pneumonectomies than 
expected based on the hospital population, whereas an O/E-ratio <1 indicates a 
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lower pneumonectomy use than expected. Between-hospital variation in O/E-ratio 
was displayed using a funnel-plot, with 95% confidence intervals (95%-CI)18.
Hospital characteristics (e.g. case volume or type of hospital) were not included 
in the model since the chance of undergoing a pneumonectomy or a different 
resection type should not depend on that. If these factors would be included in the 
model, the effect can be distorted or even nullified.19
Pneumonectomy/sleeve-resection-ratio
From 2015 on, the DLCA-S contains information on sleeve-resections. Hypothesizing 
that sleeve-lobectomies and pneumonectomies are performed in similar patient 
populations, a ratio between these two operation types could demonstrate 
differences in preference of indication per hospital.
Statistical significance was set at a threshold of 0.05, with P values calculated 
by two-sided tests. Statistical analyses were performed using SPSS (IBM SPSS 
Statistics for Macintosh, Version 23.0).
RESULTS
Population characteristics
A total of 8446 patients underwent a primary lung cancer resection and were eligible 
for analyses. Of these, 659 (7.8%) underwent pneumonectomy, 7226 (85.6%) (bi)
lobectomy or anatomical segment-resection and 561 (6.6%) wedge-excision.
After excluding the wedge-excisions, 7885 patients with an anatomical resection 
remained, of which 8.4% (659) underwent pneumonectomy. These 7885 patients 
were divided over 51 hospitals, with a mean number of patients per hospital of 155, 
SD 97, range: 8-377.
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Of patients with an anatomical resection, mean age was 66 years, 55.7% was male 
(n = 4395), 76.6% had an ECOG performance score 0-1 (n = 6040), 70.9% had an ASA 
score I-II (n = 5587), 6.3% received induction therapy (n = 498), 43.1% had a left-sided 
tumour (n = 3399), 81.5% had a pathological stage ≤II (n = 6421) and 55.2% had an 
adenocarcinoma (n = 4352).
Table 1 displays the characteristics of all patients undergoing pneumonectomy. 
Compared to the total anatomical resection group, pneumonectomies were 
performed in slightly younger patients, more often of male sex, in more advanced 
disease stages, left-sided tumours and squamous cell carcinomas.
Of all anatomical resections 5.3% (n = 417) was performed in hospitals with less 
than 20 resections a year (low volume considering the minimum annual volume 
standards set by the Association of Surgeons in the Netherlands), 56.0% (n = 4416) 
in hospitals with 20 to 49 resections a year, and 38.7% (n = 3052) in hospitals with 
50 or more resections a year. The percentage of pneumonectomies in these three 
hospital volume categories were respectively 8.9%, 7.9% and 8.9%.
Factors associated with pneumonectomy
Age, gender, cardiac and pulmonary comorbidities, tumour side, clinical tumour 
stage (cT) and histopathology are individual factors significantly associated with 
receiving a pneumonectomy (Table 2). The discriminative ability of a multivariable 
model with these factors was fairly-good (AUC); 0.80, 95%-CI 0.78-0.82.
Supplemental Figure 1 visually demonstrates the association between cT and 
histopathology and the pneumonectomy-proportion.
Between-hospital variation
The use of pneumonectomy as an anatomical resection for primary lung cancer per 
hospital ranged from 0.0 to 25.3% (national mean 8.4%). Fifty per cent of hospitals 
(Inter Quartile Range – IQR) performed a pneumonectomy in 5.5-10.1% of their 
patients.
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Table 1. Population characteristics and postoperative outcomes of patients with primary lung 
cancer undergoing an anatomical parenchymal resection, stratified for resection type.
Pneumonectomy (Bi)lobectomy and 
segmentectomy
 N % N % P value
Of total anatomical 
parenchymal resections
659 8.4% 7226 91.6% -
Gender <0.001
Male 452 68.6% 3943 54.6%  
Female 207 31.4% 3283 45.4%  
Age mean [median] (±SD) 65 [66] (±8.8) 66 [67] ± 9.4
Age (years) <0.001
<60 143 21.7% 1681 23.3%  
60-64 144 21.9% 1256 17.4%
65-69 143 21.7% 1491 20.6%
70-74 145 22.0% 1433 19.8%  
75+ 84 12.7% 1365 18.9%
Lung function  
FEV1% and DLCO% ≥80% 173 26.3% 2358 32.6% 0.004
FEV1% or DLCO% <80% 443 67.2% 4439 61.4%  
Unknown 43 6.5% 429 5.9%
Performance scorea 0.063
< 2 489 74.2% 5551 76.8%  
≥ 2 35 5.3% 260 3.6%  
Unknown 135 20.5% 1415 19.6%  
ASA score 0.323
I-II 451 68.4% 5136 71.1%  
III+ 186 28.2% 1847 25.6%  
Unknown 22 3.3% 243 3.4%  
Side 0.001
Left 408 61.9% 2991 41.4%  
Right 251 38.1% 4235 58.6%  
Induction therapy <0.001
No 589 89.4% 6798 94.1%  
Chemoradiotherapy 31 4.7% 265 3.7%  
Chemotherapy 1 0.2% 137 1.9%  
Radiotherapy 38 5.8% 26 0.4%  
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Table 1. (continued) 
Pneumonectomy (Bi)lobectomy and 
segmentectomy
 N % N % P value
Pathological stage <0.001
Stage I and occult 107 16.2% 4155 57.5%  
Stage II 266 40.4% 1893 26.2%
Stage III+ 255 38.7% 939 13.0%  
Unknown 31 4.7% 239 3.3%  
Pathological T-stage <0.001
T1 (T0, Tis, Tx) 89 13.5% 3087 42.7%  
T2 274 41.6% 2915 40.3%  
T3 214 32.5% 1048 14.5%  
T4 80 12.1% 152 2.1%  
Unknown 2 0.3% 24 0.3%  
Postoperative histology <0.001
Adenocarcinoma 189 28.7% 4163 57.6%
Squamous cell 410 62.2% 2194 30.4%
Differentb 60 9.1% 869 12.0%
Postoperative mortalityc 47 7.1% 123 1.7%
a Performance score using ECOG / WHO 
b Different: SCLC, carcinoid, adenosquamous, large cell (NET) and not otherwise specified 
c Defined as postoperative 30-day or in-hospital mortality
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Table 2. Factors associated with receiving a pneumonectomy. Number of patients included: 
N = 7885.
Resection using pneumonectomy
Unadjusted* Adjusted**
OR^ 95% CI^ OR^ 95% CI^
Age
<60 ref    ref    
60-64 1.35 1.06 - 1.72 1.16 0.89 - 1.50
65-69 1.13 0.89 - 1.44 0.88 0.67 - 1.14
70-74 1.19 0.93 - 1.51 0.81 0.62 - 1.06
75+ 0.72 0.55 - 0.96 0.47 0.34 - 0.64
Gender         
Male ref    ref    
Female 0.55 0.46 - 0.65 0.72 0.60 - 0.87
Cardiac comorbidity         
No ref    ref    
Yes 0.74 0.61 - 0.90 0.75 0.60 - 0.92
Pulmonary comorbidity         
No ref    ref    
Yes 0.75 0.63 - 0.89 0.69 0.57 - 0.83
Lung function
FEV1 a or DLCO b ≥80% ref NA
FEV1 and DLCO <80% 1.36 1.13 - 1.63 NA
FEV1 and DLCO unknown 1.37 0.96 - 1.94 NA
Side of tumour
Left ref    ref    
Right 0.44 0.37 - 0.51 0.43 0.36 - 0.52
Clinical T-stage c         
≤ T1 ref    ref    
T2 3.54 2.76 - 4.54 2.86 2.21 - 3.69
T3 8.23 6.36 - 10.64 6.75 5.18 - 8.80
T4 15.51 10.94 - 21.98 14.74 10.20 - 21.30
Unknown 4.08 2.75 - 6.04 3.78 2.52 - 5.65
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Between-hospital variation remained after adjustment for relevant factors (Figure 
1). Out of 51 hospitals, three performed significantly more pneumonectomies than 
expected (O/E-ratio>1.7) Three performed significantly less pneumonectomies than 
expected, with an O/E-ratio<0.5 the percentage of pneumonectomies performed is 
>50% less than expected. All six hospitals were middle sized non-academic centres.
After adjustment for relevant factors,5 there were no significant differences in 
postoperative mortality and complicated course after a pneumonectomy performed 
in the three hospitals with more pneumonectomies (71 patients included) compared 
to the three hospitals with less pneumonectomies (19 patients included) than 
expected (mortality: OR 0.28, 95%-CI 0.05-1.45, complicated course: OR 1.42, 95%-
CI 0.40-5.05).
When considering all anatomical resections, there were significantly more 
patients with a postoperative complicated course in the three hospitals with more 
pneumonectomies (430 patients included) compared to the three hospitals with 
less pneumonectomies (557 patients included) than expected (OR 1.51, 95%-CI 1.05-
Table 2. (continued) 
Resection using pneumonectomy
Unadjusted* Adjusted**
OR^ 95% CI^ OR^ 95% CI^
Postoperative histology         
Adenocarcinoma ref    ref    
Squamous cell carcinoma 4.12 3.44 - 4.93 3.58 2.94 - 4.35
Different d 1.52 1.13 - 2.06 1.49 1.09 - 2.03
a Forced Expiratory Volume in 1 second, percentage of expected 
b Diffuse Lung Capacity for Oxygen, percentage of expected 
c According to TNM 7 staging 
d Adenosquameus or large cell carcinoma 
* Univariable 
** Multivariable 
^ OR = odds ratio, CI = confidence interval. A confidence interval excluding 1.00 indicates statistical 
significance
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2.19), after adjustment for relevant factors. There was no significant difference in 
postoperative mortality between these groups (OR 0.66, 95%-CI 0.28-1.54).
From 2015 on, the DLCA-S contains information on sleeve-resections. Subgroup 
analysis of resections between 2015-2016 showed wide variation in the 
pneumonectomy/sleeve-resection-ratio per hospital (Figure 2). Eight hospitals 
performed no sleeve-resection and up to 10.9% pneumonectomies. Two hospitals 
performed up to 7.7% sleeve-resections and no pneumonectomies.
Figure 1. Funnel-plot of between-hospital variation in the use of pneumonectomy (2012-2016). 
* O/E-ratio: observed number of pneumonectomies divided by expected^ number of 
pneumonectomies. 
** O = E: the observed number equals the expected^ number of pneumonectomies. 
^ Expected number of pneumonectomies per hospital based on hospital population 
characteristics (age, gender, cardiac and pulmonary comorbidity, side of malignancy, clinical 
T-stage, histopathology). 
Number of hospitals included N = 51, number of patients included n = 7885.
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Figure 2. Scatter of P/S-ratio* per hospital (2015-2016). 
* P/S-ratio = number of pneumonectomies devided by number of sleeve resections per 
hospital. Number of hospitals included N = 42, number of patients included n = 3790.
COMMENT
This study is the first to report on both the national practice of pneumonectomy 
use and between-hospital variation by using Dutch nationwide registry data with 
centre-specific information. Considerable between-hospital variation exists in the 
use of pneumonectomy for primary lung cancer in the Netherlands, even after 
adjustment for patient- and disease characteristics.
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National variation
In the current study, age, gender, cardiac and pulmonary comorbidities, tumour 
side, cT and histopathology were individual factors significantly associated with 
receiving a pneumonectomy. This is in line with previous studies, although the 
current study was the first to perform multivariable analyses.20,21
Between-hospital variation in pneumonectomy use in the Netherlands ranged 
from 0.0-25.3% (IQR: 5.5-10.1%). After adjustment for relevant factors, out of 51 
hospitals, three hospitals performed significantly more and three significantly 
less pneumonectomies than expected based on predetermined patient-/disease 
characteristics. 
The proportion of severe postoperative complications was higher in the hospitals 
with significantly more pneumonectomies. There were no significant differences 
in postoperative mortality between the hospitals performing significantly more or 
significantly less pneumonectomies. However, pneumonectomy-related mortality 
and morbidity often expresses beyond the 30-day follow-up period,1,8,10 thus the 
outcomes reported in this study could be an underestimation. 
The existence of between-hospital variation suggests that for individual patients 
the risk to receive a pneumonectomy, and its related morbidity, could depend on 
the hospital of choice. Pneumonectomies may be performed on lower thresholds 
in some hospitals whereas others might perform sleeve-lobectomies or no 
resection at all. Off course one cannot simply assume that every sleeve-resection 
is an averted pneumonectomy, however the varying pneumonectomy/sleeve-
resection-ratio does indicate that considerations per hospital vary. The proportion 
of pneumonectomies per hospital might also be influenced by the availability of 
alternative treatment strategies (e.g. chemo(radiotherapy) instead of surgery in 
T3/T4-tumours) or the preference of local multidisciplinary teams. Whether referral 
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patterns or patient preferences influence the between-hospital differences could 
not be studied, since this data was not available from the DLCA-S. However, the fact 
that all six ‘outlying’ hospitals are medium-sized non-academic centres lowers the 
presumption of referral bias. In addition, potential bias was reduced by the casemix 
adjustment.
Unlike previous literature and the intuitive expectation that centres with a 
high pneumonectomy proportion would have better post-operative outcomes 
after a pneumonectomy, in this study no significant differences were observed 
in postoperative mortality and complicated course after a pneumonectomy 
performed in hospitals with a high versus low pneumonectomy proportion. This 
could suggest that high pneumonectomy proportions are rather an expression of 
varying treatment considerations per hospital than the result of referral to expertise 
centres. It can also be hypothesised that higher pneumonectomy percentages 
could be the result of more unplanned pneumonectomies due to intra-operative 
complications or a pre-operatively underestimated tumour stage.
Centralisation of care
In the past years the number of hospitals providing surgical lung cancer care declined 
from 79 in 2005 to 43 hospitals in 2015, signifying a 45% reduction.14,22 In the current 
study there were 42 hospitals performing sleeve resections or pneumonectomies 
in 2015-2016. In this period there were 30 hospitals performing between 1 and 10 
sleeve resections and 28 hospitals performing between 1 and 10 pneumonectomies. 
Although a considerable centralisation has been achieved, a further centralisation 
might be necessary for the technically difficult or high-risk procedures as sleeve 
resections or pneumonectomies, since it is know that volume could influence 
surgical outcomes.23
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International comparison
The pneumonectomy proportion in the Netherlands (7.8%) is lower than most 
European countries (7.4-19.6%), but higher than the United States (4.8%) 
(Supplemental Table 1).6–12 A pneumonectomy proportion as high as 34.6% 
was reported by a regional cohort study from the Netherlands (1984-1992).24 
More historical English and Danish registry data show significant decrease in 
pneumonectomy proportion over time.6,7 The study by Jakobsen et al. reports a 
national decrease from 23% to 11% (2000-2007).6 Postoperative mortality after 
pneumonectomy in the Netherlands (7.1%) is similar to other European countries 
(5.9-8.0%), but slightly higher than the United States (4.9%). 
Making these international comparisons, one should keep in mind that studied 
populations differ. The Society of Thoracic Surgeons - General Thoracic Surgery 
Database (GTSD) and the European Society of Thoracic Surgeons GTSD data not 
only included resections for primary lung cancer (87.0-94.5%), but also for metastasis 
(1.9-4.5%) and benign diseases (3.6-3.8%).20 Besides, the Dutch population is 
older, less frequently treated with induction therapy and tumour (pT) stage is less 
frequently missing, though comparable to European and American populations.9,20
Although there are previous studies reporting on the national pneumonectomy 
proportion and regional variation, this study is the first to report between-hospital 
variation. What also distinguishes the current study from previous ones is the way 
data is collected and used, influencing data quality, completeness and analytic 
possibilities. Data for this study was collected using a national prospective audit 
system.13,25 The audit itself is designed and maintained by clinicians, therefor 
including clinically most relevant information. Clinicians receive weekly updated 
feedback information, thereby enhancing data quality. Participation in the 
audit is incorporated in the professional quality system and registered data are 
regularly checked by external data verification, thereby stimulating unbiased 
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information. This is in contrast with registries with a more voluntary nature or a pure 
retrospectively registration.
Study limitations
A limitation of the DLCA-S is that it does not provide information on non-operated 
patients, thus resection rates cannot be calculated, nor could the indication for (not) 
operating be studied. In accordance with English and Danish registry data,6,7 another 
study showed an increasing lung cancer resection rate in the Netherlands.26 This, 
together with stable pneumonectomy rates and population characteristics during 
the existence of the DLCA-S, suggests that the relatively low pneumonectomy 
proportion in the Netherlands is not due to risk-averse behaviour. The DLCA-S data 
2012-2016 did not provide information whether a tumour is centrally located or 
extends beyond fissures. This is registered from 2017 onwards. Proxy information 
used in this study are tumour (T-) stage and histopathology, since squamous cell 
carcinoma is more often centrally located.27 Also, the DLCA-S does not provide 
information on the percentage of aborted procedures stratified by the extent of 
surgery. A probably underestimated percentage of 1.2% of all patients undergoing 
surgery for NSCLC in the DLCA-S with no resection in the end is reported previously.5
Due to differences in definitions (e.g. mortality) and applied in- and exclusion 
criteria, it is challenging to generate true international comparisons. Consensus on 
key data items therefore should be a shared objective.
Future perspectives
Awareness among caregivers on pneumonectomy use in practice can increase by 
providing benchmarked information regarding the pneumonectomy proportion per 
hospital in indicator format. 
National data can be used to evaluate current clinical practice and trigger 
improvement initiatives. In colorectal cancer surgery for example, data from the 
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clinical audit led to a modification of the national guideline adjustment and leading 
to remarkable changes in clinical practice.28
In addition, indicator results and between-hospital variation can be used to 
support a more solid quality of care discussion. Adjustment for patient-/disease 
characteristics can place this information in context.
The DLCA-S scientific committee will work towards providing caregivers with 
this information. Since a pneumonectomy remains necessary to obtain complete 
oncologic resection in certain cases a percentage of 0.0 pneumonectomies is 
not aspired. What the ideal ‘target’ pneumonectomy proportion would be is not 
yet clear. This will be subject of debate for the DLCA-S scientific committee and 
affiliated professional associations. Another point of discussion will be whether 
further concentration of high-risk procedures into expertise centres (with 
expertise in sleeve-resections, high-volume and optimal post-operative care) may 
be beneficial. Organizing this optimal care, equally accessible to all patients, is a 
combined responsibility of healthcare government and caregivers.
Conclusions
This study demonstrates that there is a considerable nationwide between-hospital 
variation in pneumonectomy use in surgical lung cancer treatment, even after 
adjustment for patient- and disease characteristics. Variation could be the result 
of varying treatment considerations or unplanned pneumonectomies. Nationwide 
registries and the development of specifically focused pneumonectomy indicators 
could be improvement-tools to further optimise surgical lung cancer care.
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Supplemental figure 1. Type of parenchymal resection according to pathological tumour 
stage (TNM7) stratified for adenocarcinoma and squamous cell carcinoma. 
*T-stage unknown n = 13, **T-stage unknown n = 5.
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Factors contributing to variation in the use 
of multimodality treatment in patients with gastric 
cancer: a Dutch population based study
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ABSTRACT
Background | Substantial variation in the use of (neo)adjuvant treatment in 
patients with gastric cancer exists. The aim of this study was to identify underlying 
(organisational and process) factors associated with the use of perioperative 
therapy.
Patients and methods | Patients with resectable gastric cancer who underwent 
surgery between 2012-2014 were selected from the Dutch Upper gastrointestinal 
Cancer Audit (DUCA). The proportion of perioperatively treated patients was 
defined per hospital. Five hospitals with the lowest percentage (LP group) and 5 
hospitals with the highest percentage (HP group) of perioperative therapy were 
identified. In the selected hospitals additional information was obtained from 
patients’ medical records using a structured list with predefined variables. 
Results | In total, 429 patients (231 in LP group, 198 in HP group) from 9 different 
hospitals were included. Perioperative therapy was given in 16.0% of patients in 
the LP group compared to 40.4% in the HP group. In the LP group, patients were 
enrolled in a clinical trial less frequently (10.8% versus 26.8%, P<0.001), and a higher 
percentage grade III-IV toxicity was observed during neoadjuvant treatment (25.7% 
versus 46.3%, P = 0.007). Multivariable analysis showed that, besides known casemix 
factors, consultation with ≥3 upper GI specialists prior to treatment decision was 
positively associated with initiating perioperative therapy (OR 2.08, 95% CI 1.19 - 
3.66).
Conclusion | Results of this study confirm considerable hospital variation in the use 
of perioperative therapy in patients with gastric cancer. Besides known casemix 
factors, use of perioperative therapy was associated with the level of involvement 
of multidisciplinary care.
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INTRODUCTION
Surgery is the cornerstone in the curative treatment of resectable gastric cancer. 
Despite improvements in postoperative mortality, prognosis remains poor with 
5-year overall survival rates of 33-50 % for patients with stage I-III gastric cancer 
that underwent a resection.1,2
Multimodality treatment improves disease-free and overall survival.3–5 However, an 
international consensus on the best approach has not been reached. Perioperative 
chemotherapy is favoured in Northern Europe, adjuvant chemoradiotherapy or 
perioperative chemotherapy in North America and adjuvant chemotherapy in 
Japan.6–8 In the Netherlands, the use of perioperative chemotherapy (according 
to the MAGIC study) is recommended for all patients with non-metastasised 
resectable gastric cancer (excluding stage I) as of 2009, provided that the patient is 
in good condition in terms of fitness and comorbidity.9
In 2011, the Dutch Upper Gastrointestinal Cancer Audit (DUCA) group initiated a 
nationwide surgical audit, including all patients that underwent surgery with the 
intent of a resection for oesophageal or gastric cancer in the Netherlands. This 
registry is used for quality assessment and it facilitates potential improvements 
by providing stakeholders with casemix corrected and benchmarked information 
on the process and short term outcomes of care.1 Results of a previous study using 
DUCA data showed that 50-55 per cent of the patients with resectable gastric 
cancer received neoadjuvant chemotherapy.1 Adjuvant chemotherapy was given to 
26-32 per cent of all patients, who underwent a resection with curative intent. In 
a subsequent study, considerable hospital variation in the use of neoadjuvant and 
adjuvant treatment was observed, even after casemix correction.10 This suggests 
that other factors than the generally known casemix factors play a role in the 
decision to prescribe perioperative treatment. 
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The aim of this retrospective cross-sectional study was to identify organisational 
and process factors associated with the use of multimodality treatment in patients 
with gastric cancer in the Netherlands.
METHODS
For this study, multiple data sources were combined, as explained below. 
Patient selection and definitions
All patients with gastric cancer, who underwent surgery with the intention of a 
curative resection between 2012-2014, were identified from the DUCA database. 
Patients with non-epithelial tumours and patients undergoing non-surgical 
treatment (such as definitive chemoradiotherapy) are not included in this registry. 
Verification of data registered in 2013 showed that data entry was complete and 
reliable.1 
Patients with stage I or IV disease (clinical tumour staging) were excluded for this 
study, as they are not candidates for perioperative chemotherapy according to 
Dutch guidelines. Minimal data requirements to consider a patient eligible for 
analyses were information on date of birth, date of surgery, tumour location, intent 
of surgery (potentially curative, palliative or no resection) and the patient’s vital 
status 30 days after surgery and / or at time of discharge. For all selected patients, 
data on patient and tumour characteristics, treatment, morbidity and mortality 
were retrieved from the DUCA. Patients were classified according to the hospital 
of surgery, since hospital of diagnosis or the hospital administering perioperative 
treatment is not registered. Clinical tumour stage was defined according to the 
seventh edition of the International Union Against Cancer tumour node metastasis 
(TNM) classification.11 No ethical approval or informed consent was required for this 
study under Dutch law.
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Hospital selection
Between January 1st 2012 and December 31st 2014, 45 hospitals performing 
gastric cancer surgery participated in the DUCA. All hospitals that were no longer 
performing gastric cancer resections at the end of the study period were excluded 
(N = 18). To minimise statistical artefacts as a result of small sample size (based on 
surgical volume), hospitals registering < 25 patients were excluded (N = 5). Among 
the remaining hospitals (N = 22) the proportion of patients treated with perioperative 
therapy per hospital was analysed (Figure 1 and 2). Subsequently, 5 hospitals 
with lowest percentages of perioperative therapy (LP group) and 5 hospitals with 
highest percentages of perioperative therapy (HP group) were approached for in-
depth investigation of patient’s medical records based on feasibility. By comparing 
two groups at opposite ends of the spectrum, potential explanatory factors were 
analysed and differences were more likely to be found. Nine hospitals participated, 
as one hospital was not able to facilitate in-depth investigation within the study 
period (Figure 1 and 2). Medical records of all included patients in the selected 
hospitals were studied using a structured variable list with predefined variables. 
This data was combined with data from DUCA and served as an extended dataset.
Perioperative therapy
Between 2007-2015, the CRITICS study was on-going in the Netherlands, 
investigating the role of postoperative chemoradiotherapy versus chemotherapy in 
patients with gastric cancer who received neoadjuvant chemotherapy.12 Therefore, 
both perioperative chemotherapy (as recommended in Dutch treatment guidelines)3 
and neoadjuvant chemotherapy combined with adjuvant chemoradiotherapy (as 
part of the CRITICS study)12 were considered as perioperative therapy. Additionally, 
at least one cycle before the operation and one cycle after the operation had to be 
completed.
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Figure 1. Flowchart describing different steps of multimodal treatment of patients in both LP 
and HP group. DUCA = Dutch Upper Gastrointestinal (GI) cancer Audit. CTx = chemotherapy, 
CRTx = chemoradiotherapy. LP group = group of hospitals with low percentage of perioperative 
therapy. HP group = group of hospitals with high percentage op perioperative therapy.
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Structured variable list
Based on literature13–16 and expert opinion, a list of potential variables associated 
with the use of perioperative therapy was created. An expert panel formed by 
health care professionals in the field of medical oncology (AC), surgery (JvS, MvBH, 
BW), and radiation oncology (FV), reviewed the list. The list was evaluated during 
a consensus meeting with the scientific committee of DUCA and finalised after a 
pilot study in one of the selected hospitals. Studied variables used for the final list 
were grouped into different subgroups including factors prior to treatment decision, 
Figure 2. Plot displaying selection of hospitals for in-depth investigation. 
 = Hospitals stopped performing gastric cancer surgery in 2014 or with < 25 patients 
registered;  = Hospitals selected in the low percentage of perioperative therapy (LP) group; 
 = Hospitals selected in the high percentage of perioperative therapy (HP) group; 
 = Non participating hospital in the HP group;  = Other hospitals.
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study participation, neoadjuvant course, surgical procedure and postoperative 
course, and adjuvant course based on timing in treatment. 
Statistical analysis
Differences in patient, tumour and treatment characteristics were analysed 
using chi square tests (categorical variables) and T-tests (continuous variables). A 
multivariable logistic regression model for the intention of perioperative treatment 
(yes/no) was employed to study the association between outcome, patient 
characteristics (sex, age, American Society of Anaesthesiologists (ASA) score and 
amount of weight loss), tumour (tumour stage and nodal stage)11 and treatment 
characteristics prior to treatment decision (referral from another hospital for surgery 
and the number of specialist consulted in the hospital of surgery). When using 
covariates with >2 categories, the first category was chosen as reference category 
(age, clinical tumour and nodal stage, amount of weight loss, number of consulted 
specialists). Missing items were included in the analysis as a separate category if > 
5.0%. Statistical significance was set at a threshold of 0.05. Statistical analyses were 
performed using SPSS (IBM SPSS Statistics for Macintosh, Version 22.0).
RESULTS
Patients, treatment and hospitals
A total of 429 patients from 9 hospitals were included: 231 patients in the LP group 
and 198 patients in the HP group. The LP group consisted of 1 university hospital and 
4 teaching hospitals. The HP group consisted of 2 university hospitals, 1 teaching- 
and 1 non-teaching hospital.
Overall hospital volumes ranged from 30-60 resections in the LP group (median 43) 
and from 26-62 (median 51) resections in the HP group. Perioperative therapy was 
administered to 37 of 231 patients (16.0%) in the LP group, and to 80 of 198 patients 
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(40.4%) in the HP group (Figure 1). Of these patients, in the LP group, 5 patients 
(13.5%) completed two-thirds or less of all perioperative cycles. In the HP group, 11 
patients (13.8%) completed two-thirds or less of all perioperative cycles. 
In the LP group, patients were older and nodal (N) stage was more frequently 
unknown (Table 1). There were no significant differences between the groups for 
other patient and tumour characteristics.
Patients in the LP group were referred less frequently for surgical treatment from 
another hospital (50.6% versus 81.8%, P<0.001) and participated less frequently in 
a clinical trial compared to patients in the HP group (10.8% versus 26.8%; P <0.001). 
In the LP group, a smaller proportion of patients visited multiple upper GI specialists 
prior to the multi-disciplinary team (MDT) meeting during which the treatment plan 
was determined (Table 1). 
No differences were observed regarding type of surgery performed, postoperative 
complications and mortality.
Perioperative therapy
On a national average, in the DUCA database, 35.4% of patients receive perioperative 
treatment, varying from 0-60% per hospital (Figure 2). 
In the selected hospitals for the current study, in the LP group, 95 patients (41.1%) 
were scheduled for perioperative therapy compared to 136 (68.7%) in the HP 
group (Table 2). In the LP group, 67 of 95 patients (70.5%) receiving neoadjuvant 
chemotherapy completed all cycles, compared to 108 of 136 patients (79.4%) in the 
HP group. During neoadjuvant treatment, a higher percentage of grade III-V toxicity 
was observed in the LP group (P = 0.004) (Table 2). Thirty-seven of 95 patients 
(38.9%) scheduled for perioperative therapy in the LP group also started adjuvant 
therapy compared to 80 of 136 patients (58.8%) in the HP group (P = 0.005) (Figure 
1, Table 2).
Reasons to omit (neo)adjuvant treatment are shown in Supplemental Table 1.
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Table 1. Patient, tumour and treatment characteristics of 429 patients stratified in two groups 
according to the proportion of patients treated with perioperative therapy per hospital.
Low perioperative 
therapy (LP) group
(N = 231)
High perioperative 
therapy (HP) group
(N = 198) P value
N % N %
Age (years), mean [SD] 70.2 [10.0] 66.2 [13.0] <0.001
Age (years)
<65 58 25.1% 74 37.4% 0.015
65-74 85 36.8% 68 34.3%  
75+ 88 38.1% 56 28.3%  
Sex
Male 144 62.3% 127 64.1% 0.699
Female 87 37.7% 71 35.9%  
ASA score a
I-II 163 70.6% 133 67.2% 0.449
III+ 68 29.4% 65 32.8%  
Charlson Comorbidity Index
0 102 44.2% 94 47.5% 0.664
1 46 19.9% 41 20.7%  
2+ 83 35.9% 63 31.8%  
Preoperative weight loss
None 53 22.9% 40 20.2% 0.442
1-10 kg 101 43.7% 94 47.5%  
>10 kg 33 14.3% 35 17.7%  
Unknown 44 19.0% 29 14.6%  
Clinical tumour stage b
T1-T2 25 10.8% 14 7.1% 0.119
T3-T4 115 49.8% 117 59.1%  
Unknown 91 39.4% 67 33.8%  
Clinical nodal stage b
N0 74 32.0% 82 41.4% 0.004
N+ 103 44.6% 93 47.0%  
Unknown 54 23.4% 23 11.6%  
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Table 1. (continued) 
 
Low perioperative 
therapy (LP) group
(N = 231)
High perioperative 
therapy (HP) group
(N = 198) P value
N % N %
Referred from other hospital for surgery § 117 50.6% 162 81.8% <0.001
Consultation with§:
(prior to treatment planning, in hospital of 
surgery)
Gastroenterologist 123 53.2% 145 73.2% <0.001
Medical-oncologist 28 12.1% 94 47.5% <0.001
Surgeon 120 51.9% 164 82.8% <0.001
Radiation oncologist 0 0.0% 30 15.2% <0.001
Specialised nurse 80 34.6% 36 18.2% <0.001
Enrolled in clinical trial§ 25 10.8% 53 26.8% <0.001
Type of surgery
Total gastrectomy 76 32.9% 82 41.4% 0.190
Partial gastrectomy 116 50.2% 87 43.9%  
Other 39 16.9% 29 14.6%  
Tumour negative resection margins (Ro)¶§ 172 88.2% 156 91.2% 0.151
No. of resected lymph nodes, mean [SD]¶ 23.3 [15.2] 26.5 [12.7] 0.039
Major postoperative complication§ 44 19.0% 37 18.7% 0.840
In-hospital / 30-day mortality§ 10 4.3% 5 2.5% 0.311
a American Society of Anaesthesiologists score 
b According to Tumour Node Metastasis (TNM) system (7th edition) 
§ In case of yes/no variables only the option yes is shown 
¶ Of patients who underwent tumour resection
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Table 2. Characteristics of perioperative therapy for 429 patients stratified in two groups 
according to the proportion of patients treated with perioperative therapy per hospital.
Low perioperative 
therapy (LP) group
(N = 231)
High perioperative 
therapy (HP) group
(N = 198) P value
N % N %
Perioperative course as decided in MDT
Upfront surgery 136 58.9% 58 29.3% <0.001
Neoadjuvant CTx and Adjuvant C(R)Tx 95 41.1% 136 68.7%
Neoadjuvant CRTx 0 0.0% 4 2.0%
Neoadjuvant treatment completed a
No / unknown 28 29.5% 28 20.6% 0.121
Yes 67 70.5% 108 79.4%
Toxicity in neoadjuvant course, highest grade a
None 14 14.7% 37 27.2% 0.004
Grade I-II 30 31.6% 44 32.4%
Grade III-V 44 46.3% 35 25.7%
Unknown grade 7 7.4% 20 14.7%
Start of adjuvant treatment a
No 55 57.9% 52 38.2% 0.005
Yes 37 38.9% 80 58.8%
Unknown 3 3.2% 4 2.9%
CTx = chemotherapy; C(R)Tx = chemotherapy or chemoradiotherapy; CRTx = chemoradiotherapy; 
MDT = multidisciplinary team. 
a Subgroup consisting of all patients planned for neoadjuvant CTx and adjuvant C(R)Tx (LP group N = 95, 
HP group N = 136).
Multivariable analysis showed that age, sex, ASA status, clinical N-stage and the 
number of upper GI specialists consulted prior to treatment decision in a multi-
disciplinary team (MDT) meeting were independently associated with the start 
of perioperative treatment (Table 3). Clinical tumour stage, amount of weight 
loss and referral for surgery were not independently associated with the start of 
perioperative treatment.
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Table 3. Risk factors associated with initiating perioperative therapy (neoadjuvant CTx and 
adjuvant C(R)Tx) in 429 patients included for in-depth investigation.
OR for starting Neoadjuvant CTx
and adjuvant C(R)Tx
OR 95% CI
Age (years)    
<65 ref   
65-74 0.79 0.45 - 1.38
75+ 0.12 0.06 - 0.21
Sex     
Male ref    
Female 0.61 0.38 - 0.97
ASA score a     
ASA I-II ref    
ASA III+ 0.42 0.25 - 0.69
Clinical tumour stage b     
1-2 ref    
3-4 0.91 0.40 - 2.05
Unknown 0.81 0.33 - 1.95
Clinical Nodal stage b     
0 ref    
1-3 1.21 0.70 - 2.08
Unknown 0.44 0.23 - 0.84
Weight loss     
0 kg ref    
1-10 kg 0.96 0.53 - 1.72
>10 kg 0.57 0.27 - 1.20
Unknown 0.89 0.43 - 1.86
Referred from other hospital for surgery     
No ref    
Yes 1.62 1.00 - 2.63
Number of upper GI specialists consulted c     
0-1 ref    
2 1.36 0.80 - 2.32
3+ 2.08 1.19 - 3.66
CTx = chemotherapy; C(R)Tx = chemotherapy or chemoradiotherapy; GI = gastro intestinal 
a American Society of Anaesthesiologists score 
b According to the Tumour Node Metastasis system (7th edition) 
c Prior to therapy decision in the Multidisciplinary Team (MDT) meeting 
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DISCUSSION
Results of this study confirm considerable hospital variation in the use of 
perioperative therapy in patients with resectable gastric cancer. Perioperative 
therapy was administered 2.5 times more frequently in the HP group compared 
to the LP group (40.4% versus 16.0%). In the LP group, a smaller proportion of 
patients was enrolled in a clinical trial. Besides known casemix factors, the number 
of consulted upper GI specialists prior to treatment decision in a MDT meeting 
was independently associated with the probability of starting with perioperative 
therapy.
Several studies have shown a benefit of multimodality treatment (perioperative 
chemotherapy, adjuvant chemoradiotherapy and adjuvant chemotherapy) 
in patients with stage II-III gastric cancer.3–5,17 This has resulted in various 
recommendations regarding optimal treatment.18,19 Absence of an international 
consensus may be one of the reasons why only subgroups of the patients with 
gastric cancer received treatment as recommended by the national guideline.1,9,10
Apart from this, there are a number of other potential reasons that could explain 
variation of patients with gastric cancer. Results of previous studies using data 
from surveillance programs, audits or cancer registries have shown that younger 
age, a lower Charlson Comorbidity Index and higher disease stage are associated 
with a higher likelihood of receiving multimodality therapy in patients with gastric 
cancer.10,13–16,20 Results of this study confirm such an association between patient 
and tumour characteristics, and the probability to receive perioperative treatment. 
Multivariable analyses in the current study did not show significant influence of the 
clinical tumour stage on the start of perioperative treatment, probably because 
the overall proportion of patients with a low T-stage was small (39 of 429 patients, 
9.1%). 
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In addition, hospital characteristics related to the decision-making with respect 
to perioperative treatment were investigated. Patients who were seen by ≥3 
upper GI specialists prior to the treatment decision in a MDT meeting had a 2 
times higher likelihood of receiving perioperative treatment. This corresponds 
with recommendations from previous studies, underlining the importance of 
multidisciplinary assessment and the role of a MDT in determining the most optimal 
treatment strategy in patients with gastric cancer.16,21 The proportion of patients 
referred from another hospital was significantly lower in the LP group compared 
to the HP group, suggesting a higher level of expertise in the treatment of gastric 
cancer in these hospitals. However, both the LP and the HP group consisted of a 
mixture of university hospitals and teaching hospitals, and hospital volumes were 
different within both groups.
Also other differences between the LP and HP group point towards differences 
in dedicated multidisciplinary assessment of patients with gastric cancer. Nodal 
(N) stage was more frequently unknown in the LP group. This could reflect less 
adequate clinical staging due to different staging methods that are used or effort 
put into adequate clinical staging. On the other hand, if a patient is found to be fit 
for surgery, but not eligible for perioperative treatment, nodal staging might be less 
relevant. Secondly, the number of resected lymph nodes was significantly higher 
in the HP group compared to the LP group (mean 26.5 versus 23.3 resected lymph 
nodes). This could be explained by differences in patient and tumour characteristics. 
On the other hand, a higher number of resected lymph nodes found in the resected 
specimen might reflect the (surgical) quality of oncological care, in which both the 
surgeon and pathologist are of importance. These findings correspond with findings 
from a previous study reporting an association between a higher lymph node yield 
and evidence based care.16 A minimum of 15 lymph nodes in the resected specimen 
is recommended by Dutch guidelines for adequate staging.9, 22, 23 Finally, compliance 
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to perioperative chemotherapy in patients with gastric cancer is known to be 
difficult, even in selected trial populations. Only 40-60% of all patients complete the 
entire course.3,5 In the present study, 70-80% of patients received all neoadjuvant 
cycles and only 40-60% started adjuvant chemo(radio)therapy. The proportion of 
patients experiencing toxicity grade ≥III was significantly higher in the LP group. 
Besides differences in patient characteristics, experience of a medical team with 
administration of chemotherapy could play a role resulting in early recognition and 
adequate anticipation e.g. switching to a different type of chemotherapy in the case 
of potential side effects.
This study has some limitations. Although the DUCA is a prospective quality registry, 
in-depth investigation of medical records was performed retrospectively. This could 
affect completeness of included data. However, no large amounts of missing data 
were observed in this study. Secondly, the DUCA is a surgical audit and only contains 
information on patients who underwent surgical treatment. For instance, if a patient 
was eligible for surgical treatment in the first place, but developed serious toxicity 
during neoadjuvant therapy and eventually did not proceed to surgery, this patient 
was not included in the DUCA. Furthermore, due to centralisation, an increasing 
number of patients with resectable gastric cancer was referred to another hospital 
for surgical treatment (reference hospital) whilst receiving perioperative treatment 
in the referring hospital. As the referring hospital is not registered in the DUCA, 
in-depth investigation of medical records took place in the reference hospital. 
Reliability and completeness of the collected data therefore relies on adequate 
transfer of all essential information between both hospitals. Standardisation of 
operative reports and reports from MDT meetings are crucial in this process, but 
not yet widely used. Finally, the effect of an evidence-based treatment may differ 
in a nationwide population. However, as the DUCA does not contain information 
about long-term follow-up, the beneficial survival effect of multimodality therapy 
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could not be investigated in this study. Future links between other databases that 
include survival data could resolve this issue, making all individual registries more 
meaningful.
In conclusion, results of this study confirm considerable hospital variation in the use 
of perioperative therapy in the Netherlands. Variation in multimodality treatment 
on both a national and international level underlines the importance of national and 
international consensus regarding optimal treatment. The likelihood of initiating 
perioperative therapy is not only associated with patient and tumour characteristics, 
but also with hospital characteristics regarding multidisciplinary care. Results from 
this study may have implications for the standard care path of newly diagnosed 
patients. Not only should they be discussed in a multidisciplinary meeting; also, a 
clinical evaluation of these patients by several specialists from different disciplines 
should take place before a final treatment plan is made.
This emphasises the importance of a dedicated MDT in oncological care.
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APPENDICES
Supplemental Table 1. Reasons to refrain from initiating perioperative therapy or adjuvant 
therapy for patients stratified in two groups according to the proportion of patients treated 
with perioperative therapy per hospital.
Low 
perioperative 
therapy (LP) 
group
High 
perioperative 
therapy (HP) 
group
N % N %
Reasons to refrain perioperative therapy a
Patient preference 9 6.6% 8 13.8%
Patient factors (age, performance score, comorbidities) 58 42.6% 21 36.2%
Tumour factors (tumour stage, differentiation) 15 11.0% 3 5.2%
Urgency of procedure (haemorrhage, perforation, obstruction) 25 18.4% 16 27.6%
Different treatment due to tumour location / pathology b 15 11.0% 3 5.2%
Unknown 14 10.3% 7 12.1%
Reasons to refrain adjuvant therapy c
Toxicity neoadjuvant CTx 17 30.9% 9 17.3%
Poor tumour response after neoadjuvant treatment 3 5.5% 1 1.9%
Progressive disease / non curative resection 17 30.9% 24 46.2%
Postoperative complicated course 4 7.3% 7 13.5%
Patient preference 8 14.5% 5 9.6%
Other 3 5.5% 2 3.8%
Unknown 3 5.5% 4 7.7%
CTx = chemotherapy 
a Calculated from the number of patients with upfront surgery (LP group N = 136, HP group N = 58) 
b e.g. neuroendocrine tumours or gastro-intestinal stoma cell tumours (GIST) 
c Subgroup consisting of all patients not starting adjuvant therapy (LP group N = 55, HP group N = 52)
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ABSTRACT
Background | Previous results from the Dutch Upper Gastrointestinal Cancer Audit 
(DUCA) have shown substantial hospital variation in use of perioperative therapy 
in patients with potentially resectable gastric cancer. This variation is not fully 
explained by patient and tumour characteristics, but could be due to variation in 
treatment preferences. The aim of this study was to explore potential barriers and 
facilitators for the use of perioperative therapy.
Methods | In-depth semi-structured interviews with surgical and medical 
oncologists (n = 17) were conducted in five hospitals with the lowest and four 
hospitals with the highest percentage of perioperative therapy use as identified 
from DUCA. Data were analysed using inductive content analysis guided by a pre-
existing implementation framework.
Results | A total of 33 factors, including 18 barriers and 15 facilitators, were identified. 
Most concerned the individual professional level. Themes of barriers and facilitators 
varied from ‘(dis)believe in added value of therapy’, ‘burden of therapy’ and ‘difficult 
extrapolation of study results’ to ‘specialist dedication’, ‘centralisation’ and ‘regional 
collaboration’. Although there were no big differences between hospital groups in 
themes reported or the number of barriers or facilitators, the quoted answers did 
differ in a nuanced way.
Conclusions | Potential barriers and facilitators for use of perioperative therapy in 
patients with gastric cancer were identified. It is suggested that between-hospital 
variation can be reduced by an up-to-date national guideline, earlier consensus on 
implementation of study results, concentration of perioperative care (leading to 
more exposure) and close (regional) collaboration.
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INTRODUCTION
In non-metastatic, locally advanced, resectable gastric cancer (neo)adjuvant 
chemo(radio)therapy improves disease-free and overall survival compared to surgery 
alone.1–3 However, there is no international consensus on the best multimodality 
treatment. In North America adjuvant chemo-radiotherapy is preferred and in Japan 
adjuvant chemotherapy is favoured.4,5 In Northern Europe, the use of perioperative 
chemotherapy (according to the MAGIC study1) is recommended.6,7
Previous studies, using data from the nationwide surgical Dutch Upper 
Gastrointestinal Cancer Audit (DUCA) showed that the use of perioperative 
chemo(radio)therapy varied considerably between hospitals.8–10 Differences in 
treatment strategies between hospitals could not be explained by patient and 
tumour characteristics alone and the use of perioperative therapy was associated 
with the level of involvement of multidisciplinary care.10 In addition, postoperative 
complications were associated with omission of adjuvant therapy.9
From these previous studies it was clear that quantitative measurable factors 
did not fully explain between-hospital differences in perioperative treatment 
strategies. It was hypothesised that variation could be the result of variation in 
treatment preferences. The aim of this study was to explore and categorise barriers 
and facilitators for perioperative therapy use in patients with gastric cancer, as 
perceived by surgical and medical oncologists in the Netherlands.
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METHODS
 
To identify barriers and facilitators for perioperative therapy use in patients 
with gastric cancer, a qualitative approach with semi-structured interviews 
among surgical and medical oncologists was used. Qualitative data analyses 
(for example by analysing interviews or videos) can reveal information not 
retrieved from quantitative analyses, since opinions and behaviours are often not 
entirely encapsulated in responses to direct questions, and can therefore provide 
information about motivations, perceptions and experiences of individuals.11 In this 
specific setting, identification of barriers and facilitators for the use of perioperative 
therapy could contribute to a further understanding why between-hospital variation 
exists and could potentially reduce unwarranted variation.
Selection of participants
The DUCA was initiated in 2011 with the main aim to improve quality of care for 
patients undergoing surgery for oesophageal or gastric cancer.8 From DUCA 
data, the proportion of patients with gastric cancer receiving perioperative 
therapy in 2012-2014 was calculated per hospital. Five hospitals with the lowest 
percentage (LP group) and four hospitals with the highest percentage (HP group) 
of perioperative therapy were included in this study. Because of the CRITICS study, 
both perioperative chemotherapy (recommended by current Dutch guidelines6) and 
neoadjuvant chemotherapy combined with adjuvant chemoradiotherapy (CRITICS 
intervention arm12), were considered as “perioperative therapy”. The selection 
methods of the LP and HP group have previously been described in full.10 From each 
selected hospital, one surgical oncologist and one medical oncologist (both referred 
to as ‘specialist’) involved in treatment of patients with gastric cancer were asked to 
represent their hospitals multidisciplinary team (MDT).
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Data collection
All specialists were invited for interviews by e-mail, which provided an explanation 
of the study purpose. Between October 2015 and April 2016, 17 of the 18 scheduled 
interviews were conducted. One interview could not be facilitated within the study 
period. All interviewees are included in the list of Collaborators.
Prior to the interview, participants were informed about study objectives and 
design. A topic guide for the interviews was developed in collaboration with a panel 
of health care professionals in the field of medical oncology, surgery, and radiation 
oncology and was based on literature13–15 and expert opinion (appendix 1). Included 
topics were hypothesised as important in treatment decision-making. Interviewees 
were encouraged to share their views on optimal curative treatment for gastric 
cancer as well as on the current national guideline and potentially explanatory 
factors for between-hospital variation in perioperative therapy.
Interviews were one-on-one, either face-to-face or by telephone, performed by 
one interviewer (NB: MD, PhD student) and audio recorded. The interviewer was 
not involved in clinical work when the interviews were conducted. Although the 
interviewer knew the performance of the hospitals being part of the LP or HP group, 
both groups were approached equally
Analysis
All audio-recorded interviews were transcribed in full. Transcripts were not returned 
to interviewees for correction. Anonymised transcripts were analysed with 
inductive content analysis using the software package ATLAS.ti version 8 (GmbH, 
Berlin, Germany) by the researcher who also conducted interviews.16 Data driven, 
open coding was performed on all transcripts. A pre-existing implementation 
framework was used to guide identification and classification of possible barriers 
and facilitators for the use of perioperative therapy.17 
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Barriers and facilitators were categorised in five levels of this framework: individual 
professional, patient, social context, organisational context and innovation. Since 
our previous study emphasised the importance of multidisciplinary care for the 
administration of perioperative therapy, there was a special focus on implementation 
of a multidisciplinary outpatient clinic within the organisational level.10
All interviews were coded. Data saturation was reached at interview thirteen. 
A second coder (SV: MD, PhD student) experienced in interview analyses, 
independently reviewed transcripts 5-13 (n = 9) for continuity of data interpretation, 
miscoded statements and inappropriately uncoded segments. Discrepancies were 
discussed until consensus was reached. Subsequently, the first coder (NB) re-
evaluated all codes in the remaining transcripts 1-4 and 14-17 (n = 8). 
After coding, the anonymised transcripts were classified to the LP or HP group to 
facilitate comparison between both groups. Representative quotes for the coded 
barriers and facilitators were extracted from interviews from both groups.
RESULTS
Seventeen interviews were completed in nine hospitals. Characteristics of the 
interviewed specialists and their hospitals are described in Table 1. In total, 33 
barriers (n = 18) and facilitators (n = 15) for perioperative therapy use were extracted 
(Table 2). When classified into the 5 levels of the framework, most barriers and 
facilitators were reported at the individual professional level. In some cases, the 
same theme could be reported both as a barrier and a facilitator, depending on the 
presence or absence of this factor. In the LP group 12 barriers and 13 facilitators were 
mentioned, while in the HP group 15 barriers and 14 facilitators were mentioned. 
Although themes can be classified into multiple levels of the framework and are 
likely to be interdependent, for the ease of interpretation they will be discussed per 
level and more or less separate from the context.
Q
ualitative analysis for betw
een-hospital variation
7
161
Table 1. Participant characteristics at hospital and interviewee level.
LP group HP group
N % N %
Hospital level (N = 5) (N = 4)
Hospital type
Academic 1 20% 2 50%
Teaching 4 80% 2 50%
Median volume of patients * 43 51
Median percentage perioperative therapy use * 20% 58%
Interviewee level (N = 9) (N = 8)
Discipline
Surgeon 5 56% 4 50%
Medical oncologist 4 44% 4 50%
Gender
Male 8 89% 3 38%
Female 1 11% 5 63%
Conduction
Face-to-face 7 78% 6 75%
Telephone 2 22% 2 25%
Median duration, minutes [IQR] 32 [18-40] 33 [31-35]
Transcript numbers 1; 3; 4; 7; 10; 12; 14; 15; 17 2; 5; 6; 8; 9; 11; 13; 16
* In the years 2012-2014 
IQR = Inter-Quartile Range 
LP group = group of hospitals with low percentage of perioperative therapy use 
HP group = group of hospitals with high percentage of perioperative therapy use
Individual-professional level
Five themes were mentioned by interviewees in both the LP group and HP group. 
Interviewees in the HP group also specifically mentioned believes or disbelieves of 
individual clinicians or the entire team in a certain treatment. 
Regarding the evidence supporting perioperative therapy use, most interviewees 
felt this evidence was clear, thereby acting as a facilitator. However, quotes from 
interviewees in the LP group tended to be more sceptical on the added value of 
perioperative therapy, with 4 of 9 even doubting the evidence (versus 1 of 8 in HP 
group), and thus acting as a potential barrier.
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“Let’s face it, neoadjuvant -or perioperative- chemotherapy improves survival. And 
improves survival with such a percentage that we all decided it to be valuable.” 
(#8, HP group)
 “Sometimes you hear one question ‘does that chemo really have an effect, or is it 
compensating for relatively bad surgery?’.” (#17, LP group)
In both groups the level of conservativeness of clinicians was regarded as potentially 
influencing the use of perioperative therapy on hospital level.
“One doctor differs from the other. One person will have a little more courage, 
or takes a little more risk, or makes a slightly different assessment than another 
doctor.” (#4, LP group)
In the LP group there were numerous interviewees that valued only a specific 
element in the total multimodal gastric cancer treatment. Some for example 
emphasised neoadjuvant or surgical treatment only.
“Excellent surgery is in any case the most important thing. Completely standardised, 
excellent surgery, for which we proctor each other. […]” (#12, LP group)
The level of experience of clinicians was indicated in both groups as influencing the 
use of any specific treatment. Interviewees from both groups indicated that the 
low prevalence of gastric cancer makes it difficult to gain sufficient experience in 
this specific patient population. Super-specialisation of clinicians or establishing 
dedicated teams with a higher patient-volume could enhance experience.
“Now I notice that I am really only concerned with the upper-GI. This ensures your 
focus. You deal with the subject, and the guidelines, in such depth. If this is all you 
do, I think it does have an effect.” (#6, HP group)
In addition, interviewees in both groups indicated to experience difficulties to 
extrapolate study results into daily practice. The guideline is based on studies 
performed in a selected group of patients. In clinical practice however, many patients 
do not meet these inclusion criteria, making it harder to choose the best treatment.
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Patient level
At patient level, mainly barriers for perioperative therapy use were reported. 
One of these was ‘patient preference not to start therapy’. Both patient (such as 
age, comorbidities or general condition) and tumour related factors (such as an 
obstructing or bleeding tumour requiring urgent surgery) were found to restrict 
therapeutic options. All interviewees mentioned such patient level barriers.
“Quite a lot of patients are not suitable [for the chemotherapy], because they are 
too old, or have too many comorbidities.” (#3 LP group)
Optimisation of the patients’ condition to enable perioperative therapy was named 
to potentially facilitate perioperative treatment use. Optimisation of the patients’ 
condition (for example by tube feeding or radiotherapy for tumour bleeding) was 
more frequently mentioned as a facilitator in the HP group (6 of 8 interviewees 
versus 4 of 9 in the LP group).
The burden of perioperative therapy was emphasised frequently (all 9 interviewees 
in the LP group and 4 of 8 in the HP group). Interviewees also mentioned neoadjuvant 
therapy could negatively impact patients’ per-operative condition and in some 
cases withhold patients from surgery due to severe side effects like sepsis, arterial 
occlusion or even death. Only one interviewee thought of the potential toxicity as 
negligible.
“A few years ago, a patient was admitted to the ICU [during neoadjuvant treatment] 
and was in such a condition that he could not undergo surgery. Of course, then you 
have totally failed.” (#2 HP group)
Social context level
Collaboration and/or communication between various disciplines within the 
hospital and, when referring patients, between hospitals were mentioned both as 
potential facilitators and barriers in both groups. Especially, good collaboration 
in MDT meetings was mentioned to positively affect quality of decision-making. 
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Also, other disciplines being easily approachable outside the MDT meeting was 
indicated to facilitate multimodal treatment. In case of referred patients, specific 
barriers were encountered influencing collaboration and communication between 
hospitals. Clinicians experienced that information of referred patients was often 
incomplete or harder to rely on compared to information from one’s own hospital, 
and that referral can cause delay in the progress and treatment.
“Our patients are often diagnosed in another hospital. Then already a week has 
passed before all diagnostic information is sent. Then only half of it turns out to be 
complete. And so on. So, it often takes two to three weeks before we actually see 
the patient.” (#8, HP group)
Organisational level
Most themes reported at the organisational level were considered to act as a 
facilitator. Interviewees suggested centralising perioperative therapy to fewer 
hospitals, in addition to the already centralised surgical procedures. Clustering 
of oesophagogastric cancer care was proposed, with interviewees pleading that 
hospitals should treat the entire spectrum of oesophagogastric cancer instead of 
only oesophageal or gastric cancer.
“It is a heavy chemo with considerable toxicity, potentially fatal. Just like we – 
surgeons – have our sub-specialisations, maybe this kind of care should also be done 
by a limited number of oncologists. And not by just anyone, in every hospital in the 
Netherlands.” (#17, LP group)
Both groups identified the MDT-meeting as an important quality control moment, 
provided that all MDT participants are well prepared.
Another facilitator was optimisation of diagnostic information prior to treatment 
planning, for which some hospitals have a specific ‘fast-track’ diagnostic pathway.
For the implementation of a structured multidisciplinary outpatient clinic, 3 
barriers and 4 facilitators were identified (Table 3). Both groups considered a 
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multidisciplinary outpatient clinic both demanding for patients as well as patient-
friendly. In terms of efficiency for specialists, some interviewees expect it to be 
time consuming, especially if they are not part of the treatment strategy, while 
others expect to save time because all specialists are well prepared. Both groups 
expect a structured multidisciplinary outpatient clinic to stimulate multidisciplinary 
teamwork, however only interviewees in the HP group expect it to positively affect 
decision-making quality (5 of 8 interviewees).
Pre-set conditions were named to maximise advantage of a multidisciplinary 
outpatient clinic, such as a sufficient number of patients, to utilise waiting time for 
patients and proper patient preparation and information.
Innovation level
More barriers than facilitators were identified at the level of the innovation. 
The current guideline being out-of-date was a frequently stated barrier (6 of 9 
interviewees in the LP group, all interviewees in the HP group), with the process 
of new guideline composition being perceived too demanding and time-intensive. 
Also, differences in (inter)national guidelines and/or local treatment protocols 
were mentioned to potentially play a role in hospital differences. Additionally, 
some hospitals tend to implement certain treatments ahead of the guideline, while 
Table 3. Barriers and facilitators to implement a multidisciplinary outpatient clininc into 
practice as part of the orginasitional context.
LP-group HP-group
Theme B F B F
Patient (un)friendly + + + +
Does not have influence on quality of decision + + +
Saves (F) / costs time for specialists (B) + + + +
Stimulates multidisciplinary team work + +
LP group = group of hospitals with low percentage of perioperative therapy use 
HP group = group of hospitals with high percentage of perioperative therapy use 
B = barrier; F = facilitator
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others are await the formal guideline changes. Implementing certain innovative 
treatments ahead of formal guidelines could be a barrier to adhere to the current 
guideline. 
“Sometimes people have the idea ‘this is better’ and already implement it, rather 
than implementing it nationwide, then of course you get differences in approach. 
I don’t think that is desirable.” (#4, LP group)
A number of interviewees indicated study participation as a facilitator. It could 
induce clinicians to become more aware of the standard of care, being more up-to-
date with the literature and being more critical (for example, more accurate patient 
selection and evaluation before start of treatment). In addition, some interviewees 
in the HP group stated that study participation could stimulate adherence to 
protocols due to structure and persistence to complete a certain treatment.
“I think that clinicians that participate in studies are forerunners in innovation. 
They also keep up with the literature better and have more frequent discussions with 
other colleagues in the country.” (#13, HP group)
DISCUSSION
In the present study, 33 potential barriers and facilitators for perioperative therapy 
use in patients with gastric cancer, as perceived by surgical and medical oncologists, 
were identified. These factors might contribute to the between-hospital variation. 
Most barriers and facilitators were encountered at the individual professional 
level. At the organisational level, mostly facilitators were identified, whereas more 
barriers were identified at the patient level. Although there were no big differences 
between the LP and HP group in the themes reported or the number of barriers 
or facilitators, the nuances in the quoted answers were quite different. While 
interviewees in the LP group emphasised the burden of perioperative therapy more 
frequently, optimisation of patients’ condition was more often mentioned in the HP 
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group. In addition, quotes from interviewees in the LP group tended to be more 
sceptical on the added value of perioperative therapy or appeared to emphasise 
only a specific element in the total multimodal treatment.
Annual exposure per hospital
The incidence of gastric cancer in the Netherlands is low and declining. Each 
year there are around 1200 new gastric cancer patients, of whom less than half 
undergo surgical treatment.8,18,19 In 2014, gastric cancer surgery was performed by 
27 hospitals. Of the surgically treated patients about two-thirds start perioperative 
chemo(radio)therapy, i.e. about fifteen patients per hospital per year. Due to these 
low numbers it could be difficult to gain experience with this specific cancer care. 
This lack of experience was identified as a potential barrier for perioperative therapy. 
Experience (and thereby the quality of decision-making) could be improved by 
collaboration in (regional) MDTs by centralising care.
Extrapolation of study results into daily practice
Interviewees in both groups reported difficulties to extrapolate results of the 
MAGIC study (underlying the current guideline) into clinical practice. In the MAGIC 
trial, about 20% of patients was over 70 years, while this was about 48% according 
national DUCA data.1,8 Also, in the MAGIC trial a WHO performance status of 0-1 
was necessary for inclusion. WHO performance status is not recorded, but ASA 
classification was III or higher in 30% of all operated patients.8 It is known that study 
patients often represent only a subpopulation of the actual patient group.
Guideline and study interpretation
Varying confidence in the current national guideline was reported as another reason 
for between-hospital differences in perioperative therapy use. Generally speaking, 
interviewees reported the guideline to be out-of-date and that updating the 
guideline is a time-consuming process.
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Some interviewees, especially in the LP group, doubted the beneficial value 
of perioperative therapy or emphasised only a specific element, e.g. only the 
neoadjuvant part. Additionally, at the time of the interviews, results from the CRITICS 
study were being analysed.20 Some interviewees indicated to already use post-
operative chemo-radiotherapy in selected patient groups outside the study context. 
In May 2018 it was documented that there was no survival benefit of postoperative 
chemoradiotherapy over postoperative chemotherapy.21 Implementing treatments 
still being studied, in this case was not beneficial for patients. Also, doing so was 
indicated as a potential barrier by some interviewees.
Burden of therapy for specific patients
Previous studies demonstrated patient and tumour characteristics as influential 
factors for treatment decisions.9,10,19 Differences in the perceived burden of 
perioperative therapy could be an explanation for the varying use between hospitals. 
In the LP group all interviewees emphasised its’ burden, influence on patient 
condition and risks of toxicity. In the HP group, half of the interviewees mentioned 
this burden, but also mentioned techniques to optimise patients’ condition.
Multidisciplinary approach
Between-hospital variation in perioperative therapy was associated with the level 
of involvement of multidisciplinary care.10 Given that the level of multidisciplinary 
care influences treatment decisions,15,22,23 a multidisciplinary outpatient clinic could 
enhance decision quality. While half of the clinicians in the HP group judged it to 
positively influence decision quality, none of the clinicians in the LP group did. Also, 
clinicians in the LP group named more barriers and less facilitators than those in the 
HP group.
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Strengths and limitations
An important strength of this study is its’ qualitative approach. Qualitative analyses 
can be used to reveal the complexity of influencing factors that would not be 
revealed by quantitative data. Though qualitative research does not validate 
or invalidate certain hypotheses, it has an explorative nature and can be used to 
generate hypotheses. Data saturation was reached, signifying an appropriate 
number of interviewees.
An important limitation in this study is that per hospital only one clinician per 
specialty was selected for the interviews, assuming that their response would 
be representative for the team. As interviewees mentioned, opinions can differ 
between specialists within the same hospital. Although the current study 
investigated an extended list of barriers and facilitators, it might be possible that 
certain themes were missed. Also, it occurred that a theme would match multiple 
levels of the pre-existing framework, while could only be categorised into one. For 
example, the barrier ‘difficulties extrapolating study results to clinic’ was classified 
at the individual professional level, since it was regarded as limited knowledge of the 
clinician. However, one could also consider it as an ambiguity in study results, thus 
at the level of innovation. To pursue objectivity, all discrepancies were discussed 
until consensus was reached. Lastly, this study does not provide insight in to what 
extent the themes actually contribute to the between-hospital variation.
Conclusion and future perspectives
In this study barriers and facilitators for perioperative therapy use in gastric cancer 
treatment were identified. These may partly explain the between-hospital variation. 
Although there were no striking differences between interviewees in the LP and 
HP group, their quoted answers did differ in a nuanced way. Interviewees in the LP 
group tended to be more sceptical on the added value of perioperative therapy, 
emphasised only a specific element in the multimodal treatment, or indicated the 
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burden of perioperative therapy more frequently. Based on the findings in this study, 
it is suggested that between-hospital variation can be reduced by an up-to-date 
national guideline and earlier consensus on the implementation of (inter)national 
study results. Concentration of perioperative care could lead to more experience. 
Together with the advanced collaboration in (regional) MDTs, this could minimise 
between-hospital variation and improve the quality of uniform decision-making.
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APPENDICES
Appendix 1. Topic list for semi-structured interviews with surgical- and medical oncologists 
working in the field of gastric cancer treatment
Introduction
• Background and objectives
• Information about interview (anonymity, safety)
General information
• Information about participant: other medical specialisation area(s), percentage of work time spent 
on gastric cancer care.
• Information about participants hospital: type of hospital (incl. residential training), possibilities for 
oesophageal cancer treatment, diagnostic and treatment facilities, study participation
In-depth investigation
• Diagnostic and treatment pathway for patients with gastric cancer (both new and referred)
O Type of specialists involved in gastric cancer care
O Role of multidisciplinary team (meeting) and influence of multidisciplinary collaboration
O Influence of patient referral
O Local / regional guidelines used
• View on the optimal potentially curative treatment of gastric cancer
• View on the current national guideline
• Potential explanation for between-hospital variation in perioperative therapy
• Use of perioperative therapy suitable as a quality indicator

CHAPTER 8
General discussion and future perspectives

D
iscussion and perspectives
8
181
DISCUSSION
Worldwide, the quality and sustainability of health care is considered a priority on 
the political agenda. This is of special importance in cancer care, due to the growing 
burden of disease, the rising complexity of care, which increasingly involves a 
multidisciplinary approach, and the expanding availability of expensive therapies. 
Despite the best intentions of well-trained clinicians and policy makers the quality 
of care and resources are not evenly distributed.1
Partly this might be overcome by the use of clinical auditing. Clinical audits are used 
as a tool to gain insight in quality of care, facilitate improvement initiatives, increase 
efficiency of care, thereby reducing healthcare costs, and reducing variation.2 In the 
last decades another effort to improve overall quality of oncologic care and reduce 
undesirable variation was made by incorporating multidisciplinary teams (MDTs) 
in the standard care. MDTs are considered to improve overall quality and reduce 
variation by better communication, patient coordination, clinical decision-making 
and practice of evidence-based medicine.3,4
Facing these trends to increase overall quality and reduce undesirable variation in 
cancer care, this thesis focused on the development and implementation of clinical 
audits for the evaluation of multidisciplinary cancer care in Part I and variation in 
surgical oncological treatment in Part II. For the latter, two eminently multimodal 
treated cancer types were highlighted.
Evaluating quality of cancer care using clinical auditing
Clinical auditing is a process of systematic analysis of quality of healthcare, with 
the aim to improve outcomes. With this tool participating hospitals can be provided 
with feedback information on population and performance (mirror information) and 
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comparison with other hospitals, the national mean or any set value (benchmark 
information).5
The fundamental thoughts for ‘clinical auditing’ have already been set a century 
ago.6,7 However, the use of data to monitor healthcare quality has only been a 
development of the last decades, partly facilitated by the increasing digitalisation 
of healthcare. Many initiatives have been developed either by professional 
associations or government authorities.2,8–11 In the Netherlands, one of the leading 
organisations facilitating clinical auditing is the Dutch Institute for Clinical Auditing 
(DICA). Chapter II of this thesis provides insight into the development of DICA 
and the nationwide implementation of clinical audits. With a narrative review 
of individual audits, the effects on care processes and outcomes for patients are 
described.
One of the main features is the central role for clinicians in the determination of 
the audits’ objectives and dataset content. Frequently updated quality of care 
information at hospital level is used to stimulate local improvement initiatives. 
By discussing audit results in scientific medical conferences and reporting areas 
for improvement in the annual report and congresses, clinicians have the chance 
to share their expertise and their ideas for quality improvement. Simultaneously, 
quality indicators – defined in a national collaboration between patient 
representatives, professionals, payers and government organisations – are used for 
public transparency.
Integrating audits into existing quality systems and stepwise transparency of quality 
indicator results, stimulated participation by all hospitals and rapid nationwide 
implementation. Although all audits and affiliated clinicians have their own learning 
curve, an overarching organisation has the advantage to enable building on the 
foundations, structures and knowledge of already existing audits. In less than ten 
years, over 20 nationwide audits were implemented in various clinical fields. Valuable 
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insights were gained in the development of quality indicators, casemix adjustment 
models, hospital variation analysis and evaluation of real world clinical practice.12–15 
Evaluation of national data even initiated national guideline adjustments.16,17 On 
numerous process and outcome indicators positive effects were observed, with 
reduction of variation and improvement of the national average.18–22 In addition, 
clinical auditing was associated with healthcare cost reduction.23
Although the observed improvements are likely to be multifactorial – with 
simultaneous centralisation, specialisation and introduction of new techniques – and 
not solely attributable to the audits, the audits provided insights into performance 
of the national healthcare system and individual providers that were previously not 
available. Of vital importance is the central role of the clinicians in the processes of 
development of the audits and evaluation of results, since the cultural component of 
constant commitment is critical in improving healthcare.24,25 Also, their continuous 
input is required to keep the audits up-to-date and relevant, as the concept of what 
presents state of the art care changes over the years.
The evolution of multidisciplinary cancer care
In most solid cancers there is a growing evidence for the added value of treatments 
besides or even replacing surgery to improve outcomes. With this growing number 
of treatment possibilities multidisciplinary team meetings (MDTs) are incorporated 
in the standard of care for patients with cancer in most countries across Europe and 
the USA. The rationale for working with MDTs is that it is important to involve all key 
professionals in making complex decisions.26 In the Netherlands, oncological MDTs 
are therefore considered mandatory and take place in a fixed frequency.27–29 They 
typically consist of surgeons, medical oncologists, radiotherapists, radiologists, 
pathologists and a case-manager or specialised nurse. MDTs are considered to tailor 
holistic treatment plans to patients’ by improving communication, coordination, 
evidence-based medicine and clinical decision-making. In certain studies the 
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discussion of patients in an MDT was associated with an improved survival.30,31
While the decision on how to treat patients with cancer is becoming more of a 
shared effort, the actual path from diagnoses to treatment and eventually follow-
up is still rather fragmented. The reorganisation of care into integrated practice 
units around medical conditions, instead of procedures, is suggested by various 
healthcare and business professionals.25,32 As Michael Porter stated “Value for 
patients comes from the overall effect of the entire sequence of activities, not from 
any individual service.”25 He also advocates measuring outcomes for a given medical 
condition over the full cycle of care. 
The evolution of multidisciplinary care evaluation
The importance of integrated care evaluation is also emphasised by the fact 
that outcomes can transcend disciplines. For example in patients with gastric 
cancer, severe postoperative complications were associated with the omissions of 
adjuvant therapy.33 Conversely, in lung cancer, the administration of neoadjuvant 
chemoradiotherapy was associated with severe postoperative complications.34 
Likewise in rectal cancer treatment, neoadjuvant chemoradiotherapy can improve 
recurrence rates, while it may lead to more postoperative complications, such 
as anastomotic or perineal wound complications. This indicates that a more 
comprehensive approach is preferably used in interpretation of outcomes. 
Simultaneously, involving multiple disciplines in the interpretation of results could 
lead to a broader perspective of indicator scores and potentially leads to further 
improvement.
Initially, DICA audits were initiated by members of the Association of Surgeons in the 
Netherlands (ASN) and focused on the quality of (mainly colorectal, upper gastro-
intestinal and lung) cancer surgery. Over time, the interest for quality evaluation 
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expanded among other professional associations and the audit subjects extended to 
surgical treatment of non-malignant diseases, non-surgical treatments of malignant 
diseases and non-surgical treatments of non-malignant diseases. Still, most audits 
were mainly mono-disciplinary and treatment-specific instead of condition-specific. 
The first step to enable the evaluation of the entire multidisciplinary care pathway 
by clinical auditing in the Netherlands was set in 2016 by the implementation of 
the Dutch Lung Cancer Audit (DLCA). The DLCA is a product of a close cooperation 
between members of various professional associations (the Dutch Society of 
Physicians for Lung Diseases and Tuberculosis - NVALT, the Netherlands Association 
for Cardio-Thoracic Surgery - NvT, the Dutch Society for Lung Surgery - NVvL-NVvH 
and the Dutch Society for Radiotherapy and Oncology - NVRO). In Chapter III of 
this thesis the core concepts, phased implementation and very first results of this 
multidisciplinary audit are presented. Although in its current format the audit is not 
at the level of an entirely integrated evaluation of care around the medical condition 
of lung cancer, the structural gathering of key professionals already seems beneficial 
in the progress of integration. One of the biggest challenges of the DLCA and other 
future multidisciplinary audits is the fact that in clinical practice diagnoses and 
treatment of patients often transcends multiple centres, in which data collection 
and display is complicated by (medical) information laws like the EU General Data 
Protection Regulation (GDPR).
However, an advantage of the multidisciplinary audit, experienced by all specialisms 
was the opportunity to address overarching issues and the quick implementation 
of new knowledge into national clinical practice; for example the nationwide in-
hospital adoption of TNM8, only a few months after publication. Related to this 
subject is the unfavourable quality of lung cancer staging that was demonstrated 
using surgical audit data.14,35 Staging is an issue of importance to all specialists, 
since it determines optimal treatment strategy. To improve pre-treatment staging, 
a multidisciplinary approach is essential.
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Although the debate remains on which indicators best reflect health care quality, 
it is known that with the use of only single parameter indicators the total aspect 
of care is not valued. To place single parameter measures in a broader context, 
most surgically focused audits incorporated composite measures such as failure-to-
rescue or textbook-outcome.15,36–39 Still, these measures only reflect part of the cycle 
of care. The main aim, and at the same time a challenge, for the DLCA is therefore to 
truly integrate quality information in a way that it enables multidimensional quality 
evaluation of the entire care spectrum, from prevention, diagnosis and treatment 
to end-of-life care. Because ultimately this is the bigger picture that matters to 
the patient. To facilitate this for the future, the International Consortium of Health 
Outcome Measurement (ICHOM)40 standard dataset was adopted as much as 
possible
Conditions for quality evaluation and comparison
The interest in using clinical audit data to analyse healthcare quality is growing 
among different stakeholders. As described, clinicians use it to gain insight in 
performance in order to improve quality. Besides this internal use of information, 
there is a growing demand for externally transparent information for government 
organisations, insurance companies and patients. Incentives vary from quality 
control and regulation to steering information for contracts or shared decision-
making. With this wide use of information and potential consequences, it is of utter 
importance to generate correct and meaningful information.
While indicators are typically classified as ‘structure’, ‘process’ or ‘outcome’, 
outcome indicators are thought to matter most for patients and reflect all 
(underlying) aspects of care.41 Criteria used to assess the suitability of indicators 
for quality evaluation purposes include relevance, usability (understand-ability 
and action-ability), feasibility, discriminative capability, reliability and validity.42 
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Reliability (repeated measures will lead to the same result) compromises data 
quality and uniform definitions. Validity refers to whether an indicator measures 
what it claims to measure. 
An important part of validity when using outcome indicators to compare hospital 
care is the adjustment for casemix (a combination of patient- and disease 
characteristics). As one can imagine, the risk on postoperative mortality for example 
differs between a healthy 60-year old woman and a 75-year old man with diabetes, 
hypertension and cardiac failure. Similarly, disease specific characteristics influence 
outcomes. For example a patient using systemic steroids that received neoadjuvant 
therapy will have a higher risk on postoperative complications compared to a 
patient with a lower stage tumour without indication for neoadjuvant therapy. Risk 
differences between patients would not be of importance if patients were randomly 
distributed over hospitals. However, this is not the case.43 Regional differences in 
patient population and referral of more complex cases to expertise centres cause 
unequal distribution of patients and their risks over various hospitals.
In Chapter IV of this thesis, the need for proper casemix adjustment when 
comparing hospitals on outcome indicators in the surgical treatment of NSCLC was 
emphasised and a casemix adjustment model useful in practice was developed.34 
A large between-hospital variation in patients undergoing lung cancer surgery 
was seen, both in individual parameters (e.g. ASA-classification and neoadjuvant 
therapy) as in more composite measures. The risk on postoperative mortality in the 
hospital with the highest risk population was 2.3 times higher than in the hospital 
with the lowest risk populations. 
To enable between-hospital comparisons or when using outcome indicators 
as transparent information to patients, policy makers or insurers (‘external 
188
accountability’), this thesis shows that a proper casemix adjustment is indispensable. 
However, when feedback information is presented to caregivers (‘internal quality 
improvement’), unadjusted data and the ability to evaluate raw data is essential. 
Every adverse outcome, regardless of the patients’ characteristics, should trigger the 
opportunity to improve care processes. Also, the possibility for caregivers to stratify 
their outcomes for various patient- or disease characteristics can be informative in 
the process of quality improvement, especially when a specific patient population 
can be identified as a target for improvement. The purpose with which information 
is displayed (‘external accountability’ versus ‘internal quality improvement’) thus 
determines the context at which information is presented (casemix adjusted versus 
unadjusted raw data). However, for both aims detailed information on patient and 
disease characteristics is indispensable and therefore needs to be included in clinical 
audits.
Quality assurance using (publicly available) indicators
As noticed, indicator results should always be seen in context of population 
characteristics. Often they should also be seen in the context of other indicator 
results. Most single-measure indicators are hard to interpret separately and do 
not always provide a one-to-one answer on what is ‘right’ or ‘wrong’, high or low 
quality of care. For instance, in rectal cancer surgery the ‘anastomotic leakage’ rate 
as an undesired postoperative outcome, can be influenced by the construction of 
a stoma. When postoperative complication rate is used as a publicly transparent 
indicator, clinicians might have the tendency to be more risk-averse and construct 
a stoma in more cases to prevent anastomotic leakages. Analysis of nationwide 
audit data demonstrated significant differences between hospitals in the use of 
stomas.13,44 Counterintuitive, a high tendency towards stoma construction did not 
result in lower overall anastomotic leakage or mortality rates, which was a real eye-
opener for the colorectal surgeons participating in the audit. The ability to select 
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the right patients for stoma construction appeared to be the key towards preferable 
outcomes for rectal cancer resections: low anastomotic leakage rates combined 
with low stoma rates.
Single-measure indicator results thus should be evaluated and interpreted in the 
context of other indicators. Another possibility lies in the use of composite measures, 
preferably transcending disciplines, to evaluate overall quality of care. Composite 
measures, such as “textbook outcome” are therefore studied as potential indicators 
involving both process and outcome measures.15,39 If all individual parameters are 
correctly weighed into the composite measure, it could be of added value in the 
evaluation of hospital performance and variation.
Critics of the public reporting of outcome measures argue that transparency of 
outcome measures might cause risk-averse behaviour of clinicians, such as omitting 
high-risk patients for certain treatments or making more conservative treatment 
choices. Fortunately, a recent study from the United Kingdom, where outcomes 
on individual clinician level are publicly available, could not detect indications for 
risk-averse behaviour.45 After the introduction of public reporting no decrease in the 
number of patients at high risk undergoing a major resection was observed. What 
was observed was an improvement in surgical mortality in eligible patients.
Quality assurance by learning from variation
While it remains a subject of debate, mostly among opponents of public 
transparency, whether the provision of outcome measures induces risk-averse 
behaviour, variation on indicator scores does provide an insight into current practice. 
Observed variation should always trigger a discussion on why the variation exists, 
whether it is desired or undesired variation and if it is the latter, how it should be 
reduced. In some cases reasons for variation cannot be distilled from the available 
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data. In these circumstances more information can be gained by performing in-
depth investigations.
Often, caregivers do not know that they differ in the use of diagnostic modalities or 
treatment techniques or have different outcomes compared to their peers. Simply 
because they have a different perspective on their own practice, the information 
is not available, or because they do not often compare their outcomes with 
other clinicians or other clinics. In a recent study evaluating guideline deviation 
in aneurysm diameter thresholds, that included questionnaires among vascular 
surgeons, the majority of surgeons estimated to deviate from the guideline in less 
than 5% of their patients, while national audit data demonstrated a 15% guideline 
deviation ranging from 2-40% between hospitals.46
Feedback of performance information could lead to more realistic perspectives 
on the area that is now sometimes considered as ‘a black box’. Especially in high-
risk procedures or therapies with potential adverse outcomes, it is important to 
contemplate the potential expected harms and benefits. Guidelines and keynote 
studies do provide guidance in this decision-making. However, there often remains 
a fair amount of ‘grey area’. For individual patients that fall outside the scope of 
the studied population, decisions often depend on MDTs or individual clinicians and 
it is plausible that varying perspectives or preferences can result in differences in 
treatment decisions.
In the treatment of lung cancer, such a high-risk procedure in which a 
careful consideration of potential harms and benefits is of utter importance 
is the pneumonectomy, the removal of an entire lung. While performing a 
pneumonectomy might lead to a curative treatment, it is known as a procedure 
that independently increases the risk on postoperative (mainly cardiopulmonary) 
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morbidity and mortality, due to the large resected volume and subsequently 
anatomical changes.47–49 The estimation whether or not a pneumonectomy should 
and could be performed is typically a multidisciplinary matter, to which expertise 
of pulmonologists, surgeons and radiotherapists contribute. In Chapter V of this 
thesis, using nationwide data, a considerable between-hospital variation in the 
use of pneumonectomy for primary lung cancer was observed.50 Hospital-specific 
results ranged from 0.0% to 25.3% pneumonectomies as a proportion of all 
anatomic resections, with six out of 51 hospitals identified as a significant outlier. 
This suggests that for individual patients the risk to receive a pneumonectomy, 
and its related morbidity, could depend on the hospital of choice. Variation could 
be the result of varying treatment considerations or unplanned pneumonectomies, 
reflecting surgical quality, per hospital. Potentially a further concentration of these 
high-risk procedures into expertise centres may be beneficial.51,52 Centralisation of 
surgical lung cancer care has already been implemented in Denmark, where lung 
surgery is performed in four hospitals, resulting in an average volume per hospital 
per year five times as high as in the Netherlands.53 Over the period of centralisation 
in Denmark a decrease in both the use of pneumonectomies and an improvement 
in 5-year survival after all surgical resections was observed, while the proportion of 
surgical resections increased.11
Another potentially harmful therapy in which substantial between-hospital 
variation was observed using nationwide audit data, was the use of adjuvant 
chemotherapy in gastric cancer.33 Although the Dutch guidelines recommend 
perioperative chemotherapy in all patients with potentially resectable gastric 
cancer, it is considered as a burdensome therapy with only 40-60% patients 
completing the comply cycle of therapy in selected study populations.54,55 
Observations from the national data initiated an in-depth investigation to identify 
reasons for this variation. In Chapter VI it was demonstrated that, in addition to the 
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known casemix and surgical treatment factors known from the existing database, 
the extent of multidisciplinary care was associated with the chance to receive 
perioperative therapy.33,56 In addition to this, a study using a qualitative approach 
with semi-structured interviews supported the hypothesis that varying perspectives 
or preferences of doctors can be associated with differences in treatment decisions 
between hospitals (Chapter VII).
Although for both pneumonectomies and the use of (neo)adjuvant therapy there 
is no set ‘target’ proportion to which caregivers can strive up to, information in 
indicator format enhances awareness among individual caregivers and MDTs. 
Within professional associations or expert groups, between-hospital variation can 
be used to support a more solid quality of care discussion contributing to quality 
improvement. Variation between countries in the use of neoadjuvant radiotherapy 
for rectal cancer was observed compared to other countries, with a relatively 
high nationwide use in the Netherlands.16 National debate on this finding led to a 
guideline adjustment. Effects of this adjustment were evaluated, again using clinical 
audit data. This demonstrated a decrease in radiotherapy use from 84.2% to 64.4% 
in two years without compromising oncologic outcomes.17
Recapitulating the evolution of quality assurance in medicine
In the end of the 20th century a shift from ‘authority-based medicine’, in which 
the expertise of individual specialists had a prominent role, to ‘evidence-based 
medicine’ in which treatment decisions rely largely on scientific evidence, has taken 
place.57,58 To translate the large amounts of study results into information useful 
in clinical practice, guidelines for the diagnosis and treatment of specific medical 
conditions are designed to support decision-making in order to secure quality. 
Parallel to this movement is the increasing use and dependency on technology, with 
the replacement of written medical records by electronic medical records being just 
one of the recent transitions in modern medical practice.32,59 Data collection and 
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analysis in medicine has taken an enormous flight due to the rapid evolution in data 
storage and processing speed. Increased accessibility of these data enables insights 
into ‘real-world’ daily medical practice. Consequently it became clear that in daily 
practice there is variation of care between individual caregivers, hospitals, regions 
or countries.1
Both the increasing availability of guidelines and the insights into practice variation 
have triggered the debate on standardisation of care. In this on-going discussion, 
medical professionals are accompanied by other stakeholders in health care such 
as patients, policy makers, insures, and regulators. One of the controversies in 
standardisation of care debate is to which degree variation is acceptable or justified. 
In other words; which variation is harmful and which is beneficial for patients. If 
practice variation is the result of subjectivity or ignorance, standardisation could 
help to reduce unjustifiable differences. On the other hand, a strict adherence to 
standardisation by guidelines could suppress professional expertise or experience 
and patient preferences by not taking the contextual factors sufficiently into 
account. These contextual factors seem to become more and more important with 
the increasing complexity of daily medical practice with on the one hand the aging 
population with an increasing number of comorbidities and on the other hand the 
growing possibilities in diagnostic tools and combinations of treatments. 
It is thus becoming clearer that the elimination of variation is not an established 
goal in itself. In the early years of the audits, clinicians were confronted with the 
existence of variation and their own performance data. There was a particular focus 
on care processes often defined by the medical guideline (e.g. discussion of patients 
in a MDT) and reduction of variation, with an important role for quality indicators. 
With the increasing complexity of patient populations and treatment options, 
making it difficult to capture within a guideline, it seems to be time to use clinical 
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data to study exactly those populations not captured by guidelines. Clinical data 
could provide valuable insights into how treatment takes place for these patients 
and can therefore be a tool for complex or relatively small subgroups of patients. To 
be of value, there should be a central role for clinicians of various medical specialisms 
from different locations. After the transition from “unregulated inconsistent care” 
to “(external) accountability” starting the end of the 20th century, it now seems time 
to shift the weight of data use to the core business of being a medical professional; 
providing the best treatment tailored to the individual patient.
FUTURE PERSPECTIVES
Although the collection of data is not a goal in itself, clinical data can help to improve 
the care and optimal treatment for individual patients. Following the above stated 
shift there are some challenges and major transitions need to be made.
Multidisciplinary evaluation of quality of care evaluation
The increasingly multidisciplinary approach of cancer treatment and the 
knowledge that outcomes transcend across disciplines advocates the importance 
of multidisciplinary evaluation of care. First of all because for patients it is the bigger 
picture that matters, from diagnoses (or even prevention) to treatment, recovery, 
recurrence and end of life, and not just any fragment of this path. Second, the 
parameters of various interventions need to be known to give context to outcomes 
of others. For example the use of neoadjuvant therapy generally increases the 
chance of radical resection but also on postoperative complications or in some cases 
even the chance of receiving surgical therapy at all. Third, with a multidisciplinary 
collaboration, overarching issues can be identified and addressed. For example the 
quality of staging before treatment, or the identification of patient groups that 
fall outside the scope of clinical trials and guidelines. Lastly, with each specialism 
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contributing to data collection the administrative burden per participating 
specialism could be reduced and data quality could improve.
Excellent support of technology and legalisation 
The burden associated with collecting data, is one of the most prominent downsides 
of clinical auditing these days. It is noted that a significant proportion of data 
collection is performed by clinicians or paramedics themselves, therefore distracting 
them from direct patient care. Distributing the registration burden among various 
physicians in a multidisciplinary data collection could be an interim solution, 
however preferably to be skipped. Ideally, data should be used from already existing 
databases, as close to the original source as possible. The most evident source is the 
electronic medical record (EMR) of patients in hospital. Some hospitals already use 
automatic extraction of EMR data for personal quality evaluation or research. On 
a national or even international level, however it is still difficult to use automated 
data extraction, due to IT-systems varying between hospitals and systems not being 
designed for quality evaluation purposes or changes to do so are too costly. Maybe 
an even more important barrier to unlock and link already existing data for audit 
purposes is the increasingly stringent privacy legislation in Europe. Today, in the 
Netherlands, it is even not allowed to share certain information between caregivers 
on various locations (e.g. general practitioner, the emergency post and the hospital) 
or clinical practice use.60 Legislation aiming to protect the peoples’ privacy in this 
case hampers the linking of data and exchange of important information, thereby 
restricting the use of data in direct patient care and in shared audit systems (indirect 
patient care). 
In order to achieve a more automated data collection, strict agreements on uniform 
definitions and structured reporting by clinicians is required, in-hospital workflow 
redesign will be necessary and close cooperation between doctors and hospital IT 
providers is indispensable. Possibilities in this field are examined by collaborating 
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initiatives as “registration at the source”.61 Other advances in data extraction in the 
medical field are the development of rapid-learning or deep-learning systems, in 
which unstructured data from various sources (including unstructured free text and 
images) are combined for automatic analyses.62 
However, the maximum benefit from these more technical developments can only 
be achieved if there is legal support. This was emphasised recently in the advisory 
report “governance of quality registrations”. In this report the committee, led by 
Van der Zande, proposes an amendment in the law to support the processing, 
storage, linking and use of data for quality registrations.63 To advance health care 
quality improvement through clinical auditing, excellent support is needed through 
both technology and legislation.
Integrating quality evaluation and improvement in daily practice of 
professionals
Clinicians and other stakeholders involved in healthcare provision need time and 
education in order to be able to use clinical practice data to improve their care. 
Like EBM, which is nowadays incorporated in the training of medical students and 
medical specialists, the analysis or at least the interpretation of clinical practice 
data are skills doctors should acquire. Currently, most local and national healthcare 
quality improvement initiatives involving clinicians largely depend on their personal 
interest, initiative and willingness to invest private time in these projects. If quality 
improvement is to be considered a part of medical practice, clinicians should be 
offered the opportunities to truly incorporate it into their practice. While feedback 
data offered by audit systems are traditionally offered in a fixed format, more 
dynamic, interactive systems should be developed to optimise information provision 
for clinicians and stimulate the internal use of data for quality improvement cycles. 
Medical teams can use this system to facilitate a feedback culture in their hospital 
through data-driven discussions (‘Codman sessions’) or to integrate in other quality 
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focussed meetings such as the morbidity and mortality conferences. As other 
studies investigating quality assurance tools demonstrate, a true culture focussed 
on quality improvement might be the most vital ingredient to achieve the greatest 
possible success for clinical auditing.25,64
CONCLUSION
In this thesis the development of clinical audit systems as tools to evaluate quality 
of care of various diseases and multidisciplinary treatments is demonstrated. 
They have the potential to catalyse improvement on both local and national level. 
With the rising complexity of cancer care and increasing use of multidisciplinary 
treatment strategies, evaluation of the ‘bigger picture’ should be maximised with 
taking contextual factors into account. In complex populations, treatment variation 
between hospitals can partly be explained by the degree of multidisciplinarity of 
care, but also seems to depend on individual choices or preferences of doctors. 
Especially in specific patient populations that are typically underrepresented in the 
more ‘traditional’ clinical trials (e.g. patients with multi-morbidity or combinations 
of treatments), population-based clinical data can have an additional value for 
more personalised treatments. When challenges of registration burden, largely 
concerning information technology and privacy legalisation are solved, discipline- 
and hospital- transcending quality information can release the true improvement 
potential in cancer care. In the next years focus should shift from merely the 
reduction of variation to the rational or value of variation. To consider continuous 
quality improvement as an essential part of medicine, all stakeholders in healthcare 
have to be willing to truly incorporate data-driven improvement cycles into daily 
clinical practice. 
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WAARBORGING VAN KWALITEIT IN DE ONCOLOGISCHE ZORG;
EEN UITDAGENDE MULTIDISCIPLINAIRE VERANTWOORDELIJKHEID
Zowel in Nederland als in de rest van de wereld neemt het aantal patiënten met 
kanker toe. Wereldwijd steeg het aantal nieuwe patiënten met kanker van ongeveer 
14 miljoen in 2012 naar 18 miljoen in 2018. De meest voorkomende vormen 
van kanker waren: borst-, long-, dikke darm- en maagkanker, waarbij long- en 
maagkanker samen verantwoordelijk waren voor ongeveer een kwart van de 
sterfte door kanker. Naar verwachting zal het aantal nieuwe patiënten met kanker 
doorstijgen naar 24 miljoen in 2035.
Multidisciplinaire oncologische zorg
Chirurgie speelt een belangrijke rol in de behandeling van veel kankersoorten. 
Echter wordt het steeds duidelijker dat andere behandelingen hiernaast bijdragen 
aan een langere overleving of zelfs een betere kans op genezing. Het gaat dan om 
behandelingen zoals chemotherapie, radiotherapie (bestraling), hormoontherapie, 
immunotherapie, doelgerichte therapie, of combinaties van behandelingen. Deze 
behandelingen kunnen voor (neoadjuvant) of na de operatie (adjuvant) worden 
gegeven. In sommige gevallen wordt de operatieve behandeling in zijn geheel 
vervangen door een ander type behandeling.
Met deze ontwikkelingen is de zorg voor patiënten met kanker een steeds 
complexere medische discipline, waarbij in het zorgproces steeds meer verschillende 
specialismen en paramedici betrokken zijn. Het werken in multidisciplinaire teams 
en houden van Multidisciplinaire Overleggen (MDO’s) is daarom een gebruikelijk en 
essentieel onderdeel geworden van de standaard oncologische zorg.
Kwaliteitsevaluatie in de multidisciplinaire oncologische zorg
In Nederland werd een aanzienlijke variatie in de behandeling en uitkomsten van 
verschillende kankersoorten op ziekenhuisniveau voor het eerst aangetoond in 
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het rapport ‘Kwaliteit van Kankerzorg’. Redenen voor de variatie konden, door de 
beperkte gegevens die er bekend waren, nauwelijks achterhaald worden. Om een 
structureler inzicht hierin te krijgen werden landelijke ‘Clinical Audits’ opgezet. 
Een Clinical Audit is een systematische analyse van zorgprocessen en de resultaten 
daarvan, met het doel deze inzichtelijk te maken en continue te kunnen verbeteren. 
In dit systeem worden gegevens uit de praktijk vergeleken met vooraf gedefinieerde 
kwaliteitsindicatoren en wordt deze informatie continue teruggekoppeld aan 
deelnemende zorgverleners.
In de afgelopen jaren is er met behulp van Audit gegevens met name onderzoek 
gedaan naar – de kwaliteit van en variatie in – de chirurgische behandeling van 
patiënten met kanker. Ook het gebruik van Clinical Auditing als kwaliteitsinstrument 
was voornamelijk gericht op de chirurgisch zorg. Over de kwaliteit en variatie van de 
andere oncologische behandelingen en combinaties ervan (multimodale therapie) 
is echter betrekkelijk weinig bekend.
Dit proefschrift richt zich daarom in deel I op de ontwikkeling van Clinical Audits 
voor de evaluatie van multidisciplinaire oncologische zorg en in deel II op de variatie 
in multimodale behandelstrategieën tussen ziekenhuizen. Voor dit laatste werden 
twee bij uitstek multidisciplinair behandelde typen kanker uitgelicht: long- en 
maagkanker.
Deel I. Kwaliteitsevaluatie in multidisciplinaire oncologische zorg
De fundamentele gedachten waarop Clinical Auditing is gebaseerd gaan terug naar 
meer dan 100 jaar geleden, met ideeën van onder andere arts Thomas Percival 
(1803), verpleegster Florence Nightingale (1820) en arts Ernest Codman (1869). Het 
gedachtegoed van Codman – waarbij “ieder ziekenhuis de behandelde patiënten 
dient te vervolgen zo lang als nodig is om te weten of de behandeling succesvol 
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is geweest en indien het niet succesvol was waarom niet, om soortgelijke fouten 
in de toekomst te doen voorkomen” – wordt beschouwd als de basis voor de 
hedendaagse Clinical Audits. 
De opzet van landelijke Clinical Audits
Hoofdstuk 2 geeft inzicht in hoe Codmans concept landelijk is geïmplementeerd in 
de Nederlandse gezondheidszorg. De in 2009 vanuit de beroepsgroep opgerichte 
Dutch ColoRectal Audit (DCRA, voorheen de Dutch Surgical Colorectal cancer 
Audit - DSCA) was het eerste landelijke initiatief om de chirurgische kwaliteit 
van zorg, in dit geval voor patiënten met darmkanker, te kunnen monitoren en 
verbeteren. Het bleek een succesvol initiatief; binnen enkele jaren werden er 
landelijke verbeteringen in processen en uitkomsten van zorg voor deze groep 
patiënten gezien. Op basis van de blauwdruk van de DCRA werden vervolgens 
andere landelijke audits opgericht, waarbij het Dutch Institute for Clinical Auditing 
(DICA, opgericht in 2010) als overkoepelende faciliterende organisatie optrad. Wat 
kenmerkend is voor deze audits is de centrale rol van artsen in de opzet en onderhoud 
ervan, de nauwe samenwerking met andere partijen in de gezondheidszorg 
(zoals patiëntenverenigingen en zorgverzekeraars), de kort-cyclische feedback 
informatie die geboden wordt, met de mogelijkheid om te spiegelen aan andere 
zorgverleners en de landelijke dekking van het systeem. De leidende rol van artsen 
en de samenwerking met andere partijen is hierbij essentieel om betekenisvolle 
kwaliteitsinformatie te verkrijgen.
In minder dan 10 jaar tijd werden meer dan 20 landelijke audits opgericht, waarbij 
ook een steeds groter aantal en meer diverse groep van artsen betrokken is. In 
deze jaren werden voor meerdere ziektebeelden en behandelingen verbeteringen 
op landelijk niveau waargenomen en nam de variatie tussen ziekenhuizen af. Met 
de grote hoeveelheid gegevens uit de klinische praktijk bleek het goed mogelijk 
om wetenschappelijk onderzoek te doen, waarbij deze ‘real-world data’ een 
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waardevolle aanvulling vormen op de meer traditionele studies (trials) in vooraf 
geselecteerde patiëntengroepen. Bovendien vormen de gegevens een basis voor 
een meer gegronde discussie over de kwaliteit van zorg.
De opzet van multidisciplinaire Clinical Audits
Initieel werden de meeste audits opgezet voor de evaluatie van de chirurgische 
behandeling van kanker. In de loop van de jaren is het interessegebied uitgebreid 
naar de evaluatie van niet-kwaadaardige ziekten (bijvoorbeeld vaatziekten of 
aandoeningen van het zenuwstelsel) en ook niet-chirurgische behandelingen. In 
navolging van het toenemende belang van multidisciplinaire zorg streven audits 
steeds meer naar een integrale evaluatie van het gehele zorgtraject. Een van de 
eerste Nederlandse nationale audits die dit in praktijk bracht was de Dutch Lung 
Cancer Audit (DLCA). In hoofdstuk 3 beschrijven we hoe deze is ontstaan en welke 
informatie de audit de eerste jaren heeft opgeleverd. De eerste subregistratie van 
de DLCA werd al in 2012 gestart. Deze was met name gericht op de chirurgische 
behandeling van longkanker. In 2014 werd hiernaast een subregistratie gestart 
om de behandeling middels radiotherapie te evalueren. De longartsen, die een 
belangrijke rol spelen in de diagnosestelling en behandeling middels o.a. chemo- 
en immunotherapie, hebben sinds 2016 een subregistratie om hun zorg te kunnen 
evalueren. Sinds 2016 zijn dus alle behandelende specialismen vertegenwoordigd 
en actief betrokken om de kwaliteit van zorg te monitoren en te verbeteren.
De DLCA werd in korte tijd landelijk geïmplementeerd, waarbij in de eerste 
jaren een groei werd gezien in het aantal deelnemende ziekenhuizen en het 
aantal geregistreerde patiënten. Hoewel er het eerste jaar zeker nog geen 
complete registratie was van alle patiënten met longkanker (ongeveer 40% 
van de landelijke incidentie), gaf het al wel een goed inzicht in de dagelijkse 
praktijk van longkankerzorg. Bijvoorbeeld in het gebruik van minimaal-invasieve 
operatietechnieken (kijkoperaties) om de tumor te verwijderen lijkt Nederland 
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voor te lopen op andere landen, waarbij uitkomsten zoals postoperatieve sterfte 
vergelijkbaar zijn. In het correct stadiëren van de tumor voorafgaand aan de 
behandeling lijken dan weer verbetermogelijkheden te liggen. Daarnaast werd het 
duidelijk dat de multidisciplinaire samenwerking in de DLCA het mogelijk maakt 
om nieuwe kennis gemakkelijker op een landelijk niveau te implementeren. Zo is 
bijvoorbeeld de invoering van de nieuwe indeling voor tumorstadiëring (TNM-
stadiëring) al enkele maanden na de internationale publicatie ervan in gebruik 
genomen in de Nederlandse praktijk. 
Hoewel de eerste stappen in de ontwikkeling van een multidisciplinaire audit zijn 
gezet, is de belangrijkste uitdaging van de DLCA om de subregistraties zodanig te 
integreren dat zowel de verzameling als het gebruik van gegevens mogelijk is vanuit 
verschillende specialismen uit verschillende ziekenhuizen, leidend tot maximale 
mogelijkheden wat betreft kwaliteitsevaluatie voor een zo minimaal mogelijke 
inspanning.
Succesfactoren en valkuilen
Wat kenmerkend is voor de in hoofdstuk 2 en 3 omschreven audits is de centrale rol 
die artsen in het proces spelen, dit in tegenstelling tot veel buitenlandse systemen 
waarbij de overheid of externe organisaties sturend zijn. Zowel in de ontwikkeling 
en implementatie ervan als in de verdere ontwikkeling zijn clinici de drijvende 
krachten. Zij vormen de verbinding met de praktijk en weten welke vraagstukken 
er spelen in de beroepsgroep. Hiernaast is ook de samenwerking met de andere 
partijen in de gezondheidszorg belangrijk om kwaliteitsinformatie te verkrijgen die 
voor meerdere groepen van betekenis is. Gegevens uit de audits worden door die 
andere partijen gezien als een belangrijke bron om verder beleid te voeren.
De grote stimulans voor clinici om deel te nemen aan de audits is de feedback-
informatie die zij krijgen over de kwaliteit van de door hen geleverde zorg. Het 
integreren van de audits in het landelijke kwaliteitsbeleid van beroepsverenigingen 
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van medisch specialisten, bijvoorbeeld via de aanlevering van informatie 
over ‘participatie-indicatoren’, en het stapsgewijs vrijgeven van bepaalde 
indicatoruitkomsten op ziekenhuisniveau hebben een snelle implementatie van 
de audits gestimuleerd. Hierdoor zijn de gegevens vollediger, beter bruikbaar en 
leveren ze belangrijke benchmarkinformatie, in vergelijking met initiatieven waarbij 
ziekenhuizen ieder voor zich, op eigen initiatief, gegevens registreren.
Voordelen voor de beroepsgroepen, wetenschappelijke verenigingen van medisch 
specialisten, om zich aan te sluiten bij een overkoepelende organisatie zoals DICA 
zijn: de ervaring op het gebied van methodologie en logistiek, de aanwezige data-
infrastructuur (en de juridische- en privacyaspecten die hiermee samenhangen), 
een reeds gevormd netwerk van medisch specialisten en ziekenhuizen (en de 
afspraken die daar mee samenhangen) en het vermijden van dubbele verzameling 
van gegevens.
De huidige audits hebben vooralsnog wel enkele punten die verbetering behoeven. 
Een belangrijk en veelgenoemd knelpunt is de administratieve last die gepaard 
gaat met het verzamelen van de gegevens voor de audit, wat voor een deel door 
zorgverleners zelf gedaan wordt. Een oplossing hiervoor is de automatische 
extractie van gegevens uit de reeds bestaande informatie, vastgelegd in de 
elektronische patiëntendossiers in ziekenhuizen. Echter vormt de steeds strengere 
Nederlandse en internationale privacy wetgeving hier wel een moeilijkheid in, met 
name in het combineren en delen van medische gegevens tussen verschillende 
ziekenhuizen. Daarnaast zijn strikte afspraken met IT-leveranciers (hoe worden 
gegevens verzameld, opgeslagen en uitgewisseld) en tussen verschillende 
specialismen (wie is verantwoordelijk voor het vastleggen van welke gegevens 
op welke wijze) noodzakelijk om dergelijke geautomatiseerde gegevensextractie 
mogelijk te maken.
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IT kan ook een belangrijke rol spelen om de gegevens makkelijker bruikbaar te 
maken voor artsen, bijvoorbeeld door de ontwikkeling van gebruiksvriendelijke 
interactieve systemen, waarbij het voor de arts mogelijk is om met een aantal 
muisklikken zijn klinische vraagstukken te beantwoorden. Hierin worden 
momenteel de eerste stappen gezet.
Een ander continue spanningsveld is de mate waarin gegevens gedeeld worden met 
andere partijen in de gezondheidszorg. In eerste instantie dienen gegevens uit de 
audit verbeterdoeleinden voor artsen. Maar zoals gezegd is er ook vanuit andere 
partijen grote interesse voor deze gegevens. In potentie zou het kunnen delen van 
uitkomsten risicomijdend gedrag in de hand kunnen werken, zoals bijvoorbeeld 
het niet meer opereren van patiënten met een complexere problematiek, zowel 
wat betreft hun performance status, comorbiditeiten of leeftijd, als een gevorderd 
stadium van de ziekte. Gelukkig laten zowel evaluaties van de audit data over de 
jaren als internationale onderzoeken geen aanwijzingen zien die wijzen op dergelijk 
risico-avers gedrag. Voor zorgverleners moet het echter altijd mogelijk blijven om 
hun gegevens in een veilige omgeving met elkaar te delen en te evalueren voordat 
ze met andere partijen gedeeld worden.
Uitkomsten vergelijken
Om ziekenhuizen betrouwbaar te kunnen vergelijken, en bijvoorbeeld het eerder 
genoemde risicomijdend gedrag te voorkomen, is het belangrijk om rekening te 
houden met de zorgzwaarte van de patiënten in dat ziekenhuis. Die zorgzwaarte 
wordt bepaald door een combinatie van patiënt- en ziektekenmerken die samen 
‘casemix’ worden genoemd. In hoofdstuk 4 hebben we onderzocht in welke 
mate het corrigeren voor deze casemix factoren van belang is bij het evalueren 
van longkankerchirurgie. Welke factoren in de casemix worden meegenomen 
wordt bepaald op basis van eerder onderzoek, kennis van experts en statistische 
methoden. Voor dit onderzoek hebben we gebruik gemaakt van gegevens uit het 
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chirurgische gedeelte van de DLCA. In totaal werden gegevens van 8040 patiënten, 
verspreid over 51 Nederlandse ziekenhuizen meegenomen in de analyse.
Factoren die van invloed bleken op de uitkomstmaten postoperatief overlijden en 
gecompliceerd beloop waren: leeftijd, twee fitheidsscores (ASA-classificatie en 
ECOG-score), longfunctie, de hoeveelheid longweefsel die verwijderd moest worden 
om de tumor te verwijderen, het tumorstadium en het type longkanker dat uit het 
postoperatieve weefselonderzoek bleek. Tussen de verschillende ziekenhuizen was 
er een aanzienlijke variatie in de individuele factoren. Op basis van de combinatie 
van deze factoren, de algehele zorgzwaarte in een ziekenhuisgroep, werden de 
kansen voorspeld op overlijden of een gecompliceerd beloop na de operatie. 
Ook dit berekende risico varieerde beduidend tussen de ziekenhuizen, waarbij de 
risico’s uiteenliepen van 1.4% tot 3.2% voor postoperatief overlijden en 11.5% tot 
17.1% voor een postoperatief gecompliceerd beloop. Door de zorgzwaarte van 
de patiëntpopulatie in het ene ziekenhuis was de kans op overlijden bij voorbaat 
dus al twee keer zo hoog als in het andere ziekenhuis. Deze variatie in casemix 
tussen ziekenhuizen benadrukt het belang van een juist correctiemodel, wanneer 
ziekenhuizen vergeleken worden op uitkomstindicatoren. Aansluitend werden in 
deze studie modellen voorgesteld die bruikbaar zijn voor casemix correctie in de 
huidige audit.
Wel moet opgemerkt worden dat er om te kunnen corrigeren een uitgebreidere 
gegevensuitvraag nodig is (dus meer registratielast) en dat men moet waken voor 
‘over-correctie’, waarbij er bijvoorbeeld keuzes die de zorgverlener in het proces 
maakt worden weg gecorrigeerd. Daarnaast blijft het voor individuele ziekenhuizen 
altijd van belang om zelf ook naar hun ongecorrigeerde uitkomsten te blijven kijken.
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Deel II. Variatie in de multidisciplinaire oncologische zorg
Waar er voorheen weinig bekend was over hoe de zorg in de praktijk daadwerkelijk 
werd geleverd, hebben audits hier nieuwe inzichten in gegeven. Zorgverleners zijn 
zich niet altijd bewust van hun eigen prestaties en of ze verschillen van collega’s of 
andere ziekenhuizen in het gebruik van bepaalde diagnostiek, behandelmethoden 
of uitkomsten. Dit omdat de informatie niet beschikbaar is of niet wordt gebruikt 
om naar verschillen te kijken. Het perspectief dat clinici hebben op hun zorg in 
de praktijk kan daardoor behoorlijk afwijken van wat data laat zien. Zo schatte, 
in een recent gepubliceerde studie, meer dan driekwart van de 44 ondervraagde 
vaatchirurgen in dat ze bij minder dan 5% van de door hun geopereerde patiënten 
afweken van de richtlijn, terwijl dit uit de landelijke data bij 15% het geval bleek te 
zijn, variërend van 2-40% van de deelnemende ziekenhuizen.
Variatie gebruiken voor verbeteringen
Met de gegevens uit de audit is het niet alleen mogelijk voor individuele 
zorgverleners of ziekenhuizen om zichzelf te monitoren en te verbeteren, ook op 
landelijk niveau of zelfs internationaal kan er gekeken worden naar mogelijkheden 
voor verbetering. Het bestaan van verschillen in gebruik van diagnostiek, bepaalde 
behandelmethoden of uitkomsten tussen ziekenhuizen, regio’s of landen kan er op 
wijzen dat de zorg op de ene plek efficiënter is ingericht of van betere kwaliteit is 
dan op een andere plek. Een internationale vergelijking die werd gemaakt in het 
gebruik van neoadjuvante radiotherapie bij endeldarmkanker liet bijvoorbeeld 
zien dat het gebruik in Nederland aanzienlijk hoger was dan in andere landen. Dit 
bracht een discussie op gang of deze behandeling, met risico op bijwerkingen, 
daadwerkelijk voor alle patiënten aan wie deze gegeven werd noodzakelijk was en 
werd de Nederlandse richtlijn aangepast.
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Het geven van terugkoppeling over eigen prestaties geeft meer realistische 
perspectieven op de geleverde zorg. Met name bij risicovolle procedures 
of behandelingen in groepen kan deze informatie van belang zijn, om een 
goede afweging van de voor- en nadelen te maken. Onderzoeksresultaten van 
gerandomiseerde studies geven vaak een richtlijn voor de besluitvorming, echter 
is dit vaak gebaseerd op een zeer geselecteerde groep patiënten, die aan de vaak 
strenge inclusiecriteria van de studie voldeden. Hierdoor blijft er een behoorlijk 
grijs gebied over voor patiënten die qua karakteristieken buiten de studies vallen. 
Het is niet gek om te bedenken dat beslissingen die voor deze patiënten genomen 
worden, tussen de verschillende ziekenhuizen en zorgverleners kunnen verschillen.
Door op verschillen in te zoomen kan er een discussie op gang gebracht worden of 
het gaat om gewenste of ongewenste variatie en als de variatie ongewenst is hoe 
deze kan worden verminderd. Soms zijn de beschikbare gegevens ontoereikend en 
is meer diepgaand onderzoek nodig.
Variatie in gebruik hoog-risico operatie voor longkanker
In de behandeling van longkanker is een dergelijke risicovolle procedure de 
pneumonectomie, het verwijderen van een gehele long. De kans om postoperatief te 
overlijden na deze procedure is ongeveer drie keer hoger in vergelijking met minder 
invasieve operaties. De kans op ernstige complicaties is na een pneumonectomie 
ook aanzienlijk hoger. Het gebruik van dit type operatie is daarom voorbehouden 
aan patiënten met een voldoende conditie, bij wie het niet mogelijk is om de tumor 
volledig te verwijderen middels een kleinere operatie. Een zorgvuldige afweging 
van mogelijke voor- en nadelen is bij dit type operatie van groot belang en is vrijwel 
altijd een multidisciplinaire kwestie.
Het was onduidelijk of het risico van patiënten op het ondergaan van een 
pneumonectomie gelijk is in de Nederlandse ziekenhuizen die longkankeroperaties 
doen. In hoofdstuk 5 onderzochten we daarom wat de Nederlandse praktijk is in 
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het gebruik van de pneumonectomie als behandeling van longkanker en bekeken 
we of er verschillen waren tussen ziekenhuizen in het gebruik ervan. Gegevens van 
meer dan 8.400 patiënten, geopereerd tussen 2012-2016, werden geanalyseerd. Op 
landelijk niveau onderging 7,8% van al deze patiënten een pneumonectomie. Per 
ziekenhuis varieerde dit aantal van 0,0% tot 25,3%. De landelijke postoperatieve 
sterfte na een pneumonectomie was 7,1%, terwijl dit bij kleinere operaties 1,7% was.
Factoren geassocieerd met een grotere kans op het ondergaan van een 
pneumonectomie waren: lagere leeftijd, mannelijk geslacht, geen hart- of 
longaandoeningen in de voorgeschiedenis, een tumor die zich in de linker 
long bevindt, een verder gevorderd tumorstadium en een tumor van het type 
plaveiselcelcarcinoom. Op basis van deze factoren werd berekend wat het 
verwachtte aantal patiënten per ziekenhuis zou zijn dat een pneumonectomie 
zou ondergaan. Dit aantal hebben we vergeleken met het aantal patiënten 
dat daadwerkelijk een pneumonectomie onderging. Van de 51 ziekenhuizen, 
bleken er 3 te zijn die significant meer pneumonectomieën uitvoerden dan op 
voorhand verwacht werd en 3 die er significant minder uitvoerden. Deze laatste 
3 ziekenhuizen voerden minder dan de helft van het vooraf verwachtte aantal 
pneumonectomieën uit en wisten dus meer patiënten te opereren met een minder 
belastende operatie. Variatie in het gebruik van deze operatie tussen ziekenhuizen 
zou een gevolg kunnen zijn van verschillen in behandelingsoverwegingen tussen 
behandelaars uit de verschillende ziekenhuizen. Ook zou het kunnen zijn dat in 
sommige ziekenhuizen tijdens de operatie vaker moet worden uitgeweken naar 
een pneumonectomie, bijvoorbeeld omdat er tijdens de operatie complicaties 
optreden. Door het aanbieden van informatie in indicator-vorm, specifiek gericht 
op het pneumonectomie-gebruik, willen we behandelaars bewust maken van de 
verschillen en hun eigen presteren hierin, om zo de zorg te verbeteren. 
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Variatie in gebruik van chemotherapie rondom maagkanker operaties 
Een andere behandeling waarbij het – gezien de grote potentiële voor- en 
nadelen – belangrijk is om een goede afweging te maken, is (neo)adjuvante 
chemotherapie in de behandeling van maagkanker. Studies wijzen uit dat het geven 
van chemotherapie zowel voor als na de operatie een winst in overleving oplevert. 
Echter is ook bekend dat deze behandeling aanzienlijke bijwerkingen kan hebben. 
Zelfs in studieverband, wat doorgaans gezondere patiënten zijn, volbrengt slechts 
40-60% van alle patiënten de gehele behandeling. Het advies in de Nederlandse 
richtlijn is dan ook om alle patiënten – met een in opzet curatieve behandeling van 
maagkanker – perioperatief (zowel voor- als na de operatie) te behandelen, “mits de 
verwachting is dat de patiënt dit qua conditie en comorbiditeit aankan”.
Uit gegevens van de landelijke audit voor maag- en slokdarmkanker, de DUCA, blijkt 
het percentage patiënten dat in de dagelijkse praktijk perioperatieve behandeling 
krijgt, circa 35%, lager dan de genoemde studies. Daarnaast bleek er een aanzienlijke 
variatie te bestaan tussen ziekenhuizen in de mate waarin ze deze perioperatieve 
chemotherapie toepassen. Zoals verwacht speelden casemix factoren hierbij een 
rol. Echter was de variatie tussen de ziekenhuizen hiermee niet geheel verklaard.
In hoofdstuk 6 en 7 hebben we onderzoek gedaan naar onderliggende verklaringen 
voor de ziekenhuisverschillen in het gebruik van perioperatieve therapie. Aangezien 
de DUCA vooral gericht was op de evaluatie van de operatieve behandeling van 
maagkanker, kon uit de gegevens van de DUCA onvoldoende informatie gehaald 
worden over andere vormen van behandeling en het besluit daartoe. In het 
onderzoek voor hoofdstuk 6 hebben we aanvullende gegevens verzameld uit de 
medische dossiers van patiënten in een aantal ziekenhuizen, die waren geselecteerd 
op basis van het percentage patiënten dat perioperatieve behandeling onderging, 
waarbij we de twee uiterste groepen met elkaar vergeleken hebben. Dossiers van 
429 patiënten werden onderzocht. In de 4 ziekenhuizen met het hoogste percentage 
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perioperatieve therapie onderging 40,4% van de patiënten perioperatieve therapie, 
tegenover 16,0% in de 5 ziekenhuizen met het laagste percentage. Uit deze studie 
bleek een verband tussen de mate van multidisciplinariteit van zorg en het geven 
van perioperatieve behandeling. Wanneer een patiënt drie of meer verschillende 
specialismen had gezien voorafgaand aan het MDO was de kans op het starten 
van perioperatieve behandeling meer dan twee maal zo groot. Verder zaten er 
tussen de ziekenhuisgroepen onder andere verschillen in het aantal patiënten 
dat deelnam aan een studie en bleken in de groep ziekenhuizen met het laagste 
percentage perioperatieve therapie meer patiënten een ernstige bijwerking van de 
chemotherapie te ervaren (46,3% versus 25,7%). Op basis van deze studie lijkt het 
dus niet alleen van belang om patiënten multidisciplinair te bespreken, maar ook 
om de patiënt daadwerkelijk door meerdere specialismen te beoordelen, om zo een 
goede inschatting te kunnen maken voorafgaand aan de behandeling.
Hiernaast bestond het vermoeden dat de variatie tussen ziekenhuizen zou kunnen 
berusten op verschillen in voorkeuren tussen behandelaars. Dit is echter lastig 
te toetsen met het kwantitatieve onderzoek dat met behulp van databases of 
patiëntendossiers gedaan kan worden, aangezien overtuigingen en gedrag hierin 
niet goed te vatten zijn. In hoofdstuk 7 beschrijven we hoe we middels interviews 
(een kwalitatieve onderzoeksmethode) met in totaal 17 chirurgen en oncologen, 
deze hypothese hebben kunnen exploreren.
In totaal werden er 33 verschillende barrières en stimuli genoemd voor het geven 
van perioperatieve therapie in de behandeling van maagkanker, waarbij er meer 
barrières werden benoemd. Een aantal barrières en stimuli die uit dit onderzoek 
kwamen: ‘(on)geloof in de behandeling’, ‘zwaarte van de behandeling’, ‘moeilijke 
implementatie van de studieresultaten’, ‘toewijding van specialisten’, ‘centralisatie 
van zorg’ en ‘regionale samenwerking’. Hoewel er geen grote verschillen tussen 
de twee ziekenhuisgroepen waren wat betreft het aantal genoemde barrières en 
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stimuli en de thema’s die deze omvatten, leken er wel genuanceerde verschillen te 
bestaan in de geciteerde antwoorden.
Suggesties om ongewenste variatie tussen ziekenhuizen te beperken op basis 
van dit onderzoek zijn: streven naar een actuele (inter)nationale richtlijn, vlottere 
consensus over de implementatie van nieuwe onderzoeksresultaten, concentratie 
van ook de perioperatieve zorg en geoptimaliseerde (regionale) samenwerking.
Conclusie en toekomstperspectief
Dit proefschrift geeft inzicht in de ontwikkeling van Clinical Audits voor de 
evaluatie van – multidisciplinaire – kwaliteit van zorg en als katalysator van 
zowel lokale als landelijke verbeteringen. Met de toenemende complexiteit 
van de oncologische zorg, waarbij de zorg voor patiënten een steeds meer 
multidisciplinaire verantwoordelijkheid wordt, is het van belang om een 
geïntegreerde multidisciplinaire evaluatie mogelijk te maken. In complexe 
populaties of behandelingen kan ziekenhuisvariatie samenhangen met de mate 
van multidisciplinariteit van de zorg. Daarnaast lijkt ook de voorkeur van individuele 
behandelaars een rol te spelen in ziekenhuisvariatie.
Er is een aantal stappen te nemen om de Clinical Audits van maximale waarde te 
kunnen laten zijn in de kwaliteitsborging van multidisciplinaire oncologische zorg. 
Het verminderen van de registratielast voor zorgverleners is één van de belangrijkste 
punten. Om tot een geïntegreerde multidisciplinaire gegevensverzameling en 
-evaluatie te komen moeten vraagstukken opgelost worden op het gebied van o.a. 
privacywetgeving, eenduidige gegevensverzameling en overeenkomsten tussen 
specialismen en ziekenhuizen. De focus die in de beginjaren van Clinical Auditing 
met name heeft gelegen op reductie van variatie zal in de komende periode moeten 
verschuiven naar meer focus op de rationale achter variatie, het onderscheid 
tussen gewenste en ongewenste variatie en de waarde van juist gewenste variatie. 
Het daadwerkelijk integreren van kwaliteitsevaluatie in de dagelijkse praktijk van 
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zorgverleners en het opnemen als onderdeel van de moderne geneeskunde is van 
belang om de volledige potentie te kunnen benutten voor de verbetering van de 
patiëntenzorg.
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